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ABSTRACT 
Culture of mouse pancreatic islet and thyroid tissue 
in an oxygen-rich atmosphere before transplantation, 
facilitates long-term allograft survival without the use of 
. . irnrnunosuppression. The work presented here, represents the 
results of i~vestigations into the susceptibility to 
rejection of such cultured allografts. These established 
allografts are resistant to rejection by alloantiserum 
and complement - a resistance which we propose is due to 
the revascularization of the graft with host vascular 
endothelium. Such revascularization, however, does not 
protect the allograft from cell mediated damage. The 
cellular requirements for rejection of cultured islet 
allografts were studied and the results obtained show 
+ + + that sensitised Thy 1, Lyt 1 2 lymphocytes and not 
Lyt 1+2- lymphocytes trigger acute graft rejection. 
Evidence is also presented to show that lymphokine release 
by these cytotoxic effector cells plays an important 
role in triggering allograft rejection. 
The susceptibility of grafts to rejection slowly 
diminishes with time but, until such time as the recipients 
develop functional tolerance, these grafts remain in a 
metastable phase. Treatment of islet allograft recip-
ients with UV irradiated spleen cells of donor origin, 
results in the stabilization of islet allografts by the 
induction of specific tolerance. The mechanism of this 
form of tolerance appears to be due to suppression, by an 
unknown mechanism, of the process of recipient sensitisa-
tion. 
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PREFACE 
This thesis is made up of seven chapters. The intro-
ductory chapter (Chapter 1) is a broad review of the extensive 
literature on allograft rejection and transplantation 
tolerance, with some emphasis on mechanisms involved in 
graft rejection and tolerance induction and maintenance. 
The work described in subsequent chapters of this thesis 
was an exploration of the susceptibility or resistance 
of established islets to rejection and the induction of 
transplantation tolerance. 
The experiments were performed using the mouse 
pancreatic islet and thyroid allograft model with H-2 
incompatible donors and recipients. Both islet and 
thyroid tissues were treated by organ culture before 
transplantation. Such culture reduces tissue immuno-
genicity but does not destroy tissue antigens. Thus, 
while cultured allografts can be successfully trans-
planted without a need for suppression of the recipient's 
immune system, such allografts are constantly under the 
threat of rejection. This is of particular significance 
in the clinical transplant situation which might apply 
these procedures to reverse insulin dependent diabetes. 
A blood transfusion, for example, could trigger rejection 
if the transfused blood carried histocompatibility anti-
gens similar to those in the graft. These potential 
threats to the established allograft were examined in the 
studies that follow. 
ll 
Chapter 3 examines the resistance of established 
islet allografts to rejection by antibody and complement. 
Chapter 4 examines the cellular requirements for the 
rejection of cultured islet allografts,and Chapter 5 
extends our investigations into the mode of function of 
these cells to reject the islet allograft. Chapter 6 
examines the ·stabilization of established islet allo-
grafts and development of tolerance, and discusses 
mechanisms which might be involved in the development 
of tolerance. Chapter 2 describes the materials and 
methods employed in this study and Chapter 7 is a general 
discussion of the findings of this study. 
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Antilymphocyte serum 
Adult thynectomized, lethally irradiated 
and bone marrow reconstituted 
Bovine serum albumin 
Chorioallentoic membrane 
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CHAPTER 1 
REVIEW: ALLOGRAFT REJECTION AND 
TRANSPLANTATION TOLERANCE 
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1.1 GENERAL INTRODUCTION 
Reports of blood, skin and organ transplantation are 
rooted in antiquity. Some are no more than legends, with 
the feat of Saints Cosmos and Damian, who flourished in the 
third century AD, being among the best known. The story is 
told of a complaining leg amputee who was restored by these 
two medical saints when they successfully transplanted the 
leg of a Moor who had recently died. Nonetheless, there are 
also many documented cases of transplantation which go back 
many centuries. These include skin grafts to restore 
mutilations to the nose, ear and lip, and blood transfusions 
from young persons to older ones aimed at rejuvenation. 
For an historical account, see Saunders (1972). In the 
nineteenth century, numerous skin allografts ·were carried 
out giving rise to many claims of success. This was 
probably a result of the initial "take" before its reject-
ion. Failures were considered by many to be a result of 
technical difficulties. 
It was with the turn of this century, however, that 
the scientific basis for transplantation really began and 
many technical advances were also made at this time. None-
theless, such advances were not able to overcome the central 
stumbling block, namely, rejection. Many subsequent experi-
ments soon made it clear that although autografts could 
survive indefinitely, allografts were rejected within a 
matter of days. 
Unfortunately, the issue of allograft reactivity 
remained confused and it was not until the investigations 
by Gorer in the 1930's and Medawar in the 1940's that the 
immunological nature of the allograft response was demon-
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strated. This recognition soon led to a rapid expansion in 
transplantation studies, with many investigations aimed at 
elucidating the precise mechanisms of rejection and the 
induction of tolerance. 
We now know that after an animal has had an appropriat~ 
contact with antigen it may respond in a number of different 
ways, including the production or non-production of anti-
body, the development of delayed type hypersensitivity, or 
even become unresponsive or tolerant. Which of these 
events occurs depends on the conditions under which the 
antigen, whether a suspension of cells or an organ allo-
graft, is delivered. If appropriate conditions are 
selected, a tolerant ~tate can result. The prevention or 
reversal of the immunologial processes which lead to allo-
graft rejection is a central problem in organ transplant-
ation and knowledge of the conditions under which differ-
ent types of immunity can be achieved, is not only of 
theoretical importance, but it also has important appli-
cations to medicine. 
Part I of this introductory chapter will review the 
development of the immunological basis of rejection, its 
effector mechanisms and lymphocyte activation, with a 
special look at organ culture as a method of overcoming 
the barrier or obstacle to allotransplantation. Part II 
will review the induction, maintenance and mechanisms of 
transplantation tolerance. 
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PART I: ALLOGRAFT REJECTION 
1.2 INTRODUCTION 
With certain exceptions, allografts as a rule closely 
resemble isografts for a short time in that they are 
initially accepted by the host. Allografts, however, are 
soon rejected following this initial "take" and the whole 
transplant becomes necrotic and may be sloughed off, 
absorbed or gradually replaced by scar tissue. In man, 
skin allografts, for example, often survive for two to 
three weeks and sometimes longer but are ultimately 
rejected. Exceptions to this inevitable rejection include 
allografts between identical twins or between animals of 
a closely inbred strain, allografts of certain tissues such 
as cartilage, and allografts to certain sites, commonly 
referred to as immunologically privileged sites, such as 
the anterior chamber of the eye (Woodruff and Woodruff, 
1950) and the hamster's cheek pouch (Billingham and 
Silvers, 1962) where allograft survival may be indefinite. 
In addition, there have been a variety of experimental 
and therapeutic procedures aimed at both the graft and 
the recipient, which have had varying success in prolong-
ing allograft survival. Two of the best known procedures 
have been the use of immunosuppression to treat the 
recipient so that it cannot respond to the stimulus of 
the graft, and organ culture to treat the graft so that 
it will be unable to stimulate the host. However, with 
these exceptions and without specific measures being 
taken, the normal fate of all allografts is destruction. 
While various hypotheses have been advanced to explain 
allograft rejection, the evidence indicates that it is 
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likely to be a process involving the interaction of many 
components of the immune system and mediated by both anti-
body and cellular mechanisms. 
1.3 GRAFT REJECTION AS AN IMMUNOLOGICAL PROCESS 
1.3.1. Early ideas 
One of the earliest ideas concerning allograft reject-
ion and first introduced by Ehrlich (1908) working on 
tumour transplantation, was that allografts perish as a 
result of "athrepsia" or the inability of transplanted 
tissue to obtain an adequate supply of essential substances 
from the host. This idea, however, has long been abandoned, 
especially in view of the finding that tissues can be 
cultured in vitro. A number of early investigators, also 
working on tumour transplantation, suggested that heredity 
might play a role in determining the fate of transplants. 
But one of the problems with the early studies was that 
genetically pure stock were not always used, or indeed 
available. 
Loeb (1930, 1945) postulated that the tissues and 
organs of a given organism have in common a chemical 
characteristic, termed the "individuality differential" 
which is peculiar to the individual. This differential, 
he saw as being the product of the genes which controlled 
tissue compatibility, and one of the ways of analysing 
such differentials was by transplantation experiments 
(Loeb, 1930). In an allograft situation two main 
events were seen to occur: the individuality differ-
ential of the transplant evokes the production of toxins, 
and the host tissue then responds to these toxins by a 
cellular accummulation, including the cellular invasion 
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of the transplant. The end result is destruction of the 
transplant (Loeb, 1930). Although Loeb's conclusions have 
been described as sometimes being vague and inadequate 
(Woodruff, 1960; Saunders, 1972), he nonetheless formu-
lated the basic idea that transplantability was essen-
tially a search for biological identity. 
A number .of early attempts were also made in an 
effort to adapt the graft to the host by first growing the 
graft in in vitro culture in the body fluids of intended 
recipients. Stone et al. (1934) reported the successful 
treatment of two patients with parathyroid tetany by 
means of an allotransplant which had been cultured for a 
time in vitro in a medium containing serum and plasma 
from the recipient. Gaillard (1948, 1953, 1954) carried 
out grafting of cultured human foetal parathyroid gland 
tissue in patients suffering from postoperative tetany. 
Of 30 patients so treated over a period of 10 years, 7 
positive results were obtained. However, these results should 
be viewed with some caution and Gaillard himself stressed 
that no histological evidence had been obtained to show 
that the transplants had remained alive. In view of the 
lack of direct evidence for graft survival in these 
clinical studies and the growing concept that rejection 
was due to the host's immune system recognizing geneti-
cally fixed foreign antigens on the tissues, such attempts 
to change the tissue by culture were treated with some 
scepticism and even outright scorn (Medawar, 1957). As a 
result, this approach was essentially abandoned until the 
1970's (Section 1.7.3). 
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1.3.2. The immunological basis of rejection 
The idea that grafts are destroyed as a result of an 
immune process was originally put forward by opponents of 
the athrepsia hypothesis, although it was opposed by Loeb 
(see Woodruff, 1960). However, it was Gorer (1937) working_ 
with mouse tumours, who provided the first clear evidence 
of an immune response to allografts. He demonstrated that 
the rejection of a tumour allograft by a host resulted in 
the formation of antibodies which were capable of agglutin-
ating donor red blood cells. This suggested that the 
antigenic differences between donor tissue and recipient 
played a role in rejection. 
However, it was not until Medawar (1944), working with 
skin allografts in rabbits, that the development of active 
immunity against the foreign tissue or allograft was 
conclusively demonstrated. He found that when skin is 
allograted there is a latent period of several days during 
which the skin graft heals and thrives. This is soon 
followed by infiltration of host lymphoid cells into the 
graft, reaching a peak at about day 8, and complete des-
truction of the graft results by about day 12. This is ' 
known as "first set" rejection. He also demonstrated 
that when a second graft is transplanted to the same 
recipient, the rejection is now greatly accelerated; 
rejection is complete within about 6 days. This is a 
"second set" rejection. This more rapid rejection indi-
cates that the recipient has become sensitised to donor 
antigens. Moreover, further experiments demonstrated 
that this sensitisation is donor specific since grafts 
from another unrelated or third party donor, are rejected 
in first set manner. These exneriments demonstrated two 
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criteria required to establish t hat allograft rejection is 
an immune reaction: specificity and memory. 
It was found that animals could become sensitised with 
other types of tissue from the same donor, thus indicating 
that the genetically controlled antigenic determinants were 
present in most body tissues. Medawar (1946) showed that 
skin allograft~ could be rejected in second set fashion by 
prior sensitisation of the host with donor type blood 
leucocytes. From these findings he inferred that leuco-
cytes and skin expressed common antigens. Other investi-
gators soon reached the same conclusion, using skin, 
kidneys, spleen and lung (see Woodruff, 1960), that such 
diverse tissues and organs have transplantation or histo-
compatibility antigens in common (Section 1.4). 
Burnet and Fenner (1949) developed a theoretical 
model for immune reactivity which was based on the idea 
that contact with foreign antigen led to the expression 
of immune responsiveness. Discrimination between self 
and nonself, or foreign antigens, was learnt during 
ontogeny. This allowed the prediction that exposure to 
foreign antigen during embryonic life should enable that 
individual in later life to be tolerant to that particular 
antigen. The question of the development of immunological 
tolerance is discussed in Part II. 
While Medawar showed rejection to be mediated immuno-
logically, it was the work of Mitchison and his colleagues 
that defined the cellular factor in allograft rejection. 
Mitchison (1953, 1954) showed that immunity to tumour 
allografts could be transferred to other mice by the 
transfer of lymph nodes draining the site of the graft. 
This passive transfer of immunity also satisfied the 
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third criterion to identify the allograft reaction as an 
immunological event. Animals receiving immune lymph 
nodes gave a second set response to a tumour allograft, 
a lymphosarcoma, which was given at the same time. 
Because sensitisation could not easily be transferred by 
serum, this argued for the presence of a predominantly 
cellular immune response to the tissue antigen. 
Various workers have since implicated either the 
antibody or the cellular response as being of predomi-
nant importance ±n transplantation. But it is now clear 
that an either/or situation does not exist and that both 
cellular and humoral factors are involved in the 
rejection process. Their relative importance depends on 
various factors such as the animal model studied, the 
type of allograft, and modification of the host's immune 
system by immunosuppression (Section 1.5). 
1.3.3 The classical view of allograft rejection 
With the establishment that allograft rejection was 
an immunological reaction, the antigens carried on tissues 
were soon regarded as being the barrier to successful 
transplantation. Medawar's interpretation was that once 
the graft healed into place and a lymphatic drainage had 
been established, the graft antigens were transported to 
the regional lymph nodes where they activated a response 
leading to the destruction of the allograft (Medawar, 
1956-57). This explanation embodied the assumption that 
antigenic recognition was sufficient to lead to lympho-
cyte activation and subsequent graft destruction (Medawar, 
1963). 
In its favour was the fact that it appeared to offer 
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an easy explanation, not only for the demonstration that 
blood leucocytes could immunize against a skin allograft, 
suggesting that both expressed common antigens (Medawar, 
1946), but also the induction of acquired tolerance to 
skin allografts by early exposure to donor specific 
antigens (Section 1.10). Medawar's group provided further 
support for this concept by showing that crude, cell-free 
extracts of spleen, thymus and lymph node tissues could 
also provoke the rejection of skin allografts in second 
set fashion (Billingham et al. 1958), suggesting that 
the different tissues all had the same antigenic makeup, 
although it was thought that the antigens were confined 
to nucleated cells (Medawar, 1956-1957). 
The phenomenon of immunological enhancement (Section 
1.13) was a contradiction to this view since the pretreat-
ment of hosts with various preparations of tissues of 
donor origin gave a result opposite to that expected, 
namely, the prolongation of tumour (Snell, 1952; Day 
et al. 1954) and skin (Billingham, et al. 1956b) allo-
grafts. Nonetheless, Medawar's explanation for the 
transplantation barrier was generally accepted and became 
the standard or classical view of graft rejection, 
remaining virtually unchallenged until the early 1970's 
(Section 1.6). 
The strategy of clinical transplantation which devel-
oped during this period is indicative of the wide accept-
ance of this view. Since transplantation antigens alone 
were seen as the major impediment to grafting and, 
the antigenic makeup of a tissue is built into its 
. 
since 
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genetic constitution, it was considered 11 infirm 11 by Medawar 
(1957) to attempt to change this makeup by using such methods 
as organ culture. Consequently, the only approach it seemed 
was to modify the recipient in some way, such as by inununo-
suppression. Procedures for tissue typing were also develop-
ed in an attempt to match both donor and recipient. In 
spite of increasingly sophisticated approaches to tissue 
typing, however, rejection still remains the major cause of 
clinical transplant failure. Tissue matching 
has been very difficult to achieve because of the complexity 
of the transplantation antigens which are coded for by a 
group of genes called the major histocompatibility complex 
(MHC) and because of the large number of possible MHC 
phenotypes. 
1.4 THE MAJOR HISTOCOMPATIBILITY COMPLEX. 
It has now long been recognized that the fate of an 
allograft is determined by the genetic relationship between 
donor and host. The recipient's inunune system recognizes 
certain molecules on the surface of grafted cells as being 
foreign and, in due course, attacks and destroys them. 
These molecules, known as histocompatibility (H) antigens 
are found on nearly all cells and are coded for by a set of 
H genes. In general, grafts exchanged between animals 
that do not differ in the H genes are accepted; those 
between animals differing in the H genes, that is, histo-
incompatible, are rejected. 
In the mouse, the histocompatibility antigens are 
coded for by a series of genes found on chromosome 17 and 
denoted as H-2. Similar complexes of genes have been 
studied in other species, including man, referred to as 
HLA (Bach and Van Rood, 1976), and rat and chicken (Klein, 
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1979). The generic name for these complexes is the maJor 
histocompatibility complex (MHC). 
The existence of the MHC reflects the fact that there 
are other (minor) histocompatibility complexes which are 
less well defined. The minor or non-H-2 antigens are 
controlled by genes which are scattered throughout the 
mouse genome. ,The intensity of an allograft response to 
individual non H-2 antigens is generally less than that 
seen when there are differences at the H-2 level, although 
curnrnulative non H-2 irnrnunogenicity may somtimes equal that 
of the H-2 complex (Graff, 1978). However, the normal 
functions of non H-2 antigens are thought to be non-
irnrnunological. This contrasts with the function of H-2 
antigens which are primarily involved in non-self recog-
nition processes (Klein et al. 1981). 
The MHC of the mouse has been the most extensively 
investigated, particularly by Klein and coworkers, and a 
number of reviews have appeared in recent years (Klein, 
1975; Bach et al. 1976; Munro and Bright , 1976; Silver 
et al. 1976; Klein, 1979; Klein et al. 1978, 1981; 
Hood et al. 1983; Sachs, 1983). Because there are so 
many aspects of MHC research, a brief summary only is 
presented in this section. It should also be noted that 
from the data available the mouse MHC appears to be a 
general model for those of other mammals, including man. 
The H-2 complex is divided into three main regions: 
K, I and D. The I region is further divided into five 
subregions: A, B, J, E and C. H-2 loci can be grouped 
into two classes according to their phenotypic expressions. 
Class I, which comprises the Kand D regions, code for 
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membrane-bound glycoproteins with a molecular weight of 
45,000 daltons. Each molecule consists of a single poly-
peptide chain noncovalently associated with a shorter poly-
peptide called S2 -microglobulin. It has a molecular weight 
of 12,000 daltons and is encoded for by a locus situated 
on chromosome 2 (Klein et al. 1981). Class I antigens are 
expressed on ~lmost all cells of the animal and close 
homology exists in the primary structure of these products 
(Sachs, 1983). 
Class II antigens are those coded for by the I 
region. These are membrane-bound glycoproteins consisting 
of two noncovalently bound polypeptide chains, the a and 
S with a molecular weight of 35,000 and 28,000 daltons 
respectively (Klein et al. 1981). The products of this 
region are referred to as Ia (I region associated) 
antigens. Class II antigens have a more restricted dis-
tribution, being expressed predominantly on B cells and 
on some macrophages (Harnrnerling, 1976; Sachs, 1983) 
although the evidence is growing that these also exist 
on non-lymphoid organs such as skin, lung and liver 
(reviewed by Nixon et al. 1982). 
Both the class I and class II loci are highly poly-
morphic and each display a large range of alleles. For 
example, 56 alleles have been found at the H-2K locus and 
45 at the H-2D locus in the house mouse (Klein, 1979). 
The allelic composition of the H-2 complex is referred 
to as the haplotype and is designated by an alphabetical 
k superscript, for example, H-2 . 
Although early interest in these histocompatibility 
antigens stemmed from their role in graft rejection, this 
is obviously not their normal biological function. It is 
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now known that these antigens play an important role in 
the body's defence system against its own cells infected 
with viruses or turned cancerous. The work of Zinkernagel 
and Doherty (Zinkernagel and Doherty, 1974a,b; Doherty 
and Zinkernagel, 1975) established that cytotoxic T cells 
made in one inbred strain of mice would kill virus 
infected cells , from that strain only. Thus, for example, 
an effector lymphocyte sensitised against vaccinia virus 
infected H-2a cells, destroys vaccinia infected H-2a cells 
but not, for example, vaccinia infected H-2b cells. They 
found that this "restriction" on killing, a term generally 
applied to the limiting effects of MHC on the immune 
response to antigen, was controlled by class I H-2 genes. 
The sensitised T cells recognise a complex of foreign 
(viral) and self (H-2) antigen, although whether this 
recognition occurs via a single receptor or two receptors 
(one for the viral antigens and the other for the H-2 
molecule) is still a matter of debate. _H-2 restriction 
has also been described for T helper cells which, in 
order to help B cells, are first activated by antigen on 
the presenting cell, such as a macrophage, and then 
recognise the H-2 molecules on the presenting cell. In 
contrast to cytotoxic T cells, however, the molecules 
recognised by helper cells are controlled by class II 
genes, that is, loci on the I region (Klein et al. 1981). 
The MHC molecules, therefore, serve as structures which 
are recognised in conjunction with antigen by T cells. 
Thus, a major biological role for the MHC is to signal 
changes in self to the immune system. 
The H-2 has now been shown to control a number of 
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other functions such as collaboration between T and B cells, 
the reactivity of mixed lymphocyte reaction and, in partic-
ular, controls the activation of different subclasses of T 
lymphocytes. These subclasses are characterized by the 
expression of T cell specific Lyt antigens - Lyt 1, Lyt 2 
and Lyt 3 (Cantor and Boyse, 1975, 1976). T cells activated 
against class I antigens carry the Lyt l+ 2+ 3+ phenotype 
and those responsible to class II antigens express only the 
Lyt l+ 2- 3 antigen. Contrary to early reports, all T 
cells have now been shown to carry some Lyt 1 (Ledbetter 
et al. 1980; Nakayama, 1982). The Lyt molecules of the 
mouse have been particularly of great importance in 
defining functionally distinct T cell , subsets (reviewed 
by Swain and Dutton, 1980 -r see Chapter 4). The variation in 
immune response between some mouse strains, such as the 
ability to produce different levels of antibodies to 
a given antigen, is controlled by immune response (Ir) 
genes, many of which also map in the I region of the H-2 
complex (Klein et al. 1981). The question of how Ir genes 
may operate is discussed by Blanden (1980). 
In an attempt to simplify the "traditional" view of 
the maze of regions and subregions, Klein and his coll-
eagues (Klein, 1981; Klein et al. 1981) have recently 
proposed a simpler interpretation of the H-2 complex. 
They suggested, firstly, that a single H-2 locus controls 
a variety of traits, that is, loci are pleiomorphic and, 
secondly, that the basic function of the H-2 complex is 
to guide T cells in their role of distinguishing self 
from nonself. H-2 controlled traits, such as rejection 
of allografts, are artifacts derived from this basic 
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function. These suggestions led them to propose a simpler 
nomenclature for the MHC - a proposal which has also been 
supported by Mitchison (1980, 1981). 
1.5 EFFECTOR MECHANISMS IN GRAFT REJECTION 
With the establishment that the rejection of allo-
grafts is an immunological reaction, numerous studies were 
soon undertaken with the aim of elucidating the mechanisms 
of rejection. By the late 1950's, however, the debate on 
the respective roles of cellular and humoral mechanisms 
had reached the general consensus that the latter played 
little, if any, role. While humoral antibodies were seen 
as important in the rejection of an allograft composed of 
dispersed cells (Stetson, 1963), solid tissue grafts were 
destroyed by cell-mediated mechanisms (Mitchison, 1954; 
Snell, 1957; Brent, 1958). This view persisted into the 
early 1960's when a number of observations which had led 
to this interpretation were then being challenged. 
It now seems quite unlikely that allograft rejection 
is brought about solely by cell mediated or humoral 
mechanisms. Both play a role and the relative contribution 
of each of these components depends on such factors as 
the animal model, the type of tissue used for grafting 
and whether the response induced is a primary or secondary 
response. 
1.5.1. Role of antibody 
The idea that humoral immunity was of little import-
ance in allograft rejection, was based largely on experi-
ments which demonstrated a failure in general to: 
(i) induce allograft rejection by passive serum 
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transfer - a failure which persisted even when 
the serum dosage, timing and route of injection 
were varied (Billingham et al. 1954; Billingham 
and Brent 1956; Stetson, 1963), 
(ii) induce rejection of various endocrine tissues, 
tumours and split skin allografts placed in 
difftision chambers - a failure which persisted 
even when hosts were sensitised against the 
donor tissues (Algire et al. 1954, 1957; 
Woodruff, 1957; Brooks et al. 1960), 
(iii) passively transfer skin allograft immunity by 
sensitised cells confined within diffusion 
chambers (Billingham et al. 1963; Wilson et al. 
1966), and 
(iv) demonstrate haemagglutinating and cytotoxic 
antibodies in skin allografts (Brent, 1958; 
Woodruff, 1960). 
However, by the early 1960's, a number of reports 
emerged which showed that under certain circumstances, 
humoral antibodies could play an important part in the 
rejection of solid tissue grafting. In earlier work, 
aside from some technical difficulties, the skin graft 
model was probably not the best model to demonstrate the 
effect of antibody in rejection because the graft is 
isolated from circulation prior to revascularization and 
the antibody may not reach the graft (Najarian and Poker, 
1972). Also, subsequent work with millipore chambers 
indicated that, although antibody and complement pene-
trated the chamber with difficulty, enclosed tissue could 
in fact be destroyed by antibody when their level was 
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appropriate (Algire, 1959; Amos and Wakefield, 1959}. 
A number of reports also emerged which showed that 
serum transfer caused accelerated allograft rejection. 
Kretschmer and Perez-Tamayo (1961) demonstrated that the 
rejection of skin allografts in rabbits was significantly 
accelerated by the local administration of serum obtained 
from immunized animals, and Dubernard et al. (1968) 
induced the rejection of an isologous kidney in dogs by 
the transfusion of immune serum. There is now a large 
body of evidence, both from human and animal transplantation 
studies, using skin, kidneys, heart and other tissues and 
organs, for the involvement of antibody in allograft 
rejection. 
1.5.1.1. Hyperacute rejection of human kidney allografts 
Convin8·ing evidence for the role of antibody has been 
obtained with the demonstration of hyperacute rejection 
of kidney allografts in human and animal studies. Kiss-
meyer-Nielsen et al. (1966) were the first to show hyper-
acute rejection of human kidney allografts in two patients 
from a series of 21 consecutive transplants. This reject-
ion was attributed to circulating antibodies in the serum 
of recipients which were reactive against donor antigens -
both patients had undergone blood transfusions before 
transplantation. The pathological findings in the two 
patients showed cortical necrosis with extensive glomer-
ular thrombosis. Moreover, the absence of cellular 
infiltration was interpreted as indicating a positive 
effect by humoral antibodies. 
Williams et al. (1968) in a similar human study, 
found that this form of rejection is very rapid, occurring 
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within hours or even minutes of removing the clamps from 
the blood vessels. Its characteristic feature is the 
accummulation of large numbers of polymorphonuclear (PMN) 
leucocytes in the graft vasculature. Where rejecting grafts 
were left in situ, progressive fibrin deposition, thrombosis 
and widespread cortical necrosis occurred. They were also 
able to detect qntibodies in eluates from renal allograft 
tissue. 
This very rapid onset of the reaction, the elution of 
cytotoxic and agglutinating antibodies from graft renal 
tissue (Williams et al. 1968; Pedersen and Morris, 1974) 
and the lack of mononuclear cell infiltration into the 
grafts, argued against the involvement of cell mediated 
immunity in hyperacute rejection. It should also be noted 
that antibodies in the form of circulating immune complexes 
may also play a role, especially in late deterioration of 
renal grafts (Milgrom, 1977). These and other investiga-
tions have led various workers (Williams et al. 1968; 
Winn et al. 1973; Hurne, 1974; Bogman et al. 1980) to 
argue that hyperacute rejection is a result of the inter-
action of antigraft antibodies with the endothelium of the 
graft vasculature (Chapter 3). 
1.5.1.2. Hyperacute rejection in animal studies 
Hyperacute rejection studies have since been extended 
to animal models using the passive transfer of antiserum. 
Such rejection has been demonstrated with kidney allo-
grafts in rats (French, 1972; Hart et al. 1980; 
Winearls et al. 1980), rabbits (McDowall et al. 1973) and 
sheep (Pedersen and Morris, 1974); skin allografts in 
mice (Koene et al. 1973; Gerlag et al. 1975, 1980; 
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McKenzie and Henning, 1978), and rats (Jooste and Winn, 
1975); and with xenografts of kidney (Chavez-Peon,et al. 197], 
heart (Burdick et al. 1979), skin (Jooste et al. 1973, 1981a, 
b; Winn et al. 1973; Jooste and Winn, 1975; Gerlag et al. 
1980; Berden et al. 1981) and pancreatic islets (Frangipane 
et al. 1977a,b; Naji et al. 1979a,b). That antibodies can play an 
important role in the destruction of grafts is clearly illus-
trated in these studies. However, these studies have also 
shown that the sensitivity of grafts to rejection can vary 
enormously depending on the interval of time between trans-
plantation and the injection of antisera, its dosage and 
the type of allograft. 
Unlike kidney allografts, freshly transplanted skin 
is resistant to anti-donor alloantibody. Gerlag et al. 
(1975) showed that mice could reject skin allografts only 
when injected with antiserum and rabbit complement from 
day 4 post transplantation, with the greatest sensitivity 
to rejection on days 7 and 8. ·-With rat skin transplanted 
to mice or allografted to rats, antisera injected during 
the first week after grafting have no detectable effect 
on survival times, whereas sera given at about 2 weeks 
after transplantation are particularly effective (Jooste 
et al. 1973, 1981a; Jooste and Winn, 1975; Gerlag et al. 
1980). These studies found that while grafts are 
initially resistant to damage, they rapidly develop sen-
sitivity and after a short peak at about two weeks, this 
sensitivity is gradually lost over a period of several 
weeks. Skin grafts surviving beyond 35 to 40 days become 
resistant to antisera (Jooste and Winn, 1975). 
The initial resistance of skin grafts was explained 
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by the time taken for the establishment of an adequate 
vascular network between graft and host (Jooste et al. 1973; 
Gerlag et al. 1975; Jooste and Winn, 1975). This . is con-
sistent with reports that primary healing and vascularization 
of skin grafts is completed by day 4 after transplantation 
(Medawar, 1944; Jooste et al. 1981a). However, as Jooste 
et al. (1981a) point out, this could not be the whole 
explanation as it would explain the resistance only for the 
first 4 days after transplantation, whereas sensitivity to 
rejection is delayed for a further 2 to 3 days. They 
postulated that this early period of resistance is due to 
the immature properties of the young, regenerating vessels 
in the graft. This explanation for the early insensitivity 
of skin to rejection is also consistent with observations 
that primary vascularized grafts such as kidneys and heart, 
in which there is little or no formation of new vessels, 
are highly sensitive to humoral antibodies immediately 
following transplantation (French, 1972; Burdick et al. 
1979; Jooste et al. 1981a). 
The suggestion which emerges from these studies then, 
is that the antibody mediated attack is targeted on the 
vascular endothelium of donor organs and tissues. This 
would explain the changes in sensitivity with time seen 
in skin allografts. Following the initial establishment 
of a vascular connection between the host and the graft, 
the skin tissue rapidly becomes sensitive to antibody 
mediated rejection but, as its vascular endothelium is 
replaced by donor cells, the graft gradually loses its 
sensitivity. Conversely, the uniform sensitivity of 
heart allografts, was explained on the basis that 
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extensive endothelium replacement does not occur (Burdick 
et al. 1979). More recent reports have provided good 
evidence for this proposal of endothelium replacement and 
is discussed in Chapter 3. 
Several studies have also suggested that the mechanism 
of hyperacute rejection is dose dependent. While studies, 
particularly in the rat model, have shown a requirement ·for 
a heterologous source of complement (Section 1.5.1.3), 
Fabre and Morris (1974) found that hyperacute rejection can 
occur in the DA to Lewis strain combination in the absence 
of this additional complement, provided a large enough 
dose of antiserum is given at the time of transplantation. 
Similarly, McDowall et al. (1973) suggested that antiserum 
dosage is likely to be a significant factor since, depending 
on dose, either hyperacute rejection or enhancement can be 
produced in rabbits carrying kidney allografts. A 
relatively high dose (40 to 60ml) of antidonor alloantibody 
led to hyperacute rejection,whereas lower doses either had 
no effect or caused graft enhancement. 
1.5.1.3. Complement dependence 
The complement system has also been shown to play an 
important role in hyperacute rejection. French (1972) 
demonstrated that hyperacute rejection could be produced 
in AS rats carrying August kidney allografts, when recip-
ients were given anti-August alloantiserum and guinea pig 
serum as an additional source of complement. Alloantibody 
in the absence of guinea pig serum, failed to produce 
hyperacute rejection - a failure attributed to a defective 
complement pathway or inadequate fixation of native 
complement to the graft (french, 1972; Morris, 1980). 
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The complement activity of guinea pig serum was essential 
to the production of hyperacute rejection, since this 
activity was lost by heating the serum to 56°C for 30 mins 
(French, 1972). More recently, Hart et al. (1980) and 
Winearls et al. (1980) reported similar findings in the 
DA to Lewis rat strain combination. Without an additional 
source of complement, therefore, rats appear to be 
peculiarly resistant to this form of rejection. Incident-
ally, this resistance to antibody damage has probably been 
a major reason why the rat has proved such a good model 
to produce immunological enhancement (Section 1.13). 
This complement dependence has also been demonstrated 
in hyperacute rejection of skin allografts in mice (Koene 
et al. 1973; McKenzie and Henning, 1978). Interestingly, 
guinea pig complement was ineffective in hyperacute 
rejection of mouse skin allografts whereas rabbit comple-
ment was effective, thereby illustrating that the source 
of complement is an important factor (Koene et al. 1973). 
Koene and McKenzie (1973) showed that there is an in vitro 
difference in cytolytic efficiency between the sources of 
complement and proposed that this difference was due to 
guinea pig complement requiring the activation of 2 
adjacent cell surface sites for cytolysis, whereas rabbit 
complement requires only one site. 
The prevention of the activation or modification in 
some way of the complement system, can prevent or 
considerably delay hyperacute rejection. Winn et al. (1973) 
found that hyperacute rejection of rat skin grafted onto 
mice was inhibited if the recipients were treated with 
chicken-anti-rat serum (a non-complement-fixing anti-
donor antiserum), or with F (a b')2 antibody fragments. 
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Pretreatment with cobra serum factor which depletes 
circulating complement levels, had the same inhibatory 
effect and rejection was also delayed in mice with a genetic 
deficient CS complement component. They suggested, however, 
a secondary, though essential role for complement. This 
role lies in its ability to produce chemotactic factors 
which may attract the polymorphs. This suggestion was 
based on their evidence that, despite normal levels of 
complement, there was an absence of graft damage when PMN 
leucocytes were reduced by pretreatment of recipients 
with nitrogen mustard or anti-PMN serum. More recently, 
Berden et al. (1981), also using skin xenografts in mice, 
showed that although complement activation is important 
in graft destruction, it is not essential. The inhiba-
tory effect of cobra venum factor treatment and CS 
deficiency can be overcome by raising the mouse anti-rat 
serum dose. Moreover, rejection could also be elicited 
by the non-complement fixing IgG subclass. 
Donor specific antibody may contribute to graft 
rejection by the process of antibody dependent cell 
mediated cytotoxicity which does not require complement 
fixation. This phenomenon reflects the cytotoxic ability 
of a subpopulation of cells with Fe receptors against 
antibody (most commonly IgG) coated targets (MacLennan, 
1972; Section 1.5.2.2). 
1.5.2. Cellular rejection mechanisms 
As already indicated, the notion of the cellular 
basis of allograft rejection came from the early studies 
of Mitchison (1953, 1954, 1955) who showed that immunity 
to tumour allografts could be transferred by lymph nodes 
draining the site of the gra f t. That is, accelerated 
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rejection of a tumour allograft could be transferred to a 
naive animal by cells from these nodes. Billingham et al. 
(1954) used a similar experiment in an analysis of the 
transfer of immunity to skin allografts and they too found 
that immunity can be passively, or to use their phrase, 
"adoptively" transferred, thereby confirming Mitchison's 
observations. Further evidence for the concept of the 
cellular basis of allograft rejection came from studies 
which showed that mice made neonatally tolerant and now 
carrying skin allografts of the tolerated genotype, would 
reject these grafts if injected with normal lymphoid 
cells syngeneic with the recipient. An accelerated 
rejection occurred if the lymphoid cells came from a 
sensitised animal (Billingham et al. 1963). Gowans et al. 
(1963) used a similar experimental system to show that 
rats rendered tolerant by neonatal inoculation of F1 
hybrid marrow cells and carrying long-standing skin 
grafts, will have these grafts rejected soon after the 
injection of syngeneic thoracic duct cells. 
1.5.2.1. Role of T cells 
While rejection is a process involving the inter-
action of many components of the immune system, . there is 
good evidence that the rejection process can be triggered 
by sensitised T lymphocytes. The evidence for the role 
of T lymphocytes and requirement for thymus function in 
graft rejection, comes from several sources. For example, 
it has been shown that neonatal thymectomy or the congeni-
tal absence of the thymus results in poor graft rejection. 
Miller (1961) demonstrated that skin allograft rejection 
is severely impaired in neonatally thymectomized mice. 
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Reconstitution of the thy~us with a foetal thymus of simi-
lar histocompatibility, restored the recipient's capacity 
to reject skin allografts. Kindred (1971) and Wortis (1971) 
showed that skin allografts on nude micererrBined intact for 
the period of the survival of the recipients, which varied 
between 4 and 10 weeks after grafting. Mice homozygous 
for the mutation nude lack a thymus (Pantelouris, 1968) 
and are deficient in lymphocytes in the thymus dependent 
areas of the spleen and lymph nodes (de Sousa et al. 1969), 
as well as having a marked depletion of cells bearing the 
cell surface antigen theta (8) found on thymocytes and 
thymus dependent cells (Raff and Wortis, 1970). Manning 
et al. (1973) extended these observations by :showing that 
nude mice accepted for their lifetime a wide range of 
skin xenografts, including human, bird, reptile and 
amphibian. The importance of the thymus was again 
established by showing that thymus implantation 
enabled nude mice to reject such xenografts. 
Workers have also purified T lymphocytes, either by 
virtue of surface markers like Thy 1 in the mouse (Reif 
arrlAllen, 1963; Raff and Wortis, 1970) or by the ability 
of human T cells to bind to sheep red blood cells (Jondal 
et al. 1972) and have shown that these cells are necessary 
for the development of cytotoxic lymphocytes. 
Recent evidence for the role of T cells has come from 
the work of Hall and his colleagues who studied the cellu-
lar requirements for graft rejection by using the adoptive 
transfer technique and testing known cell populations for 
their ability to cause rejection of heart allografts in 
irradiated rats. They established that Ig-, recirculating, 
long-lived T lymphocytes restored the graft rejection 
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response. Neither B lymphocytes nor antibodies were 
required for the first set rejection (Hall et al. 1978a). 
The transfer of cells from sensitised animals showed that 
memory was carried by long-lived, non-recirculating, Ig 
small lymphocytes (Hall et al. 1978b). 
More recent reports from Loveland and his coworkers 
have presented evidence for the role of particular T cell 
subsets and these findings are discussed in Chapter 4. 
Analysis of the particular cells involved in graft 
rejection is of increasing importance with development 
of monoclonal antibodies which may be capable of modify-
ing the immune response to prevent the rejection of the 
graft. 
1.5.2.2. Cellular inflammatory response 
Acute rejection of allografts is associated with a 
wide variety of pathological patterns and as already 
indicated, is thought to be mediated by cellular immune 
mechanisms - an interpretation supported histologically 
by the dense, host cellular infiltration into the 
rejecting graft (Lindquist et al. 1971; Hebertson, 1973). 
However, although the cell-mediated immune response to 
alloantigens has been widely studied using cells of the 
peripheral lymphoid system and analysing their functions 
in vitro, the immune mechanisms operating within the allo-
graft itself have received relatively less attention - a 
situation brought about by the difficulty in isolating 
functionally viable, infiltrating host cells. The histo-
logical techniques have been limited in distinguishing 
the different kinds of mononuclear cells, let alone 
performing any quantitative evaluation of the different 
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cell types or subpopulations. In recent years, however, 
with the development of mechanical disruption and enzymatic 
methods to recover cell infiltrates, it has been possible 
to show that the inflammatory response consists of a 
heterogeneous collection of cell types, including mono-
cytes, macrophages, Band T lymphocytes, null cells and 
polymorphs (Strom et al. 1977; Tilney et al. 1979~; 
von Willebrand et al. 1979a; Hayry et al. 1979; 
Carpenter, 1981). Other methods of cell recovery, 
such as the sponge matrix allograft model (Roberts and 
Hayry, 1976) which allows a relatively higher~. recovery 
rate of cells, and the multicellular tumour spheroid 
model (Lord and Nardella, 1980), have been used to 
quantitatively recover and study the infiltrating cells. 
These methods have the added advantage in that they avoid 
proteolytic digestion which would otherwise destroy many 
surface markers. 
The relative accummulation of each cell type within 
the graft is influenced by such factors as the time after 
transplantation when the infiltrate is analysed, the type 
of tissue grafted and even the method of cell recovery 
(reviewed by Carpenter, 1981). Thus, for example, in 
rejecting rat heart allografts, the predominant cell t ype 
at day 4-6 post transplantation when cellular infiltration 
has peaked, were T cells (Strom et al. 1977). Tilney et al. 
(1979~ reported that lymphocytes comprised 75-90 % of cell 
infiltrates recovered from rejected human renal allografts, 
and lymphocytes were also the major population infiltrating 
the sponge matrix allograft (Roberts and Hayry, 1977). In 
contrast, studies using the multicellular spheroid model 
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have found macrophages to be the predominant infiltrating 
host cell, whereas lymphocytes were present in low numbers 
(Lord and Nardella, 1980; Sordat et al. 1980). 
Infiltrating cells have been tested for their capacity 
51 to lyse Cr-labelled target cells in vitro as a way of 
identifying potential rejection mechanisms and it has been 
shown that, in addition to T lymphocytes, several other 
infiltrating cell types have the potential to express 
effector cell function. Strom et al. (1977) showed that 
by treating harvested cells from rejecting rat heart 
allografts with T cell specific antiserum, the predomi-
nant killer cell present during the early post trans-
plantation period were T lymphocytes. This was simi-
larly demonstrated in the mouse sponge matrix model 
(Ascher et al. 1979), although in this model, macro-
phages and monocytes were also active in target cell 
lysis (Roberts and Hayry, 1977). In addition, Strom 
et al. (1977) demonstrated that a separate population 
of Fe receptor-positive cells and distinct from macro-
phages, lysed cells coated with anti donor IgG. There-
fore, antibody-dependent cell-mediated cytotoxicity 
has been shown to represent another possible mechanism 
for allograft rejection. The factors which regulate 
the non-specific inflammatory response are unknown, 
although both chematoxis and lymphokine mediation 
have been suggested (Ascher et al. 1979). 
- 29 -
1.6 LYMPHOCYTE ACTIVATION 
Once the immunological basis of allograft rejection 
was demonstrated, it was postulated that grafts were 
rejected because transplantation antigens from the graft 
were carried to the recipient's lymph nodes which then 
led to lymphocyte activation and subsequent graft des-
truction (Section 1.3.3). This idea was based on the 
widely held assumption that antigen alone was sufficient 
to cause lymphocyte activatioli (Medawar, 1963). From 
the late 1960's, however, this assumption came under 
question and considerable evidence has since accummu-
lated which now makes the assumption untenable. In its 
place, a two-signal model for T cell activation has been 
developed in which both antigen and lymphokine, a 
hormone-like molecule produced by lymphoreticular cells, 
play a co-equal role in T cell activation. Experimental 
evidence which supports this model comes from early 
investigations into the graft versus host (GVH) reactions 
and, more recently, from studies on the mechanisms of 
T cell activation in vitro. These studies have been 
extensively reviewed elsewhere (Simonsen, 1962; 
Lafferty and Jones, 1969; Lafferty, 1980; Lafferty 
et al. 19 8 0, 19 8 3a) and a summary only is presented in 
this section. 
1.6.1. Insufficiency of antigen alone for lymphocyte 
activation 
Studies of the GVH reaction carried out in the late 
1960's renewed interest in the role of lymphocytes in 
allograft rejection. Elkins and Guttman (1968) suggested 
an important role for the cells because of the GVH 
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reaction produced when normal parental Lewis strain rat 
spleen cells were introduced under the kidney capsule of 
Lewis kidney freshly grafted into F1 hybrid hosts. 
Studies by Lafferty and Jones (1969) into the species 
specificity of GVH reactions in the chicken embryo began 
to question the assumption that antigen alone was 
sufficient to lead to an allograft rejection. They found 
that lymphoid cells taken from adult chickens and intro-
duced on the chorioallen:toic membrane (CAM) of genetic-
ally different chick embryos led to a GVH reaction in the 
chick embryo - a reaction which normally leads to the death 
of the embryo or newborn chick, and which occurs because 
of the chick's immaturity. This type of 
reaction is one which had already been shown to be an 
immune response; it is produced only when adult lymphoid 
cells are placed on the recipient and no response is 
produced when cells are placed in syngeneic embryos 
(Simonsen, 1962). Lafferty and Jones (1969), further 
demonstrated that xenogeneic lymphoid cells from ducks, 
pigeons or sheep failed to produce the GVH lesions onto 
CAM of the chicken embryo - a failure which had earlier 
been observed by other workers (Simonsen, 1957; Payne 
and Jaffe, 1962). In these earlier studies it was a 
failure to observe splenomegaly in chicks - another assay 
for GVH reactions. 
Thus, it seemed that contact with antigen did not 
always lead to a damaging reaction in the host. 
Conventional ideas on transplantation biology would have 
predicted that pigeon cells should react even more 
strongly than allogeneic chicken cells. Failure to do 
so would have to be due to a failure of the cells to 
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survive and function in the foreign environment (Simonsen, 
1962). This failure to cause a GVH reaction was soon shown, 
however, not to be due to the cells' inability to survive 
or react immunologically in the embryo. Sheep lymphocytes 
reacted positively in the skin of other sheep, and pigeon 
spleen cells, although they could not react against the 
chicken host on the CAM, could destroy foreign pigeon 
embryo bones also transplanted on the CAM (Lafferty and 
Jones, 1969). Further studies in the chicken embryo 
showed that these transplantation reactions involved an 
interaction between foreign lymphocytes and blood cells 
in the target tissue. Heart muscle from incompatible 
embryo was not attacked if the blood cells were washed 
out by perfusion, but if perfused with embryonic spleen 
cells before transplantation, the graft was rapidly 
rejected. Similarly, the destruction of bone tissue 
could be blocked by inactivating the blood forming cells 
of the marrow by gamma irradiation (Lafferty and Jones, 
1969). Work in other species also indicated that GVH 
reactions depend on the interaction of lymphocytes with 
foreign haematogenous cells (Elkins, 1971). 
The conclusion drawn from these studies was that 
antigen alone was not a sufficient requirement, and that 
activation of the allograft response required both 
antigen recognition and the passage of a specific 
inductive molecule between the interacting cells 
(Lafferty et al. 1972). 
A similar conclusion indicating that T cell acti-
vation is a 2 signal process was arrived at from studies 
of T cell activation in vitro. The in vivo response to a 
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tissue allograft is much more complex than in the in vitro 
reaction because of the greater range of potential cellular 
interactions. Nonetheless, the mixed lymphocyte culture 
(MLC) and cell mediated lympholysis (CML) assays have been 
widely used and it is commonly accepted that the in vitro 
lysis of allograft target cells by primed cytotoxic cells 
is a good model for studying the rejection of allografts 
(Bach et al. 1976). Using such techniques, several 
important observations have been made: 
(i) Only metabolically active cells are capable of 
stimulating T cells. Cells killed by a variety 
of procedures, including UV irradiation and 
treatment with chemical agents, do not stimulate 
incompatible T cells, even though such cells 
have been shown to express transplantation 
antigens (Lafferty and Jones, 1969; Hardy 
and Ling, 1969; Schellekens and Eijsvoogel, 
1970; Lindahl-Kiessling and Safwenberg, 1971; 
Wagner et al. 1973; Lafferty et al. 1974). An 
additional factor to antigen has been postulated 
(Lafferty and Jones, 1969; Schellekens and 
Eijsvoogel, 1970; Lindahl-Kiesling and 
Safwenberg, 1971; Batchelor et al. 1978). 
(ii) Only certain viable cells are capable of stimu-
lation. Nonlymphoid cells such as erythrocytes 
(Hardy and Ling, 1969), fibroblasts, PMN 
leucocytes (Greineder and Rosenthal, 1975), 
epithelial tumours (Talmage et al. 1977), and 
platelets (Lindahl-Kiessling and Safwenberg, 
1971}, do not stimulate allogeneic lymphocytes 
(iii) 
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even though they can be shown to express MHC 
antigens. 
The capacity to stimulate is restricted phylo-
genetically. The response to xenogeneic leuco-
cytes is either poor or non-existent in spite of 
the much greater antigenic disparity (Lafferty 
and Jones, 1969; Wilson and Nowell, 1970; 
Woolnough et al. 1979). 
Clearly then, these studies all indicated that antigen 
recognition alone was not sufficient for T cell activation 
by allogeneic cells; something else was also required. 
Attempts to explain the requirements for this activation 
have led to the development of 2 basic models. 
1.6.2. Models for T cell activation 
The two models which have been developed for T cell 
activation are both based on the Bretscher and Cohn (1970) 
suggestion that two signals are required for lymphocyte 
activation. The basic difference between the two models 
is their perceived origin of the second signal. 
(i) The Lafferty model. This was proposed by Lafferty and 
his coworkers (Lafferty and Cunningham, 1975; Lafferty and 
Talmage, 1976; Lafferty et al. 1978), although support for 
the requirement of 2 signals was independently proposed by 
other investigators (Lindahl-Kiessling and Safwenberg, 
1971; Batchelor et al. 1978). Simply stated, lymphocyte 
activation was seen as a two signal process in which the 
stimulating cell, and one which presents foreign antigen, 
plays a unique role in regulating this response. The 
model postulated that the stimulator cell, designated s+, 
was required for the presentation of antigen to the 
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potentially responsive T cell (signal 1). + The S cell 
simultaneously also provides an inductive molecule which 
expresses costimulator (CoS) activity (signal 2). Toget-
her, signal 1 and signal 2 lead to activation of the T 
lymphocyte; neither signal alone is sufficient for T cell 
activation (Lafferty and Cunningham, 1975; Lafferty and 
Woolnough, 1977). 
Experimentally, viable cells of the lymphocyte-
+ macrophage class were shown to express the S phenotype 
(Greineder and Rosenthal, 1975; Lafferty and Cunningham, 
1975; Talmage et al. 1977). Non-lymphoid and metabolic-
ally inactive S+ cells, were unable to stimulate. These 
were designated S cells. The inability of S cells to 
stimulate, however, was shown to be capable of being 
rectified by adding to the cell cultures a lymphokine 
containing supernatant obtained from concanavalin A (ConA) 
activated spleen cells (Talmage et al. 1977; Lafferty 
et al. 1978; Shaw et al. 1980). This was clearly a demon-
stration for the existence of a lymphocyte costimulator or 
signal 2. The presence of the lymphokine-containing super-
natant by itself was not sufficient to activate T cells. 
For a discussion of the history, nature and function of 
lymphokines, their production and release, see Andrus et al. 
(1980), Lafferty et al. (1980), Watson et al. (1980), 
Waksman (1980) and Watson (1981). In order to account for 
the phylogenetic specificity of cell reactivity, it was 
proposed and later shown that Cos was a species-specific, 
hormone-like molecule or lymphokine (Lafferty and Cunning-
ham, 1975; Lafferty and Woolnough, 1977; Woolnough et al. 
1979). That is, although individuals could respond to xeno-
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antigens, they normally fail to do so because the S+ cells 
presenting these antigens fail to provide an effective or 
homologous signal 2. 
The 2 signal model has since been incorporated into a 
broader theoretical system to describe the process of clonal 
selection and expansion. Using a symbolic terminology, the 
characteristics of the immune system that follow from these 
postulates can be described (Lafferty et al. 1983~). 
(ii) The Bach model. This model originally proposed by 
Bach and his colleagues (Bach, 1973; Bach et al. 1976, 
1977), also postulates 2 signals. Binding of class I 
antigen on the stimulating cell by the cytotoxic cell 
converts the latter to a "poised" state. This,however, . lS 
not sufficient for activation. To bring it to an activated 
cytotoxic cell requires a second signal from an activated 
helper T cell. According to the original model, the helper 
cell, is itself activated following binding of its receptor 
to a class II antigen on the surface of the stimulator cell. 
The help given by the helper to the "poised" T cell, might 
be delivered either by direct cell-cell contact or by a 
"collaborating" factor which is secreted from the stimu-
lated helper T cell. This would provide signal 2. Thus, 
in the Bach model, the stimulator cell has a less direct 
role in the stimulation of cytotoxic T cells. This model 
has been supported more recently by Brent et al. (1981) 
who found that mouse liver parenchyma cells, which were 
shown to lack class II antigens, failed to cause an 
accelerated rejection of skin grafts. They postulated 
that this lack of irnrnunogenicity was "directly attributable" 
to the absence of class II antigens, that is, these 
antigens provide the seconc signal. 
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As a general explanation for T cell activation, the 
model has several problems. The helper and cytotoxic T 
cells are regarded as initially exclusive T cell subsets, 
but there is now considerable evidence which suggests it is 
incorrect to make rigid distinctions between the properties 
of cytotoxic and helper T cells. T cells activated to 
either class I or class II alloantigens can be shown under 
appropriate conditions, to express both helper and cyto-
toxic potential (Section 4.1). Moreover, experimental 
observations have not supported their proposal that 
recognition of class II alloantigens activates helper T 
cells and hence provides the second signal for cytotoxic 
T cell activation. Lafferty et al. (1978) have shown that 
the stimulator tumour cells P815 and EL-4, neither of 
which express detectable class II antigens, can still 
generate strong cytotoxic T cell responses. That is, 
cytotoxic T cell activation can occur without a require-
ment for helper T cells. Cantor and Boyse (1975) have 
also reported cytotoxic T cell activation without the 
+ -requirement for the Lyt l 2 helper cell and Bach and 
Alter (1978) have themselves demonstrated cytotoxic T 
cells in MLC's where the only difference between the 
stimulating and responding population was in class I 
antigens. As a result of these findings, the original 
Bach model was extended to provide an alternative path-
way for cytotoxic cell activation in the presence of 
only class I antigen differences (Bach and Alter, 1978). 
Nonetheless, this modification is not compatible with 
the evidence that UV inactivated cells which carry 
class II antigens, are non irnrnunogenic (Lafferty et al. 
1974; Chapter 6). The second signal is Cos activity 
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which can be provided by lymphok ine. 
In both models the stimulator cell, either actively or 
less directly, is of critical importance. Because such 
cells on the graft are positive for class II antigens it 
follows that such class II positive cells will make up an 
important irnrnunogenic component of the graft. However, 
although there is a strong correlation between class II 
antigen positivity and expression of S+ phenotype, 
exceptions do occur and reveal that recognition of 
class II antigen itself cannot provide the source of the 
second signal required for cytotoxic T cell activation. 
That is not to say that class II positive cells are 
unimportant in the T cell activation process. For 
example, inactivation of these cells with antisera and 
complement removes the cells' stimulating capacity 
(Yamashita and Shevach, 1977). However, not all class 
II positive cells stimulate. B lymphocytes were not 
able to reject rat islet (Zitron et al. 1981a) or rat 
kidney (Lechler and Batchelor, 1982) allografts. On 
the other hand, some class II negative cells, such as 
P815, also stimulate. Thus, a distinction needs to be 
clearly drawn. The importance of the stimulator cell 
does not lie in its possession of class II antigens 
per se. Rather, such antigens happen to be a marker 
+ for the cell that expressses the S phenotype, that 
is, the cell that can provide a source of Cos activity 
or signal 2. Experimental evidence supports the 
dendritic cell, a class II antigen-rich cell, as the 
most likely candidate for the stimulator cell (Hart and 
Fabre, 198la,b; Steinman, 1981; Lechler and Batchelor, 
1982). 
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1.7 OVERCOMING THE OBSTACLE TO TRANSPLANTATION 
Excluding the rather limited technique of transplanting 
tissues to privileged sites (reviewed by Barker and Billingham, 
1977), theoretically there are really only two basic 
approaches which may be taken to avoid allograft rejection; 
treatment of the graft and treatment of the recipient. 
Both procedures have been widely used, the former moreso 
experimentally, and each is based on a different perception 
of the nature of the barrier or obstacle to allotransplant-
ation. 
1.7.1. What is the real obstacle tb transplantation? 
Treatment of the recipient has been by far the most 
widely used method, both experimentally and clinically, 
and the reason for this lies in part on the historical 
and theoretical development of transplantation biology 
(Section 1.3.3). The ideas which developed at that time , 
stressed that since the obstacle to transplantation was 
in the antigens of the graft tissue, the only rational 
means of overcoming the rejection was by tissue typing 
and host irnrnunosuppression. Many cytotoxic drugs have 
therefore been used but these have severe side effects 
because of their non specific effect. Identical tissue 
matching has in practice been very difficult to achieve. 
Experimentally, graft survival has also been induced by 
treating the recipient with anti-donor antibody, sub-
cellular donor antigen such as membrane fragments and 
donor cells. The effects of these treatments have 
been varied (see Part II). 
From the discussion in Section 1.6 above, it follows 
that antigen per se is not the obstacle to transplanta-
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tion. The obstacle is encountered when antigen is presen-
ted to recipient T cells on donor stimulator or S+ cells. 
Alloantigen carried on graft parenchyma cells will not 
activate T cells directly because parenchyma cells cannot 
provide a source of cos activity. Although free antigen 
shed from the graft can be presented on recipient stimu-
lator cells to recipient T cells, such indirect presen-
tation could not lead to the activation of the graft 
specific T cells; these T cells would be specific for 
graft in association with the MHC of the recipient 
(Lafferty et al. 1983a). Thus, it is antigen carried on 
the surface of stimulator cells which themselves are 
carried as passengers within the graft, that become the 
real obstacle. It is they which constitute the major 
source of tissue immunogenicity (Lafferty and Talmage, 
1976; Sollinger and Bach, 1976; Lafferty, 1980). 
If what is stated above holds, then it should be 
possible to overcome the obstacle to allotransplantation 
by treatments which are directed at eliminating or in-
activating such passenger cells in the graft tissue -
a procedure which is clinically preferable because it 
eliminates the need for recipient immunosuppression. 
Experimentally, organ culture (Section 1.7.3) has been 
shown to eliminate the immunogenicity of tissues, such 
as thyroid and pancreatic islets, without removing MHC 
antigens from tissue parenchyma cells. 
1.7.2. Passenger leucocytes 
This concept originated in a review on the allograft 
reaction by Snell (1957) who suggested that donor leuco-
cytes carried in the graft might play an important role 
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in invoking immunity. Subsequently, various workers 
produced experimental evidence implicating passenger 
leucocytes in graft immunogenicity. Elkins and Gutmann 
(1968) made this implication in the rejection of kidneys 
and suggested that attempts to rid the graft of such cells 
could be of clinical importance. At about the same time 
Steinmuller (1967, 1969) showed that skin grafts taken 
from neonatally tolerized mice would sensitise normal 
syngeneic animals against subsequent skin grafts from 
the tolerance inducing strain. This immunity was similar 
to that induced by skin allografts taken from normal 
donors. Because the tolerant donors were haemopoietic 
chimeras, Steinmuller attributed the sensitising 
capacity of the skin isografts to the pass i ve transfer 
of leucocytes carried in the vasculature (Steinmuller, 
1967). Subsequently he demonstrated the relationship 
of the immunizing capacity to the number of leucocytes 
present and the degree of leucocyte chimerism of the 
donors (Steinmuller, 1969). For a review of the role 
of passenger leucocytes in the immunogenicity of skin 
grafts, see Steinmuller (1980). 
These early findings established the potential 
importance of passenger lymphocytes, and considerable 
attention was soon turned towards methods aimed at 
eliminating such cells from graft tissue. These methods 
have included whole body irradiation (Stuart et al. 
1971), antilymphocyte serum (Guttman et al. 1967) and 
the administration of cyclophosphamide and other cyto-
toxic drugs (Guttmann et al. 1969, 1975). However, 
although results varied, especially where different 
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tissues were used, these techniques were generally unsatis-
factory. Most did not give a consistent reduction in graft 
imrnunogenicity (Billingham, 1971). Moreover, the clinical 
efficacy of donor pretreatment remains controversial. This 
lack of success helped to raise some doubts as to the 
significance of passenger leucocytes in allograft rejection 
(Billingham, 1971; Stuart et al. 1971). 
Stuart et al. (1971) suggested that in renal allo-
grafts at least, passenger leucocytes as well as vascular 
endothelium might provide a strong irnrnunogenic stimulus 
leading to allograft rejection. However, Lafferty's 
group (Lafferty et al. 1976b; Talmage et al. 1976) have 
argued that because as few as 10 3 viable lymphocytes are 
required in a graft to initiate a host response, it is 
possible that the techniques they employed (total body 
irradiation) may have been inadequate to ensure complete 
elimination of passenger leucocytes. 
More recently, Hirschberg and Thorsby (1981) have also 
challenged the passenger leucocyte concept by proposing 
that vascular endothelial cells could be an alternative 
to passenger leucocytes as the stimulating cells. On 
this basis, the reduction in tissue irnrnunogenicity 
following in vitro culture of thyroids and pancreatic 
islets (Section 1.7.3), was seen by them as being due to 
the degeneration of vascular endothelium (Parr et al. 1980b) 
rather than the inactivation or elimination of passenger 
leucocytes. One of their strong lines of evidence has been 
that isolated vascular endothelial cells, both freshly 
explanted and after several weeks in culture, can stimu-
late allogeneiclymphocytes in vitro (Hirschberg et al. 
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1975), whereas lymphocyte preparations rapidly lose their 
ability to stimulate in culture (Opelz and Terasaki, 1974; 
Miller et al. 1975). However, the results of Hart and his 
group have demonstrated that long-term surviving rat kidney 
allografts retain donor-type vascular endothelium (Hart 
et al. 1980; Hart and Fabre, 198Ja,b). If endothelial cells 
had stimulating activity, these long-term allografts should 
have been rejected. They in fact went on to emphasise that 
it is the loss of passenger leucocytes, and most likely the 
dendritic cells (Hart and Fabre,1981.a,p) which most adequately 
explains long term survival and graft adaptation in their 
system. Moreover, the finding that cyclosphosphamide pre-
treatment of tissue donors can prolong thyroid allograft 
survival - a situation in which the graft has an intact 
vascular bed at the time of transplantation - would also 
argue against endothelium providing the stimulus for the 
host's immune response (Lafferty et al. 1976b; Lafferty 
and Woolnough, 1977). It would seem, therefore, that 
whatever stimulating capacity endothelial cells have, it 
is at best of secondary importance. The evidence points 
to the passenger lymphoid cells as being the "professional" 
stimulator cells (Parr et al. 1980b). Nonetheless, the 
loss of endothelium during organ culture and subsequent 
host revascularization following transplantation, may 
protect the tissue from an antibody mediated attack 
( see Chapter 3) . 
1.7.3. In vitro organ culture 
The idea that organ culture might reduce tissue irnmuno-
genicity is not new and early attempts were made in the 
1930's and 1940's to condition graft tissue for clinical 
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transplantation (Section 1.3.1). For a review of the 
development of organ culture see Fell (1976) and Hodges 
(1976). These early studies, however, were criticised both 
because they lacked genetic control and because they went 
against the current dogma of the newly discovered immuno-
logical basis of graft rejection (Medawar, 1957; Section 
1.3.1). As a consequence, it took some years for interest 
in this work to be rekindled. 
In the late 1960's Jacobs and Huseby (1967, 1968) 
reported the growth of several neoplastic tissues in allo-
geneic rats and mice following organ culture, and concluded 
that the culture used had been able to regress or reduce 
tumour immunogenicity. They later made the further 
suggestion that the reduced immunogenicity following 
culture may be due to a depletion of lymphoid cells 
(Jacobs, 1969). With the reports of Summerlin and his 
coworkers (Summerlin et al. 1970; Summerlin, 1973; 
Summerlin et al. 1973), but subsequently not confirmed, 
wide interest in organ culture was aroused. The potential 
for clinical application was evident. This group 
reported the successful allografting of adult human skin 
following organ culture for 6 weeks (Summerlin et al. 1970). 
This work and subsequent reports with mouse skin (Summerlin 
1973; Summerlin et al. 1973) led to a number of fruitless 
attempts to confirm their results (Ninnemann and Good, 
1974; Lafferty et al. 1975). Nonetheless, although 
Summerlin's work was soon discredited because of falsifi-
cation of experimental evidence, the organ culture technique 
was pursued independently by several groups who subsequently 
reported that this technique could be used to prolong the 
' 
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survival of mouse ovarian (Jacobs, 1974; Lueker and 
Sharpton, 1974) and thyroid (Lafferty et al. 1975, 1976a,b) 
allografts. With these successes the in vitro culture 
technique became firmly established as a tool in allotrans-
plantation. 
Extensive use of this technique, particularly in the 
study of graft rejection mechanisms, has been made in our 
laboratory. Mouse thyroid has been found an especially 
suitable tissue for culture and transplantation. Not only 
is the procedure a relatively simple one, but also its 
characteristic structure enables easy histological assess-
-
ment and it can be readily transplanted under the kidney 
capsule where it quickly becomes revascularized. Using the 
graft's ability to concentrate radioactive iodine as a 
measure of graft function, as well as histological examin-
ation, Lafferty and coworkers have shown that while 
uncultured allografts were acutely rejected within 15-20 
days, organ culture in 95 % o2 and 5% co 2 for 12 days 
enhanced survival, although the degree of prolonged 
survival depends on the strain combination used (Lafferty 
et al. 1975). By extending the culture period to 3-4 
weeks, allografts showed no evidence of rejection over 
an observation period of several months (Lafferty et al. 
1976a,b; Talmage et al. 1976). Pretreatment of tissue 
donors with cyclophosphamide (300mg/kg) 4 and 2 days 
before harvest of thyroid tissue, reduced the period of 
organ culture required for allograft survival. This 
treatment, together with a 7-10 day culture period, 
allowed indefinite survival ( >250 days) of thyroid allo-
grafts (Lafferty et al. 1976b; Lafferty and Woolnough 
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1977). This effect by cyclophosphamide is probably due to 
its leucotoxic activity (reviewed by Turk and Parker, 1982). 
Talmage (1980) has been able to reduce the period of organ 
culture even further. By using donor treatment with hydro-
cortisone and hyperbaric oxygen for culture, the organ 
culture period can be reduced to 1 day. 
With the demonstration that organ culture facilitated 
thyroid allotransplantation to non-immunosuppressed recip-
ients, similar attempts were soon made using pancreatic 
islets. A strong motivating factor was the potential these 
techniques offered for clinical application and, in 
particular, the hope that such methods might be able to 
reverse juvenile onset diabetes and its many degenerative 
complications. For a recent and extensive review of islet 
and pancreas experimental studies as well as clinical 
trials which includes tissue treatment by organ culture, 
see Sutherland (198la,b). A summary only is outlined in 
this section. 
Islet isolation techniques had already been developed 
before organ culture was conclusively shown to prolong 
survival (Moskalewski, 1965; Lacy and Kostianovsky, 1967) 
and the ability of isolated pancreatic islets to synthe-
size and secrete insulin in tissue culture was soon 
established (Lacy and Kostianovsky 1967; Andersson and 
Hellerstrom, 1972; Andersson, 1976). Kedinger et al. 
(1977) found that in vitro culture of allogeneic islets 
4-5 days before transplantation in rats increaased the 
survival of grafted tissue to > 161 days; mean graft 
survival time with uncultured islets was 56 days. 
A number of studies have been undertaken by Lacy's 
group who initially used a short culture period (1-2 days) 
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as well as donor pretreatment with irradiation and silica, 
in conjunction with a single injection of antilymphocyte 
serum (ALS) given to recipients (Lacy et al. 1979a). Only 
a moderate prolongation (40 days) of islet allograft 
survival was achieved. By increasing the length of the 
in vitro culture to 7 days (24°C) and still maintaining 
a single injection of ALS for recipients, prolonged 
survival (>100 days) was obtained (Lacy et al. 1979b,c, 
1980a). 
This work was extended by transplanting rat isl e t xenografts 
to mice which demonstrated prolonged survival of islets 
and a return to normoglycaemia in diabetic mice (Lacy 
et al. 1980b, 1981) . More recently, ,they were able to reverse 
diabetes in mice with neonatal rat islets following 
culture, but without ALS treatment of recipients (Serie 
et al. 1983). 
In our laboratory the culture and transplantation of 
adult and foetal mouse pancreatic tissue has been exten-
sively investigated using a similar culture system to 
thyroid, namely, 95% o2 in 5% co2 at 37°C (reviewed by 
Prowse et al. 1982a). Culture of isolated adult pancreatic 
islets fcir 7-12 days enables their long term survival in 
MHC incompatible recipients without the use of immuno-
suppression (Bowen et al. 1980). Talmage has shown the 
importance of high oxygen tension in the gas phase for 
successful allotransplantation (Talmage and Dart, 1978; 
Talmage, 1980). This effect may result from the 
selective toxicity of oxygen for passenger leucocytes. 
We have been unable to culture single mouse islets 
because they break down in high oxygen, although 
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clusters of about 50 islets will fuse and can be cultured 
in this way - a procedure which also enables greater ease 
of transplantation under the kidney capsule (Bowen et al. 
1980). As few as 300 islets or 6 clusters treated in this 
way can reverse diabetes in nonimmunosuppressed recipient 
mice (Bowen and Lafferty, 1980; Bowen et al. 1981). A 
similar protocol of high oxygen tension and aggregation 
of islets has recently been shown to reverse diabetes 
mice transplanted with rat islets (Lacy et al. 1982). 
. in 
More 
recently our group has also shown that transplanted mice 
respond normally to an intragastric challenge with 
glucose (unpublished data). 
The development of juvenile onset diabetes may 
involve an autoimmune response, perhaps triggered by 
viral infection (Craighead, 1981), which leads to islet 
antibodies and insulitis, or an infiltration of mono-
nuclear cells, which ultimately destroy the insulin-
producing beta cells (Lernmark and Baekkeskov, 1981; 
Nerup and Lernmark, 1981). This response, it has been 
suggested, may also lead to the destruction of the graft 
islet tissue (Naji et al.1979a, 198Ja,b).However, our group 
has shown that islets allotransplanted to recipients 
suffering from insulitis induced by subdiabetogenic 
doses of streptozotocin did not suffer the same fate, 
but rather permanently reversed the diabetes in the 
recipients (Prowse et al. 1982b). Moreover, a CBA mouse 
found to have spontaneous diabetes, also had its diabetes 
successfully reversed with a cultured islet transplant-
ation (Prowse et al. 1982b). Thus the cultured allo-
grafts did not succumb to the same fate as the original 
pancreas. 
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While the success with adult islet tissue is encourag -
ing, technical problems which are associated with the iso-
lation of islets at present prohibit this technique to be 
used clinically despite recent advances which have vastly 
improved islet yields (Haraguchi and 
Merrell, 1981). As a result, much attention has turned 
to the foetal pancreas as source of islet tissue. 
However, in comparison with ·adult islets, foetal pancreas 
is a much more difficult tissue to condition for successful 
allotransplantation (Mandel and Higginbotham, 1979; 
Simeonovic et al. 1980). This increased irnrnunogenicity 
in foetal pancreas appears to be related to the large 
amount of lymphoid tissue which is associated with it 
(Simeonovic et al. 1980). Prolonged culture of human 
foetal tissue has shown that while this procedure will 
greatly deplete the irnrnunostimulatory cells such as 
dendritic cells, they were not abrogated completely. 
However, while Mandell and Higginbotham (1979) were not 
able to prevent allograft rejection following prolonged 
organ culture, in our laboratory it has been shown that 
it is possible to allograft £oetal pancreas successfully 
to nonirnrnunosuppressed recipients when a relatively 
longer period of organ culture (17-20 days) is used, 
although some islet tissue is lost during this extended 
culture (Simeonovic et al. 1980; Simeonovic and 
Lafferty, 1981). This partial loss of tissue was 
reflected in the fact that tissue from 2 cultured 
pancreas isografts does not function as well as a single 
uncultured pancreas in reversing diabetes in syngeneic 
recipients (Simeonovic and Lafferty, 1981). More 
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recently, mouse foetal islet precursors, "proislets" have 
been isolated and when cultured for 4 days in 5 % co 2 
at 37°C, can be successfully transplanted and reverse 
diabetes in syngeneic recipients (Simeonovic and Lafferty, 
1982a). In contrast to uncultured and 10 day cultured 
foetal pancreas allografts which are acutely rejected, 
20% of mouse proislet allografts were not rejected at 
12 weeks following transplantation (Simeonovic and 
Lafferty, 1982b). This method may ~herefore become a 
more suitable alternative for the transplantation of 
foetal islet tissue. Very recently A~cher (1983) main-
tained neonatal pig islets in monolayer culture for 
several weeks and these were shown to synthesise DNA 
and release insulin, suggesting that tissue cultured in 
this way may be a potential source of material for trans-
plantation. 
The differences observed in immunogenicity between 
adult islets, foetal pancreas and foetal proislets can 
be attributed to the differences in contamination by 
passenger leucocytes. By handpicking isolated adult 
islets it is possible to avoid contamination by small 
lymph nodes. Foetal pancreas, on the other hand, is 
contaminated with primitive lymphoid tissue and because 
it is not organized into discrete structures, cannot be 
removed by dissection at harvest (Simeonovic et al. 1980). 
The weak immunogenicity of foetal proislets probably 
results from damage to the lymphoid tissue during the 
collagenase digestion followed by destruction during 
culture of remaining passenger leucocytes (Simeonovic 
and Lafferty, 1982b). 
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These findings that organ culture of donor tissue can 
reduce immunogenicity and allow allograft survival, are 
consistent with the Lafferty 2 signal model of graft 
rejection (Section 1.6.2). That is, the prolongation in 
survival is not due to the loss of tissue antigens during 
culture, because such tissues can later be rejected with 
donor cells or uncultured donor grafts (Lafferty et al. 
1976a; Talmage et al. 1976; Lacy et al. 1979c; 
Simeonovic et al. 1980), but is attributed to the loss 
of stimulator cells which had been carried as passengers 
within the graft before culture. The theory of allo-
genic reactivity (Lafferty and Talmage 1976; Lafferty 
et al. 1983a) postulates that these passenger cells play 
two roles in rejection: stimulator cells trigger the T 
cell response to graft antigens and leucocytes in the 
tissue are also involved in a nonspecific inflammatory 
reaction when activated by host stimulating cells. This 
was shown when cultured BALB/c allografts carried by CBA 
recipients were retransplanted back to normal BALB/c 
recipients. While an acute inflammatory reaction 
caused local damage, it did not lead to rejection of 
the thyroid graft (Lafferty et al. 1976b; Lafferty and 
Woolnough, 1977). Bach and his colleagues (Sollinger 
and Bach, 1976; Sollinger et al. 1977; Gose and Bach, 
1979) have confirmed and extended these findings with 
cultured thyroid xenografts and have also concluded that 
the immunogenic stimulus is provided for by antigen on 
metabolically active leucocytes. More recently, 
Faustman et al. (1981) have demonstrated that treatment 
of uncultured, isolated adult mouse islets with donor 
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specific Ia antiserum and complement before transplantation, 
can result in indefinite graft survival. Because mouse beta 
cells lack Ia antigens (Faustman et al. 1980; Parr et al. 
1980b) the result is further confirmation for the passenger 
cell concept since it suggests that the antibody and comple-
ment treatment of islets removes an Ia or class II bearing 
passenger cell which is required for cytotoxic T cell 
activation. 
While the organ culture techniques cannot be applied 
to larger organs such as the kidney, in principle it 
should be feasible to develop other techniques aimed at 
removing irnrnunogenic components of such organs. For 
example, the method of pretreatment of the islets with 
antiserum and complement (Faustman et al. 1981), is 
potentially applicable to various organs such as heart, 
liver and kidney whose parenchymal cells, at least in 
the rat, have been shown to lack Ia antigens (Hart and 
Fabre, 1981b). Faustman et al. (1982c) recently extended 
their earlier findings with islets, by demonstrating a 
prolongation of mouse heart allograft survival after 
treatment with anti-donor antiserum and complement. 
PART II: TRANSPLANTATION TOLERANCE 
1.8 INTRODUCTION 
The earliest workers in immunology realised that, as 
a rule, an individual does not react immunologically to 
self antigens - a fact formulated in Ehrlich's principle 
of horror autotoxicus, or fear of poisoning oneself 
(cited in Boyd, 1966). It is now known that this immuno-
logical unresponsiveness or tolerance is not necessarily 
restricted to self but, under appropriate conditions, 
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can be extended to foreign antigens. 
It should be noted from the outset that there has been 
considerable semantic confusion in the past concerning the 
definition of tolerance. The term has been used both in a 
very broad sense to indicate any condition where an immune 
response is not manifested, to more restricted meanings 
depending on particular experimental situations. 
"Tolerance" was initially used to describe a specific 
state of unresponsiveness to antigens in adult life as 
a consequence of exposure to those antigens in utero 
or during the neonatal period - the latter situation also 
being termed "neonatal tolerance". Tolerance has also 
been used interchangeably with such terms as "unrespon-
siveness", "nonresponsiveness" and "immunologic paralysis". 
For the purpose of this discussion, an operational defini-
tion of tolerance is adopted (Scott and Amos, 1978) which 
defines tolerance as a specific unresponsiveness or 
hyporesponsiveness induced by prior exposure to antigen. 
A total absence of specific reactivity is not implied, 
but rather, it means a functional failure to achieve 
rejection. 
Because tolerance is a complex immunological 
phenomenon of great significance, anything more than a 
bird's-eye view of the subject is beyond the scope of 
this introduction. Moreover discussion will be restricted 
mainly to transplantation tolerance. For comprehensive 
recent reviews on immunological tolerance, s~e Hraba 
(1977), Elkins (1979), Hasek and Chutna (1979), and 
Nossal (1983). 
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1.9 HISTORICAL 
Although the concept of tolerance did not emerge until 
the classical studies by Medawar and coworkers in the 1950's 
the term has since been used to describe earlier discovered 
states of specific inhibition of the immune response. These 
were seen to have much in common with acquired transplan-
tation tolerance (Billingham et al. 1956a) and include the 
Sulzberger-Chase phenomenon, immunologic paralysis and 
tolerance to various heterologous proteins. 
In 1929 Sulzberger observed that an intradermal 
injection (150µg) of neoarsphenamine, which would sensitise 
guinea pigs, would not do so in animals previously 
injected intravenously with a larger dose (6mg) of the 
same antigen (cited in Chase, 1959). Independently, 
Chase (1946) demonstrated that guinea pigs could be 
rendered tolerant to the sensitising action of a variety 
of chemicals, including picryl chloride and dinitrochloro-
benzene, by first feeding the substances before the 
sensitising treatment. This nonreactivity, which came to 
be known as the Sulzberger-Chase phenomenon (Hraba, 1977) 
was long-lasting and specific and later also shown to be 
reversab}e by adoptive transfers of cells from immune 
animals (Chase, 1959). 
Felton (1949) discovered that while an injection of 
a relatively small amount (0.5 µg) of pneumococcal poly-
saccharide would immunize mice, the injection of larger 
doses ( for example O. 5mg) did not immunize bu·t rather 
suppresssed or "paralysed" the ability to form antibody, 
hence the term "immunological paralysis". 1ice so 
treated were vulnerable to the living organism. The 
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specificity of this inhibition was later shown in mice 
where paralysis to one type of pneumococcal polysaccharide 
did not reduce their antibody forming ability to a poly-
saccharide of another type (Felton et al. 1955). 
At about the same time as the classic studies on the 
induction of transplantation tolerance (Section 1.10), 
various workers demonstrated tolerance to heterologous 
serum proteins (Hanan and Oyama, 1954; reviewed by Chase, 
1959). Rabbits given injections of bovine serum albumin 
(BSA) just after birth had their antibody forming ability 
suppressed when challenged with the same protein after 
reaching immunologic maturity (Hanan and Oyama, 1954). 
Dixon and Maurer (1955) demonstrated that adult rabbits 
could be made, to use their term, "immunologic unresponsive" 
if they injected very high doses of the proteins. This 
effect was specific as it did not prevent antibody 
responses to closely related antigens. Cinader and Dubert 
(1955) similarly demonstrated this inhibition of response 
to human albumin and which they termed "acquired immuno-
logic tolerance". Specificity was again demonstrated by 
showing that rabbits made unresponsive to human serum 
albumin, responded normally to tobacco mosaic virus. It 
should be noted that besides heterologous serum proteins, 
other antigens such as sheep erythrocytes, bacteria, 
bacterial lipopolysaccharides, viruses and nucleic acids, 
have all been used for the induction of tolerance (see 
Weigle, 1973; Hraba, 1977). 
The concept of transplantation tolerance owes its 
origins to the observations made with dizygotic bovine 
twins by Owen (1945). He showed that such non-identical 
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twins have a double popul a tion of blood cells and that 
this "mosaic" or "chimera" was a result of an exchange 
made between placental blood vessels following anastomoses 
during foetal life. Moreover, it persists in each cattle 
twin into adult life. Interestingly, erythrocyte chimerism 
is not unique to cattle twins for it has also been 
reported in other animals including sheep (Stormont et al. 
1953), chickens from double yolked eggs (Billingham et al. 
1956a), marmoset monkeys (Gengozian et al. 1969) and also 
in man (Dunsford et al. 1953). 
The finding of erythrocyte chimerism in cattle pro-
vided an important stimulus to Burnet and Fenner (1949) 
who speculated that tolerance might be induced experi-
mentally. An adult animal does not normally react immuno-
logically to its own tissues because, they suggested, its 
body cells carry some sort of "self-marker" and the 
animal learns to recognize self from non-self in 
embryonic life. Thus, if a foreign antigen can be intro-
duced early enough, the prediction was that the embryo 
will accept it as part of self and therefore not cause it 
to develop the capacity of responding immunologically to 
that particular antigen. Burnet failed, however, to prove 
his hypothesis experimentally. Using influenza virus, 
bacteriophage and human blood cells as foreign antigens 
in the chick embryo, they were unable to detect any 
change in the subsequent response of the hatched chicks 
to the antigens (Burnet et al. 1950}. Triple~t (1962) 
was later able to show that self tolerance was acquired 
during ontogeny. He removed the buccal component of 
the pituitary gland from embryonic tree frogs, Hyla 
regilla, and then grew the embryo and the gland apart 
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for about 60 days before regrafting them back together. The 
now adult gland was rejected because it was recognized not 
as part of self, but as foreign. 
1.10 ACTIVELY ACQUIRED TOLERANCE 
Burnet and Fenner's speculation that tolerance might 
be induced experimentally was given some credence when 
Anderson et al. (1951) reported that the majority of non-
identical cattle twins did not reject reciprocally 
exchanged skin grafts; control grafts from unrelated 
calves were rejected normally. These findings led 
Billingham and coworkers to undertake the experimental 
induction of transplantation tolerance and were soon 
able to fulfill the prediction that this tolerance can 
be established artificially (Billingham et al. 1953). 
Tolerance was induced in mice by the injection (0.01ml) 
of an allogeneic viable cell suspension into the embryo. 
When the embryos were born or later in adult life, they 
accepted skin grafts from the otherwise incompatible 
strain. This phenomenon they terrred "actively acquired 
tolerance". Moreover, they demonstrated, firstly, the 
specificity of this tolerance since CBA mice tolerant of 
A-strain skin rejected allografts from the unrelated AU 
strain and, secondly, that it was not an "all-or-
nothing phenomenon, but it covered all stages from 
complete tolerance to normal reactivity. They suggested, 
however, that animals displaying normal reactivity may 
have been inadvertantly missed when their l{tter mates 
were injected in utero. They also induced similar tol-
erance in chicks. Cannon and Longmire (1952) had 
earlier shown that tolerance could be obtained in day old 
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chicks by direct skin grafting , although the proportion 
becoming tolerant using this method was only 5-10 %. Follow-
up studies by Billingham's group in mice, chickens, rats 
and rabbits confirmed and extended their earlier findings 
and also demonstrated that immunological reactivity can be 
easily restored in tolerant animals (Billingham et al. 
1956a; Section 1.11). 
At the same time that Billingham's group demonstrated 
acquired tolerance, Hasek independently reported the in-
duction of tolerance to alloantigens in chicks and ducks 
(cited in Hasek, 1959). He reproduced Owen's phenomena 
in chickens by using the technique of embryonic parabi-
osis - the grafting of a whole animal onto another -
which gave a prolonged mutual exchange of embryonic blood 
cells. After hatching, the chickens were separated and 
able to tolerate mutually exchanged skin allografts. 
Parabiosis of different species such as duck-chicken 
and turkey-chicken, produced only a moderate prolongation 
of skin graft survival (Hasek, 1959). Billingha~ et al. 
(1956a) using similar techniques, found that a similar 
low degree of tolerance existed in duck-chicken para-
bionts. That is, transplantation tolerance is much more 
difficult to induce with xenogeneic differences. For an 
early review of tolerance induction using parabiosis, 
see Simonsen (1962). 
Woodruff and Simpson (1955) using rats were able to 
confirm the early findings of Billingham et ~l. (1953). 
Moreover, they demonstrated that, in the rat, unlike the 
mouse, the period during which tolerance may be conferred 
extends beyond the foetal stage for up to 2 weeks after 
birth. In the mouse this period corresponds roughly with 
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foetal life. 
The types of cells injected into the foetus or neonate 
were also shown to be important. When tolerance was induced 
with non-immunologically reactive cells such as foetal or 
adult testicular or kidney cells, the resultant tolerant 
animal showed no pathological changes. When injections of 
adult spleen cells and blood cells were used, the immuno-
logically competent cells became sensitised. Because the 
host cannot respond, a GVH reaction results which can lead 
to the death of the host. In intermediate cases the 
reaction, termed "runt disease", causes stunted growth 
(Billingham and Brent, 1957; Simonsen, 1957; reviewed 
by Hasek et al. 1961). This ability of injected cells 
to give a GVH reaction is a major impediment in clinical 
bone marrow transplantation. 
The term "actively acquired tolerance" given by 
Billingham et al. (1953), is an apt description because 
it, firstly, defined tolerance as that of the graft by 
the host and, secondly, stated that, like acquired 
immunity, this tolerance was also an outcome, albeit an 
opposite one, of the encounter with antigen. Their 
explanation for it was that cells which are able to 
produce an immune reaction to the tolerated graft are 
absent in the tolerant animal. Accordingly, tolerance 
was defined as "the specific and systemic failure of the 
mechanisms of immunological response which is brought 
about by exposing embryos or very young animals to 
'antigenic' stimuli" (Billingham et al. 1956a). 
This work also influenced Burnet (1959) who explained 
tolerance on the basis of his clonal selection hypothesis 
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of antibody formation. Briefly, his hypothesis stated 
that an organism has a large pool of potentially reactive 
lymphoid cells, each of which is capable of dividing after 
contact with a specific antigen and which would then pro-
liferate into clones making only one kind of antibody. 
During embryonic development, the encounter of young 
lymphoid cells with self antigens or indeed with injected 
antigens, results in the elimination of those cells. 
Therefore, tolerance results from an elimination of 
specific alloantigen reactive clones in the recipient 
during a critical state of immunological development. 
Put another way, transplantation tolerance occurs, 
to use Burnet's words, when "the content of self-
components in the body has been enlarged by an experi-
mental manipulation" (Burnet, 1961). 
The conventional view of transplantation tolerance 
therefore, has been one based on the clonal elimination 
of the reacting cells. However, work in the early 
1970's on blocking factors and suppressor T cells were 
an obvious challenge to this view (Section 1.14). 
1.11 DURATION AND ABOLITION OF TOLERANCE 
The induction, degree and duration of transplantation 
tolerance depends on a number of factors which include the 
species and strain of the animals used, source of cells 
or antigen and its dose, route of inoculation and the 
irnrnunocompetence of the host (reviewed by Weigle, 1973; 
Elkins, 1979). Some of these points have already been 
covered in Section 1.10. Suffice to say that once 
tolerance is induced, there is a requirement for the 
persistence of antigen (the tolerogen), for the mainten-
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ance of tolerance, otherwise it will terminate spontaneously 
(Weigle, 1973). For example, if tolerance of non-replicat-
ing antigens such as serum proteins is to be maintained, 
repeated administration of the antigen is necessary (Dixon 
and Maurer, 1955). 
Medawar and Woodruff (1958) 
reported a weakening of tolerance of skin grafts following 
removal of the established grafts and noted that a second 
allograft (transplanted one month later) from the same 
donor was rejected. Where tolerance is not complete, 
allograft survival may be considerably prolonged but 
eventually it will be rejected (Hasek, 1959). Irres-
pective of the degree of tolerance induced, however, 
tolerance can be readily abolished. 
The abolition of tolerance to heterologous serum 
proteins has been demonstrated by the injection of 
antigens closely related to the tolerogen. Thus, 
tolerance to human serum albumin was terminated by 
injecting an azobenzene derivative of albumin (Cinader 
and Dubert, 1955), and to BSA by administering serum 
albumin from various related species (Weigle, 1961). 
Curtain (1959) was able to terminate tolerance to 
Bence-Jones protein by injecting myeloma proteins from 
the same individual. 
The abolition of transplantation tolerance has been 
achieved using several methods including irradiation 
(Fefer and Nossal, 1962), but more commonly through the 
adoptive transfer of normal or sensitised lymphocytes. 
Billingham et al. (1956a) were able to reject CBA skin 
grafts in tolerant A strain recipients by adoptive 
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transfer of both immune and normal lymph node cells from 
other A-strain animals. Tolerance abolition was much more 
prompt, however, with immune cells. A similar finding was 
reported by Kilshaw et al. (1974) using tissue extracts and 
ALS to induce tolerance (Section 1.12). Hasek and Chutna 
(1979) also confirmed these findings and further found that 
the dose of immunocompetent cells make no difference to 
abolition. Billingham's group interpreted this abolition 
as an indication that tolerance represents a "central 
failure" of the immune response and cannot be explained 
by a peripheral interference of the allograft reaction by 
processes such as antibody absorption or by graft adapta-
tion (Billingham et al. 1956a). 
1.12 INDUCTION OF TOLERANCE IN ADULT ANIMALS 
Although transplantation tolerance has been success-
fully induced in neonates in various experimental systems 
there has been little success in finding a truly clinically 
applicable transplantation technique in adult animals. 
longed allograft survival and induction of tolerance in 
adult animals has usually required modification of the 
host's immunocompetence. This has been achieved using 
such methods as immunosuppressive drugs, antilymphocyte 
serum, irradiation, thoracic duct treatment, thymectomy 
Pro-
and combinations of any of these. In addition, pretreat-
ment of recipients with donor tissue extracts and blood 
products have also been used. In our laboratory we have 
used a combination of cultured islet allograft and treat-
ment of the recipient with ultraviolet irradiated spleen 
cells of donor origin to induce adult tolerance (Chapter 
6). Many experimental procedures which give a measure of 
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specific tolerance, main ly in rats and mice, have been 
described and early studies have been reviewed by Weigle 
(1973). Many of these techniques have also been used 
clinically but despite varying success, the resultant 
infectious, neoplastic, pharmacologic or radiologic side 
effects have yet to be adequately controlled. Various 
grafts have also been protected by transfer of hyper-
immune serum and this will be discussed in Section 1.13. 
1.12.1. Immunosuppressive drugs 
This is a rather broad topic and beyond the scope 
of this review . However, because of the clinical importance 
of the various cytotoxic drugs and steroids used for 
prolonging allograft survival, a brief summary is given . 
It should be stressed that without such drugs, much of the curren t 
clinical transplantation would not be possible. For a r ecen t 
review of immunosuppressive drugs, see Salaman, 1983. 
Graft rejection was and remains the primary 
obstacle. One widely used drug has been azathioprine. 
For example, Ballinger and Lacy (1972) reported the first 
successful transplantation of isolated islets in rats 
using this drug. The use of corticosteroids, azathio-
prine and other such drugs, however, is limited by their 
side effects and by the danger of reducing the patient's 
ability to combat infections (Opelz and Lenhard, 1983). 
By combining drugs, an accummulation of toxic effects 
may result. Floersheim (1969) combined several drugs, 
including cyclophosphamide, methotrexate and azathioprine 
to prolong BALB/c skin survival in CBA mice. Drugs have 
also been combined with other treatments such as ALS 
(Section 1.12.2) and thymectomy (Chernyakhovskaya et al. 
1980). 
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In recent years cyclosporine (CyA) (also referred to 
as Cyclosporin A) has been shown to be a very promising 
and important irnrnunosuppressant in numerous experimental 
studies and clinical trials carried out since its extrac-
tion and purification in the mid 1970's. Unlike other 
drugs, CyA is primarily lymphocyte specific and also has 
a very low degree of myelotoxicity (Thomson, 1983). These 
features make its clinical use most attractive, particu-
larly in bone marrow transplantation. Because it does 
not affect the migratory capacity of phagocytic cells, 
its use ensures that the anti-microbial defences of the 
recipient are not completely destroyed. The irnrnuno-
biology, mechanism of action and clinical use of this 
drug, have recently been extensively reviewed 
C Britton and Palacios, 1982; White and Calne, 
1982 ; Laff erty et al. 1983b; Thomson, 1983). In 
addition to its irnrnunosuppressive use, CyA is proving 
a valuable analytical tool in the study of the role of 
T cell subpopulations in cell mediated immunity (Borel 
and Lafferty, 1983; Chapter 5). 
1.12.2. Antilymphocyte serum 
Antilymphocyte serum (ALS) - an immune serum raised 
in one species against the lymphocytes of another species -
has been used both experimentally and clinically for many 
years. Numerous reports have shown ALS to prolong survival 
of skin, renal, hepatic and cardiac allografts in e xperi-
mental animals across major histocompatibilities 
(reviewed by Lance et al. 1973; Wonigeit and Pichlmayr, 
1977). 
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The effect of ALS on allograft survival can be 
enhanced by combining ALS with procedures such as thoracic 
duct drainage (Woodruff and Anderson, 1963) and thymectomy 
(Steinmuller, 1979). Others have combined bone marrow 
cells and ALS to induce tolerance of skin allografts 
mice (Monaco et al. 1971; Wood et al. 1971, 1972). 
Synergy has sometimes been achieved by combining ALS 
. in 
with various cytotoxic drugs. Floersheim (1969, 1973), 
and Brent and Opara (1979) reported that ALS treatment 
combined with procarbazine gave prolonged skin and heart 
allograft survival in miqe. This synergy was also demon-
strated with ALS treatment combined with splenic and liver 
cell extracts (Brent and Kilshaw, 1970; Brent et al. 
1971). Pinto et al. (1974) achieved long term survival 
of skin allografts by the administration of a combin-
ation of liver or spleen extracts, ALS and Bordetella 
pertussis vaccine. The effect was strain specific. 
Moreover, these workers found that induction of toler-
ance was dose dependent on both the extract and ALS, 
as well as on the timing of ALS injections (Brent et al. 
1971, 1973). Marquet and Heystek (1975) were able to 
gain considerable pancreatic islet allograft survival 
in rats by using a short ALS treatment. 
Although ALS has been shown to prolong allograft 
survival in several animal models, there are conflicting 
data as to whether it is able to prolong the survival 
of renal, hepatic or cardiac allografts in human recip-
ients (reviewed by Heyworth, 1982). This conflict may, 
in part, be explained by the different types and doses 
of ALS which have been used clinically by different 
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workers. In addition, assessment is also complicated 
because of other immunosuppressive agents used and by 
the different patterns of treatment given to suit the 
needs of different patients. Heyworth (1982) is of the 
opinion that for human renal allografts, the clinical 
experience with ALS has not convincingly demonstrated 
prolonged survival. In any case, the evidence that ALS 
does have marked immunosuppressive activity in humans, 
is not without its complications. The question of side 
effects of ALS in clinical use has been reviewed by 
Lance et al. (1973). 
The development of suitable monoclonal antibodies 
which, unlike conventional antisera, are well defined, 
may become a better method of immunosuppression 
(Williams, 1979; Diamond et al. 198l;Millstein, 1981). 
Cosimi et al. (1981a) recently undertook a trial of 
monoclonal antibody therapy in human renal allograft 
patients. Eight such patients had their rejection 
crisis reversed with OKT 3 monoclonal antibody (reactive 
with all mature T cells). These workers have also used 
this approach to monitor the patients' immunologic status 
(Cosimi et al. 1981b). By using flow cytometry and 
monoclonal antibodies to T cell subsets, they were able 
to monitor changes in patients' peripheral blood lympho-
cytes including total numbers of T cells (using OKT3), 
helper T cells (OKT4) and cytotoxic T lymphocytes (OKT8). 
While there is considerable evidence that ALS 
depletes E-rosette-positive lymphocytes in humans 
(Heyworth, 1982), the precise mechanism remains unknown. 
Kilshaw et al. (1975) have suggested an important role 
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for suppressor T cells in ~aintenance of tolerance follow-
ing ALS and tissue extract treatment. They found that 
8 
adoptive transfer of 2 x 10 spleen cells from tolerant 
CBA mice to normal syngeneic mice and subsequent grafting 
with A strain skin, produced a significant prolongation 
in skin survival. CBA female recipients injected with 
tolerant viable spleen cells (1.4 x 10 8 ) showed an 
impaired ability to reject A-strain tumours and treatment 
with anti-8 antibody and complement abolished suppressor 
activity from tolerant spleen cells (Kilshaw et al. 1975). 
Other mechanisms may be involved and these are discussed 
in Section 1.14. 
1.12.3. Irradiation 
Whole body irradiation (WBI) has been used for 
inducing tolerance to bone marrow and kidney allografts 
although high doses of irradiation produced unacceptable 
side effects such as irreversible bone marrow aplasia 
(Slavin et al. 1980). The impact of ionizing irradia-
tion on the immune system in clinical transplantation 
has been of some concern because of the many detrimental 
effects on immunological defence mechanisms which increases 
the risks of infectious diseases (reviewed by Serrou and 
Rey, 19 81; Doria et al. 1982). As a result, more 
selective approaches to the use of irradiation have 
been stimulated. Strober and coworkers have recently 
revived interest in the use of irradiation by the intro-
duction of total lymphoid irradiation (TLI; Strober 
et al. 1979). This technique is based on that used to 
treat human lymphoid malignancies such as Hodgkin's 
disease (Kaplan, 1981) and uses X-irradiation of the 
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lymphoid organs only. Animals are given daily doses or 
fractions (200 rads) while shielding bones, lungs and 
most of the gastrointestinal tract, until a total dose 
(usually 3400 rads) is reached before the animal is 
grafted. Using this technique, the induction of specific 
transplantation tolerance has been reported for skin and 
heart allografts in mice and rats (Slavin and Fuks, 1979; 
Strober et al. 1979). More recently TLI has been used 
to establish specific and long-lasting tolerance of 
bone marrow without GVH (Slavin et al. 1980). Vaiman 
et al. (1981) used an adaptation of this protocol to 
obtain prolongation of skin allograft survival in pigs. 
Strober's group also combined TLI with CyA or anti-
thymocyte globulin in the hope of demonstrating a syner-
gistic effect on cardiac allograft survival in monkeys 
but failed (Pennock et al. 1981). However, CyA alone or 
in combination with TLI was associated with the develop-
ment of malignancies. Using a reduced total irradiation, 
the TLI method was equally effective in inducing toler-
ance to liver and kidney allografts in baboons (Myburgh 
et al. 1980a,b). 
The mechanism of action is uncertain but evidence 
suggests the presence of suppressor cells. Spleen cells 
from TLI chimeras were assayed for their ability to 
suppress the MLR of responder lymph node cells and were 
found to suppress the response for prolonged periods 
after bone marrow transplantation (Strober et al. 1979). 
Myburgh et al. (1980a,b) also demonstrated in vitro 
evidence of suppressor cell activity although much of 
it was nonspecific. The presence of nonspecific and 
donor specific suppressor cells following TLI was also 
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shown by the inhibition of MLR after the addition of mito-
mycin treated peripheral blood lymphocytes from treated 
animals (Smit et al. 1980, 1981; Myburgh et al. 1983). 
Another selective irradiation approach has been used 
by Hardy et al. (1979) using the systemic administration o~ 
Palladium (Pd)-109-hematoporphyrin. However, no significant 
effect was demonstrated on rat heart allograft survival, 
although its combination with a short course of ALS gave 
prolonged survival. 
1.12.4. Blood pretreatment 
Although the effect of blood pretreatment and trans-
fusion on transplantation is highly variable, it has been 
widely used both clinically and experimentally in the hope 
of inducing tolerance, or at least prolonging survival in 
adult recipients. Early studies include those of Halasz 
et al. (1964) who demonstrated some prolongation of kidney 
allograft survival in mongrel dogs following pretreatment 
of recipients 10 and 5 days before transplantation with 
2ml of blood from the prospective kidney donor, and 
Marquet et al. (1971) who achieved marked prolongation of 
survival for kidney and heart allografts in rats which 
had been pretreated with small quantities of donor blood. 
A similar effect was demonstrated by Fabre and Morris 
(1972) with rat kidneys. Attempts by them to transfer 
tolerance by the passive administration of serum were · 
unsuccessful. More recently, Faustman et al. (1982a,b) 
obtained long term survival of islet allografts . . in mice 
by treating recipients with donor blood treated with 
antiserum to class II antigens, and Lau et al. (1983) 
demonstrated prolonged islet survival in rats by treat-
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ment with blood irradiated with ultraviolet (UV) light. 
Clinical investigations were at first discouraged 
because it was early recognized that antibodies, as a 
result of blood transfusions, can cause hyperacute rejection 
(Kissmeyer-Nielsen, 1966; Section 1. 5 .1.1). However, Opelz 
et al. (1973) found that contrary to the then common view, 
pretransplant blood transfusions improved renal allograft 
survival. Many independent studies have since been under-
taken and various prospective trials have confirmed those 
of retrospective studies indicating that transfusions do 
improve the transplantation survival rate (Fehrman et al. 
1980; Opelz et al. 1981a; reviewed by Opelz and Lenhard, 
1983). 
These clinical findings were also subsequently 
confirmed in a number of animal studies which combined 
blood pretreatment with various levels of immunosuppressive 
treatment. These include . skin allografts in mice 
(Okazaki et al. 1980; Horsburgh et al. 1981; Wood et al. 
1981), islet allografts in rats (Selawry et al. 1981), 
and kidney allografts in dogs (Obertop et al. 1978) and 
monkeys (Van Es et al. 1978) ~ 
Despite the risks of hepatitis transmission and the 
sensitisation of potential recipients, particularly when 
many transfusions have been administered, most clinical 
workers would now agree that pretransplant transfusions 
will improve renal allograft survival. The bene fi ts are 
seen to outweigh by far the risks involved and trans-
fusions with random blood have become mandatory in most 
clinical transplant centers (Opelz and Lenhard, 1983; 
Van Rood, 1983). 
The use of donor-specific blood in recipients of 
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living related kidneys may, in the future, assume greater 
importance. Cochrum et al. (1981) used transfusions from 
the actual kidney donor in HLA-mismatched related-donor 
transplants and were able to obtain graft survival rates 
comparable to those pretreated with random blood trans-
fusions. In experimental studies with mice, conflicting 
results have been obtained. While Okazaki et al. (1980) 
demonstrated that prolongation of skin graft survival was 
induced only by nonspecific blood transfusions and not by 
specific blood transfusion, Wood et al. (1981), . in con-
trast, found that small quantities (0.5-2µ1) of donor 
specific blood can induce long lasting survival of skin 
allografts. This difference may reflect a difference in 
blood dose since, when higher volumes (0.1ml) of blood 
were used, donor specific blood did not induce tolerance 
(Wood et al. 1981). 
Despite the wide use of random blood transfusions 
for clinical kidney transplantation, there is still a 
lack of consensus on transfusion protocols, and conse-
quently a number of controversies and discrepancies exist 
among the published results. Considerable variations 
exist, for example, in number and interval of transfusion. 
While some workers have found that patients who received 
many transfusions did better than those who received only 
a few (Fehrman et al. 1980, 1982; Opelz and Terasaki, 
1980), others have reported that even a single dose or 
very few transfusions were adequate to achieve the 
maximum benefit (Williams et al. 1979; Feduska et al. 
1981; Persijn et al. 1981). The interval between trans-
fusions has varied ranging from several months to just a 
few hours, but this variation apparently does not matter 
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(Opelz et al. 1981b; Fassbinder et al. 1982). Van Es 
et al. (1978) noted that a single blood transfusion given 
0-12 hours before kidney transplantation, prolonged allo-
graft survival in monkeys. Even transfusions given during 
transplantation surgery have been claimed to be effective . 
by some investigators (Williams et al. 
1980), although in series with large numbers of patients 
and regardless of the number of such transfusions, this 
could not be confirmed (Opelz and Terasaki, 1980, 1981). 
While most would agree that blood depleted of white cells 
is not effective (Wood et al. 1981; Opelz and Lenhard, 
1983), in rhesus monkeys it was recently reported that 
donor platelets were as effective as whole blood trans-
fusions (Borleffs et al. 1982). 
The mechanism involved in the beneficial effect of 
blood transfusion remains obscure. Many explanations 
have been proposed (reviewed by Opelz and Van Rood, 
1983) and it now seems that several mechanisms may be 
involved. Some have agreed that this effect in human 
renal transplants can be explained simply by a selection 
mechanism, that is, patients with a positive lympho-
cytotoxic crossmatch test are automatically excluded 
(Opelz et al. 1972). However, the extensive data 
analysed by Opelz and coworkers suggests that although 
this form of selection may play a role, it cannot 
account for the entire beneficial effect (Opelz et al. 
1981a; Opelz and Terasaki, 1981). Several immuno-
logical mechanisms have been proposed, the most import-
ant of which appear to be the induction of suppressor 
cells (Maki et al. 1981; Marquet and Heystek, 1981; 
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Lenhard et al. 1982) and antiidiotypic antibodies 
(Miyajima et al. 1980; Singal et al. 1982), with the 
former being favoured by the majority of investigators 
(Opelz and Van Rood, 1983; Section 1.14). 
1.13 IMMUNOLOGICAL ENHANCEMENT 
Immunological enhancement is the prolonged survival 
of an allograft as a result of the presence in the 
recipient of either endogenous or passively transferred 
antidonor alloantibody. The terms "active enhancement" 
and "antigen-induced suppression" have been used synony-
mously for the former situation where antibodies have 
been produced in the host in response to the injection 
of preparations of donor tissue, and "passive enhancement" 
or "antibody-induced suppression" for the latter. 
The concept of enhancement arose from the work on 
tumour allografts by Casey and his colleagues in the 
1930's (cited in Woodruff, 1960). They demonstrated the 
prolonged survival of tumour allografts in recipients 
which were pretreated with injections of similar tissues 
and which had first been killed by lyophilization and 
other methods. This phenomenon was termed the "enhancing 
effect," the "XYZ effect" and the "conditioning the host 
effect". Kaliss and Molomut (1952) found they could 
obtain the enhancement of tumour allografts by the 
passive transfer of serum and later work demonstrated 
this phenomenon was dependent on the presence of anti-
bodies in the serum (Kaliss and Bryant, 1958). Mitchison 
and Dube (1955) reported that like actively acquired 
tolerance, enhancement also could be abolished with 
immune cells from the regional lymph nodes but, unlike 
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tolerance, could not be abolished with normal cells. 
Billingham et al. 1956b) performed studies with mouse 
skin allografts and showed that enhancement was not 
restricted to neoplastic tissues. 
Since the mid 1950's, numerous investigations have 
reported the survival of both tumour and normal tissue 
allografts as a result of either active, passive enhance-
mentor a combination of both. While various model 
systems have been used with resultant variations in the 
effectiveness of the enhanced state, the immunological 
status of recipients of long-term surviving allografts 
is very similar and unlike classical tolerance, in 
general lymphoid cells from long-term recipients retain 
the ability to react normally in vitro to donor-type 
antigens (Feldman, 1972; Carpenter et al. 1976; Stuart 
et al. 1979, 1980). 
The relationship between enhancement and tolerance 
has been a source of some controversy. While Snell 
(1954) proposed that the term "actively acquired toler-
ance" should be extended to include enhancement, 
Billingham et al. (1956b) argued for a distinction 
between the two phenomena on the basis that the means 
of achieving them and probably the mechanisms involved, 
were different. The unresponsiveness in classical 
tolerance was seen to be due to an antigen induced state 
which led to the elimination or inactivation of the clone 
of cells capable of responding to the specific antigen 
(Section 1.10). In contrast, enhancement was seen as an 
antibody-induced state resulting in the protection of 
the antigen-bearing target cells. However, the distinc-
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tion between classical tolerance and immunological enhance-
ment was becoming less clear by the 1970's with the work, 
for example, of the Hellstroms (Hellstrom and Hellstrom, 
1974) who proposed an alternative mechanism to clonal 
deletion, namely, that tolerance depends on circulating 
serum-blocking factors (Section 1.14). This suggested 
that tolerance and enhancement were part of a single 
spectrum. Recent developments which have made an impact 
on our understanding of tolerance and enhancement are 
investigations into the role of class II antigens, 
suppressor T cells and anti-receptor or anti-idiotypic 
responses in the induction and maintenance phases of 
immunological suppression (Section 1.13.6). 
This discussion will be restricted to enhancement 
of normal tissue allografts. For recent reviews see 
Wonigeit and Pichlmayr (1977), Stuart ~t al. (1979, 
. 
1980) and Morris (1980). 
1.13.1. Active enhancement 
Active enhancement is less predictable than passive 
enhancement and is more likely to result in accelerated 
rejection rather than enhancement (Stuart et al. 1979, 
1980). Experimentally, antigen treatment with and without 
the addition of non-specific immunosuppressive agents 
such as ALS and various drugs, has been used to induce 
prolonged survival in various models. These include 
skin allografts in mice (Brent and Kilshaw, 1970; Brent 
et al. 1971; Section 1.12.2) and renal allografts . in 
the rat (Ockner et al. 1970) and dog (Zimmerman et al. 
1968), although Calne et al. (1966) were not able to 
prolong kidney allograft survival in dogs after treat-
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with a variety of different antigen preparations, with or 
without immunosuppressive drugs. Mullen (1980) could gain 
a marked prolongation of foetal pancreas allograft survival 
in rats only by combining donor antigen with ALS and pro-
carbazine hydrochloride. 
1.13.2. Passive enhancement 
Because enhancement does not involve a generalised 
depression of immune responses, its potential for clinical 
application was quickly realised. But although tumours 
were readily enhanced by the passive administration of 
antibody (Kaliss amd Molomut, 1952), similar attempts 
using skin allografts were generally unsuccessful and, 
consequently, clinical interest in the phenomenon waned. 
With the development of microvascular surgical techniques 
in the 1960's, which enabled the grafting of vascularized 
grafts such as heart and kidney, passive enhancement was 
again reexamined. The rat renal allograft model became 
widely used. Stuart et al. (1968) were the first to 
demonstrate prolonged survival of kidney allografts in 
rats following treatment with both donor antigen and 
passive transfer of anti-donor alloantibody. French and 
Batchelor (1969) confirmed this enhancement in AS rats 
using only a passive transfer of antiserum. Numerous 
other studies soon followed which confirmed and extended 
these findings in the rat renal allograft model (French 
et al. 1971; French and Batchelor, 1972; Fine et al. 
1973; Mullen et al. 1973; Fabre and Morris, 1974, 1975; 
Fabre and Batchelor, 1975; Winearls et al. 1980). 
Donor specific alloantiserum is usually administered 
intravenously either at or shortly after transplantation, 
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and quite small doses - as little as 50 µ 1 for 160-200gm rat 
(Fabre and Morris, 1973) - are sufficient to enhance rat 
kidney allografts. The enhancing antisera have been raised 
in various ways, but generally it is done by hyperirnrnuniza-
tion of the recipient with donor lymphoid cells (Stuart 
et al. 1979). 
While the passive enhancement of renal allografts 
has been shown to be achieved consistently in the rat, in 
other species it has been both more difficult to achieve 
and runs the risk of inducing hyperacute rejection 
(McDowall et al. 1973). 
Variation in the effect of enhancement also exists 
with strain combination and type of allograft. For example, 
in the Lewis to DA rat strain combination, passive 
enhancement prolongs renal allograft survival to >300 days, 
whereas in the August to AS, the mean survival is 43 days; 
untreated recipients undergo acute rejection, surviving 
only 12-14 days (Morris, 1980). The type of tissue used 
for transplantation also has a strong influence on the 
effectiveness of enhancement, with variations existing 
for different tissue allografts in the same strain cornbina-
tion. Generally, kidney allografts may survive indefinitely 
while heart allograft survival is moderate and skin is 
rrarginal (Tilney and Bell, 1974; Nash et al. 1977). Islet 
allografts behave somewhat similarly to skin. Finch and 
Morris (1976) found that while about half of the pancreatic 
islet allografts in rats could be enhanced using the F1 
hybrid donor, rejection could not be delayed with homozy-
gous islets. Nash et al. (1977) compared the enhancement 
of rat islets with heart, kidney and skin allografts. Pro-
longation in survival was best with kidney and then heart, 
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islet and skin in descending order. Only 4/10 islet allo-
grafts showed some prolongation in survival. More recently 
Reckard et al. (1981) confirmed this spectrum of increasing 
immunogenicity in rats, with renal allografts being least 
immunogenic, followed by heart, segmental pancreas and 
isolated islets. 
The reason for this degree of variation with different 
tissues is not known. Differences in antigenic composiiton 
have been suggested (Lance et al. 1973). Skin specific 
antigens (Sk antigens) were thought to be responsible for 
the difficulty experienced with skin allografts (Stein-
muller and Lofgreen, 1977) but even if enhancing sera 
are raised with skin grafts instead of the usual hyper-
immunization with lymphoid cells, there is still relatively 
little improvement on the survival (Morris, 1980). The 
great variation in amount of class II antigens expressed 
on different tissues, might account for the variation in 
enhancement of different tissues (Hart and Fabre, 1979; 
Davies and McKenzie, 1980). 
Clearly, then, the rat is not only the most thoroughly 
investigated model but it is also the experimental animal 
in which enhancement of vascularized organs seems to be most 
easily achieved, whether using active or passive enhance-
ment or a combination of both. The few clinical studies 
attempted have not given convincing evidence of improvement 
in kidney graft survival in man and, according to Fabre, 
much of the clinical hope of enhancement has now faded 
(Fabre, 1982). 
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1.13.3. Class and subcl a ss o f enhancing antibody 
The evidence indicates that the class of antibody 
conferring enhancement is confined to the IgG class (Mullen 
and Hildermann, 1971; Carpenter et al. 1976; Mullen et al. 
1977) although Voisin et al. (1969) have reported enhancing 
activity by the IgA class in mice. IgM does not enhance 
and has in fact been shown to be cytotoxic thereby reducing ) 
the length of survival of rat kidney allografts (Mullen 
and Hildemann, 1971; Mullen et al. 1977). 
Jansen et al. (1975b) obtained pure preparations 
of mouse 7S IgG subclass by means of affinity chromatography 
and demonstrated that IgG1 and IgG2 were both able to enhance 
skin allografts in mice, although only the latter subclass 
was also able to induce both enhancement and hyperacute 
rejection. In rat kidney allografts, only IgG2 has been 
shown to induce enhancement (Mullen et al. 1977). Due 
et al. (1982) found that the Sa 1 mouse tumour can be 
enhanced with IgG1 but not IgG 2 . 
1.13.4. Specificity of enhancing antibody 
Early studies with tumour (Moller, 1963) and skin 
(Jeekel et al. 1972) allografts in the mouse suggested a 
strong specificity of the enhancing sera. Later studies 
using the rat kidney model, however, indicated considerable 
cross reactivity or lack of specificity (Fabre and Morris, 
1974; Fabre and Batchelor, 1975), although more detailed 
serological studies by Morris' group have since shown that the 
cross reactivity is less than what had been previously 
thought (Morris, 1980). 
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1.13.5. Target antigen of enhancing antibody 
One of the most important questions to arise from 
studies of enhancement of normal tissue allografts has been 
whether the enhancing activity is associated with antibody 
directed towards products of one or several regions of the 
MHC. Following the demonstration by Davies and Alkins 
(1974) that enhancement of rat heart allografts could be 
achieved by antisera absorbed with erythrocytes, which 
express class I antigens only and not by antisera absorbed 
with spleen and thymus cells, which are both class I and 
II positive, they developed the view that passive enhance-
ment was produced by the anti-class II antibody in the 
enhancing antisera. The removal by absorption of anti-
bodies directed at class II antigens is not formal proof, 
however, that class I antibodies are not able, on their 
own, to enhance graft survival. Nonetheless, a number 
of studies using both absorption techniques and recom-
binant strains, soon followed which supported these 
findings. Class II antibodies were confirmed in mouse 
skin (Staines et al. 1975; McKenzie and Henning, 1977) 
and kidney allografts (Soullilou et al. 1976 ). Io an 
extensive review of rat and mouse experimental studies, 
Davies and Staines (1976) concluded that anti-class II 
antibodies were sufficient to achieve passive enhancement 
of rat heart and mouse skin allografts, and Winearls et al. 
(1980) have more recently demonstrated this with rat renal 
allografts. 
Others, however, have since reported that anti-class I 
activity is sufficient to enhance. Gallico et al. (1979) 
demonstrated with a rat recombinant haplotype that kidney 
allografts can be enhanced by antibodies directed at the products of · 
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either class I or class II regions. More recently, Davies 
and coworkers have themselves shown that heart allografts 
in mice c a n be enhanc e d t o a simi l ar e x tent with a nti bodies to the 
products of e ithe r cl a ss I o r c lass I I r e g i ons, a l t h ou gh sk i n 
could only be enhanced with anti-class II 
(Davies and McKenzie, 1980). De Waal et al. (1980) 
reported that both anti-H-2K and H-2D or class I allo-
antibodies have a weak but significant protective effect 
in mouse skin allograft survival. More recently still, 
Due et al. (1982) showed that mouse SA 1 tumour allo-
grafts can be enhanced with anti-class I antibody, although 
anti-class II antibodies have some activity on Sa 1 cells 
when grafted on C57BL/Ks mice. 
Thus, antibodies against donor class II antigens are 
not uniquely involved in enhancement as earlier believed. 
It is clear that both class I and class II antigens can 
induce enhancement depending on the models used and the 
techniques applied. This may even suggest that there 
are a number of ways in which the antiserum acts to 
induce enhancement. 
1.13.6. Mechanisms of enhancement 
The question of mechanisms by which enhancing anti-
bodies prolong allograft survival has been the subject 
of considerable controversy and speculation, and the whole 
issue is complicated by the use of different tissues and 
organs, different protocols and different rejection 
criteria. Early view;on mechanisms tended to apply a 
single mechanism and often equated induction with long 
term enhancement. For example, Billingham et al. (1956b) 
suggested that antiserum prevents or delays the graft 
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antigens from reaching the regional lymph nodes, thereby 
preventing a cellular response. This inhibition was called 
an "afferent inhibition" and which Snell (1957) called a 
"walking off" of the graft. This idea is based on the 
division of the locus of effect of the rejection response 
at 3 levels: afferent,central and efferent. Billingham 
argued that enhancement cannot be efferent inhibition because 
it cannot be induced in animals which are already immunized 
with living cells. Central inhibition also seemed to be 
out since Mitchison and Dube (1955) failed to abolish 
enhancement with normal lymph node cells - a procedure 
which could abolish actively acquired tolerance which 
was considered to be due to a central inhibition 
(Billingham et al. 1956a). In contrast, Kaliss and 
Bryant ( 195 8) argued for a form of efferent inhibition in which 
the antibodies somehow lead to an adoptive change in the 
graft and, as a result, the graft survives. One of their 
main arguments against the concept of afferent blockage 
was that immunity can be detected at the same time and in 
the same recipient carrying an enhanced graft. Graft 
adaptation has been repeatedly suggested (Woodruff, 1952, 
1954, 1960; Cannon, 1957) and is discussed in Section 
1.13.6.2. 
However, the mechanisms of afferent, central and· 
efferent blockage need not be mutually exclusive, as one 
or more may be operating at various times during the 
survival of an enhanced graft. Any discussion of 
mechanisms of enhancement, therefore) ought to make a 
distinction between at least two phases: the induction 
phase in which the immune reaction is either delayed or 
suppressed, and the maintenance phase which enables long-
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term or indefinite graft survival. 
1.13.6.1. Induction phase of enhancement 
The induction phase might operate peripherally such as 
by antigen masking or "coating'~ (Morris and Lucas, 1971) , 
which would delay or prevent antigen recognition, or via 
a central mechanism which requires the active suppression 
of the immune response after antigen recognition has 
occurred (Morris, 1980). The basic assumption behind 
ideas of peripheral blockade is that such a process leads 
to a complete masking of the antigenic determinants of 
the graft by the enhancing antisera and consequently 
inhibits the interaction of recipient lymphocytes with 
donor antigens. However, a peripheral effect by antigen 
masking is unlikely because, firstly, it has been shown 
that enhancement can be induced with very small (50µ1) 
amounts of antisera (Fabre and Morris, 1973) and, secondly, 
passively administered alloantibody disappears very 
rapidly (French and Batchelor, 1972; French, 1973}. 
The evidence seems to favour a central mechanism 
and three main ones have been suggested. The first is 
based on the role of anti-class II antibody which could 
directly affect the passenger leucocyte component 
(Davies and Staines, 1976; Soulillou et al. 1976). 
Passenger leucocytes are class II positive and play a 
key role in the induction of an immune response (Section 
1.6). Another idea is that antigen-antibody complexes 
interfere with the central part of the rejection reaction 
(French and Batchelor, 1972; Wonigeit and Pichlmayr, 
1977). The precise mechanism of their blocking effect 
is not known but several possibilities have been suggested 
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(see Theofilopoulos, 1980), including opsonization and 
phagocytosis. Hutchinson has proposed that antigen-
reactive cells are opsonized by graft antigen-antibody 
complexes and are subsequently destroyed by Fe receptor-
bearing host cells such as macrophages (Hutchinson, 1980; 
Hutchinson and Brent, 1981). Hutchinson (1980) has 
reviewed the data in support of this hypothesis and their 
most direct evidence comes from their studies in which 
syngeneic radiolabelled antigen reactive cells were taken 
up by macrophages when injected intravenously into rats 
carrying enhanced renal allografts, or mice carrying 
enhanced skin allografts. However, opsonization is 
obviously not so complete as to remove all antigen 
reactive cells because normal proliferative and cyto-
lytic responses occur in in vitro assays using lympho-
cytes from enhanced graft recipients (Stuart et al. 
1980). The proportion and subpopulation of host T cells 
which bind to the antigen need to be demonstrated before 
adequate assessment of the relative importance of this 
mechanism can be made. A third possibility might be 
that the passively administered alloantibody induces 
antibody formation to the antigen combining site of the 
antibody itself, that is, anti-idiotypic antibody. This 
antibody would also react with receptor sites for that 
antigen on T lymphocytes and thus again block the 
induction of the immune response at a central level. 
For example, Stuart et al. (1976) induced Lewis rats to 
make antibody against Lew anti-Brown-Norway (L anti-BN) 
by immunization of Lewis rats with complexes of BN 
antigen and anti-BN antibody. They demonstrated that the 
acceptance of LBN kidneys by Lewis recipients occurred 
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when transplants were performed at 10 days post treatment 
with antigen and antiserum, that is, when the titre of L 
anti-(L anti-BN) idiotypic antibody was at its peak. 
Kidneys transplanted either before the appearance or after 
the disappearance of anti-idiotypic antibody were rejected. 
At present then, the mechanism by which the induction 
of enhancement might operate remains speculative and it is 
also possible that more than one mechanism might be 
operative. 
1.13.6.2. Maintenance phase of enhancement 
Once enhancement is induced, either passively, actively 
or by a combination of both, the maintenance phase seems 
to require an active process on the part of the recipient. 
This phase is much more complex and may depend on more 
than one mechanism. Three general mechanisms have been 
proposed for this phase: clonal deletion, graft adapta-
tion, and regulation in some way of the host's response to 
the allograft. 
Clonal deletion proposes that a specific clone of 
antigen reactive cells are deleted during the induction 
of enhancement, thus allowing a stable maintenance phase. 
However, existing evidence provides little support for 
this mechanism. For example, the injection of syngeneic 
lymphocytes into recipients carrying long surviving kidney 
allografts did not lead to rejection (McKenzie and Morris, 
unpublished, cited in Morris, 1980). Moreover, spleen 
cells from similar recipients proliferate normally in MLC 
(Stuart et al. 1979) and produce a normal GVH reaction in 
a popliteal lymph node assay (French et al. 1971; Mullen 
et al. 1973). 
Graft adaptation has long been suggested as a 
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mechanism for allograft protection following the Woodruffs' 
demonstration that guinea pig thyroid allografts which 
remained in the anterior chamber of the eye for some time, 
remained invulnerable when retransplanted to non- privileged 
sites in the body (Woodruff and Woodruff, 1950). To explain 
this phenomenon, Woodruff (1952, 1954) formulated the 
hypothesis of the "critical period" according to which 
allografts became progressively less vulnerable with time 
and after a certain critical period are capable of 
surviving indefinitely in the host. Although this idea 
was criticised by those who saw tolerance as an adaptation 
of the host (Billingham et al. 1956a), some support has 
been given in more recent years (Sharav et al. 1969; 
McKenzie et al. 1972; Warden et al. 1973; Hart et al. 
1980). Batchelor's group was able to demonstrate indefin-
ite survival when long term surviving kidneys in the 
(AS x Aug) F1 to AS and (ASxWF) F1 to Lewis rat strain 
combinations were retransplanted to fresh AS and (ASxWF) 
F1 recipients respectively (Batchelor et al. 1979; Welsh 
et al. 1979). They attributed the lack of response to 
the retransplanted kidney to the absence of passenger 
leucocytes in the enhanced kidney - a conclusion also 
arrived at in an extensive study by Hart et al. (1980). 
Antigenic deletion or modification has been suggested 
to account for adaptation in tumour studies (Woodruff 
and Symes, 1962; Boyse et al. 1963) but this has not 
been demonstrated for normal tissues. Antigen alter-
ation in the enhanced kidney is unlikely since there 
is evidence that long surviving grafts carry a normal 
complement of MHC antigens as measured by antibody 
absorption (French, 1972) or 125 r labelled antibody 
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uptake (Fine et al. 1973 ). Moreover, antigen in sufficient 
amounts to lead to allograft rejection, persists in the 
enhanced graft following retransplantation (Stuart et al . 1970), 
although this persistance varies with the strain combination 
used (Hart et al. 1980 ). Using radioimmune binding assays, 
Hart et al. (1980) have also demonstrated that there is no 
qualitative difference in the amount of class I or II 
antigens in long surviving (DA x Lewis) F1 kidneys compared 
to that in fresh kidneys. More recently they confirmed the 
findings using monoclonal antibodies to rat class I and II 
antigens. Therefore, in the broad sense of making a graft 
fit or suitable,adaptation does occur in enhanced grafts, 
but this seems to be best attributed to the loss of 
passenger cells. 
It appears most likely that enhancement is maintained 
by an active regulation of the host response to the donor 
graft antigens, although the mechanisms underlying this i 
regulation are unclear. While an anti-idiotypic response 
might assist in the induction phase of enhancement this 
mechanism could not be supported for the maintenance 
phase (Batchelor et al. 1977; Stuart et al. 1979; 
Morris, 1980). For example, circulating anti-idiotypic 
antibody could not be detected in recipients carrying 
long-surviving kidney allografts (Stuart et al. 1976). 
Serum-blocking factors likewise have been generally 
discounted as a mechanism. The rapid destruction of 
enhanced mouse skin allografts following the injection 
of rabbit complement alone, argues against the idea ' 
that a graft is protected by a coating of blocking 
antibody (Koene et al. 1973). Also no blocking activity 
has been found in the sera of long-surviving renal allo-
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51 grafts using MLR and Cr release (Stuart et al. 1979; 
Morris, 1980). The role of T cells in the suppression of 
the immune response has been widely reported in various 
models (reviewed by Tilney et al. 1979b) and will be further 
discussed in Section 1.14. Suppressor T cells have been 
implicated in adoptive transfer and in in vitro experi-
ments where prior tolerance has been induced following 
ALS and tissue extract treatment (Kilshaw et al. 1975) or 
TLI (Strober et al. 1979; Myburgh et al. 1980a,b, 1983; 
Smit et al. 1980, 1981). The evidence of Dorsch and 
Roser (1977) suggests that neonatal tolerance is main-
tained in the adult rat by long lived recirculating 
suppressor T cells, and Stuart · et al. (1976) were able 
to prolong renal allograft survival following the 
adoptive transfer of spleen cells from enhanced kidney 
recipients. Batchelor et al. (1977), on the other hand, 
were not able to demonstrate suppressor activity in 
enhanced renal allograft recipients. While a defini- · 
tive evaluation of the many different mechanisms that 
contribute both to the induction and maintenance of 
enhancement is not possible, the role of T suppressor 
cells remains the most plausible explanation for the 
maintenance phase. 
1.14 MECHANISMS OF TRANSPLANTATION TOLERANCE 
One of the key questions in transplantation immun- · 
ology is whether transplantation tolerance is induced 
and maintained by passive central clonal deletion or 
active peripheral suppressor mechanisms, or a combination 
of both. Classical neonatal transplantation tolerance 
was originally thought to be maintained by the deletion 
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of specific antigen reactive cells. This notion has not 
remained unchallenged, however, and is slowly being 
modified as evidence accummulates which supports the role 
of an active mechanism (Dorsch and Roser, 1977; Gruchalla 
and Streilein, 1982). Several mechanisms have been 
proposed besides clonal deletion, the main ones being 
serum-blocking factors, anti-idiotypic antibodies and 
T suppressor cells. These have already been noted in 
the above discussion on enhancement (Section 1.13.6) 
but, in this section, it is proposed to present some 
further evidence for these mechanisms. Because a very 
large body of evidence exists in support of these 
proposals, once again it is possible to give only a 
brief summary. For general reviews on mechanisms, 
see Brent et al. (1976), Elkins (1979) and Nossal (1983). 
1.14.1. Clonal deletion 
As already indicated, Billingham et al. (1956a) 
attributed neonatal tolerance to a central failure of 
the immune response, since the transfer of syngeneic 
lymphocytes could restore immunological reactivity -
an idea consistent with Burnet's clonal selection 
hypothesis (Section 1.10). This idea essentially 
became the conventional view of transplantation toler-
ance. 
However, the evidence from subsequent studies has 
not been unequivocal. Some studies where normal lymphoid 
cells have been used to abolish the tolerance state have 
given evidence of successful abolition of tolerance and 
hence interpreted as consistent with clonal deletion 
(Billingham et al. 1963), while others were not able to 
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abolish similar tolerance (Ramseier, 1973; Rieger and 
Hilgert, 1977; Hilgert, 1979; reviewed by Elkins, 1979). 
Similarly, some studies which looked at T cell function in 
neonatal tolerized animals using MLC, CML and GVH assays, 
supported the idea of donor-reactive lymphocytes having 
been deleted or inactivated in such animals (Wilson and 
Nowell, 1970; Atkins and Ford, 1972; Brooks, 1975; 
Gruchalla and Streilein, 1982), while others have demon-
strated that residual cytotoxicity may persist in experi-
mentally tolerant animals and in tetraparental chimeras 
(Hellstrom et al. 1971; Hellstrom and Hellstrom, 1974; 
Bansal et al. 1973; Droege and Ma yer, lq75; Dorsch 
and Roser, 1977; Tutschka, et al. 
1981a; Section 1.12). In studies in our own laboratory 
we have shown that adult tolerant animals respond 
normally to donor alloantigens in vitro (Chapter 6). 
As a consequence of these and other investigations, 
the clonal deletion concept has been seriously 
challenged and there now seems to be a general consensus 
that unresponsiveness is maintained through active 
regulatory mechanisms rather than through the passive 
clonal deletion mechanism (Hilgert, 1979). 
1.14.2. Serum blocking factors 
Antibodies or immune complexes have been suggested 
as a mechanism of suppressing the immune response, either 
by the direct masking of potential activating determinants 
by specific antibodies in the serum, or by the presence of 
antigen-antibody complexes. Voisin et al. (1968, cited 
in Brent et al. 1976) raised the idea that humoral 
blocking factors inhibited immunological function in tol-
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erant animals by enhancing tumour ~rowth with serum from 
tolerant mice. Subsequently, Hellstrom and coworkers 
reported that serum from tolerant animals blocked killing 
of donor-type cells in vitro with evidence pointing to an 
antigen-antibody complex as being the blocking factor 
(Hellstrom et al. 1971; Bansal et al. 1973; reviewed by 
Hellstrom and Hellstrom, 1974). Similar findings were 
reported by Chutna et al. (1973). However, the animals 
used by these workers were not fully tolerant and Brent 
et al. (1972) who used completely tolerant mice could not 
confirm this. Other studies soon confirmed that blocking 
activity was detectable but only in sera from partially 
tolerant mice (Brooks, 1975). 
Elkins (1973) using rat bone marrow chimeras was unable 
to find evidence for an active cellular or humoral 
suppressor mechanism and Hasek· et al. (1975) could not 
show that blocking factors played any role in tolerance 
induction. More recently, other groups have failed to 
demonstrate the presence of blocking factors in vitro 
(Waterfield et al. 1981; Moran et al. 1983). 
Controversy concerning the role of serum blocking 
factors has arisen from the different assay systems 
used (Law et al. 1974) and the relevance of in vitro 
observations to tolerance maintenance in vivo (Brent 
et al. 1976). 
1.14.3. Anti-idiotypic antibodies 
Ramseier (1973) and Rowley et al. (1973) suggested 
that anti-idiotypic antibodies may eliminate lymphocytes 
carrying receptors for the tolerated antigens in chimeric 
animals, and the work of Binz and Wigzell (1975), 
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suggested an important role for anti-idiotypic antibodies 
in tolerance maintenance. However, its true role in 
maintenance of transplantation tolerance remains speculative 
and, as already noted in Section 1.13.6.2, this mechanism 
could not be supported for enhancement studies. More 
recently, Moran· et al. (1983) could find no evidence for 
an anti-idiotypic antibody suppression mechanism. According 
to Batchelor (1983), one of the problems in analyzing this 
mechanism has been the difficulty in setting up reproducible 
experimental systems. 
1.14.4. T suppressor cells 
The greatest body of evidence for an active mechanism 
has come from studies on suppressor function. Since the 
early work by Dorsch and her colleagues who described 
suppressor cell activity in neonatal tolerance and 
presented evidence for the involvement of T cells (Dorsch 
and Roser, 1974, 1975; reviewed by Roser and Dorsch, 
1979), there has been a flood of reports, using both 
in vivo and in vitro assays in a number of different 
experimental models, all of which suggest the involvement 
of an active cellular suppressor mechanism in the 
maintenance of transplantation tolerance. Experimental 
systems include: neonatal tolerance induced by F 1 bone 
marrow cells in rats (Dorsch and Roser, 1977, 1982a,b; 
Hilgert, 1979); neonatal tolerance in mice(Hasek and 
Chutna, 1979; Streilein, 1979; Holan et al. 1980; 
Vegh et al. 1980; Janossy et al. 1983); adult tolerance 
(Section 1.12) induced by various methods such as bone 
marrow chimeras in lethally irradiated rats (Tutschka 
et al. 198la,b, 1982, 1983); bone marrow transplants to 
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recipients of TLI (Strober et al. 1979; Myburgh et al. 
1980a,b, 1983; Smit et al. 1980, 1981), ALS and tissue 
extracts (Kilshaw et al. 1975; Brent and Opara, 1979; 
Hilgert, 1979), blood pretreatment (Horsburgh et al. 
1981; Maki et al. 1981; Marquet and Heystek, 1981; 
Lenhard et al. 1982), cyclosporine 
(Hutchinson et al. 19-81; Hess et al. 1983), human 
kidney transplant patients maintained on immunosuppressive 
drugs (Charpentier et al. 1982), organ culture of islets 
and ALS treatment of recipient (Zitron et al. 1981b), 
and enhancing antibody (Stuart et al. 1976; Section 1.13). 
However, not all investigators have been as successful. 
While some could not consistently demonstrate suppressor 
cell activity (Moran et al, 1983~, others failed to detect 
any evidence at all for such activity (Elkins, 1973; 
Brooks, 1975; Batchelor et al. 1977; Weigle, 1978; 
Gruchalla and Streilein, 1982). 
A number of studies have pursued the phenotype and 
functional aspects of the suppressor cells (reviewed by 
Roser and Dorsch, 1979; Roser et al. 1983). Studies in 
the rat by Dorsch's group have shown the suppressor cell 
distribution to reside within the lymphoid tissues of 
tolerant animals and suppression is mediated by long-
lived, thymus-derived (Dorsch and Roser, 1977), rapidly 
recirculating (Dorsch and Roser, 1975) cells. More 
than 95 % are T cells (Dorsch and Roser, 1977) as judged 
by several phenotype criteria. These cells carry the 
monoclonal W3/13 (Williams et al. 1977; Roser and 
Dorsch, 1979) and serologic pta (Roser and Dorsch, 1980) 
markers and lack surface immunogobulin and Fe receptors 
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(Dorsch and Roser, 1977). In the mouse these cells carry 
the Thy-1 marker (Hilgert, 1979), but the Lyt phenotype 
is not yet known (Roser et al. 1983). Some have reported 
results which implicate the existence of more than one 
suppressor cell type in tolerant mice (Gorczynski and 
Macrae, 1979). 
In most studies, suppressor activity has been shown · 
to be specific (Roser et al. 1983). Some have reported 
the development of a progression from alloantigen non-
specific suppressor cells to specific suppressor cells 
after transplantation. Tutschka et al. (1981b) 
demonstrated the appearance of nonspecific suppressor 
cells in rat bone marrow chimeras at 40 days after 
grafting, being replaced by specific suppressor cells 
at 250 days. This sequence is similar to reports with 
recipients conditioned by TLI (Strober et al. 1979; 
Section 1.12.3). 
Beyond identification of their presence in particular 
models, the precise mode of action of suppressor cells 
is not clear. Some have suggested that the effect of 
suppression might be to delete or inactivate clones of 
graft antigen reactive lymphocytes (Dorsch and Roser, 
1977; Tutschka et al. 1981a). Tutschka's group found 
that, in their model, spleen cells harvested at various 
times after transplantation and tested both in vivo and 
in vitro, could no longer be detected by in vitro methods 
at 720 days post-transplantation (Tutschka et al. 1981b). 
More recently, Heuer et al. (1982), using a T suppressor 
cell clone originally isolated from mice rendered 
tolerant to BSA, suggested that clonal deletion could 
result from T suppressor cell activity. 
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While the majority of investigators it seems, favour 
an active T cell suppressor mechanism as being responsible 
for the maintenance of transplantation tolerance, some 
have questioned the significance of the suppressor 
mechanism. For example, much evidence for suppressor cell 
activity has come from adoptive transfer experiments of 
T cells to syngeneic recipients which are then test 
grafted. HowevaT, since it is usually necessary to 
partially 1mmunosuppress recipients using sublethal 
irradiation or ALS (Kilshaw et al. 1975; Hasek and Chutna, 
1979; Roser and Dorsch, 1980), the relative importance of 
suppressor cells has come under question (Batchelor, 1983). 
Furthermore, Hasek and Chutna (1979) have argued that if 
suppressor cells play a maJor role in tolerance induction, 
then a sublethal dose of irradiation should terminate the 
tolerance state. While Fefer and Nossal (1962) were able 
to abolish partial tolerance with doses of 350-450 rads 
of irradiation, Hasek's group failed to abolish tolerance 
in rats using 400 rads. This led them to suggest that 
suppressor cells may not be the only mechanism involved 
(Hasek and Chutna, 1979) - a conclusion arrived at recently 
by Gruchalla and Streilein (1981). Roser and Dorsch (1980) 
also failed to abolish suppression with irradiation (750 
rads), although they could do so by combining irradiation 
with small doses of normal lymphoid cells. Classic in vitro 
suppression assays have also come under criticism because 
of the difficulty of interpretation in cell mixture experi-
ments between genuine suppression and artifact due to 
culture conditions (Auchincloss and Sachs, 1983). 
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1.14.5. Conclusions 
The mechanism of transplantation tolerance is still 
poorly understood some 30 years after the first experimental 
induction. Factors which have contributed to this confusion 
are the lack of universal criteria by which tolerance can be 
assessed and the use of many different experimental systems 
to induce adult tolerance. 
Although clonal deletion has been a widely held and 
unifying concept in immunological tolerance, it has for 
some time come under challenge. The clonal selection 
concept has failed to account for the fact that there are 
present self-recognizing Band T lymphocytes in normal 
animals, and F1 animals do respond to parental antigens 
(Streilein, 1979; Ebringer, 1981). Moreover, there is 
mounting evidence that other mechanisms are involved in 
achieving unresponsive or tolerant states. T suppressor 
cells, as an active mechanism in transplantation tolerance 
maintenance, has been increasingly demonstrated in 
tolerant animals during the past decade. Finally, the 
numerous studies suggest that transplantation tolerance 
is a complex phenomenon which possibly involves more than 
one mechanism in its maintenance (Brent et al. 1976; 
Charpentier et al. 1982). 
CHAPTER 2 
MATERIALS AND METHODS 
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2.1 EXPERIMENTAL ANIMALS 
All animals used were inbred strains of mice obtained 
from the Animal Breeding Establishment at the John Curtin 
School of Medical Research. 
Male BALB/c (H-2d) mice, approximately 6-10 weeks old, 
were used as donors of pancreatic islets, thyroid tissue, 
k peritoneal and spleen cells. Male CBA/H (H-2), 10-15 
weeks old, were used as recipients of donor tissue. 
BALB/c foetuses at 17 days gestation were used as donors 
of foetal pancreatic tissue. Foetuses were obtained in 
the following way: BALB/c breeding pairs were set up and 
mating was monitored by daily inspection of female mice 
for the presence of a vaginal plug. Seventeen days after 
identification of the plug, pregnant mice were killed by 
cervical dislocation and the foetuses were removed by 
hysterectomy. Male C57BL10J (H-2b) 8-10 weeks, were also 
used as a source of thyroid tissue in some experiments. 
Experimental animals were housed either singly or 
in groups of up to 10 in wire topped cages containing 
normal litter, as well as cotton wool in the case of 
diabetic animals. Animals were provided with food and 
water ad libitum and the standard feed was Mecan rat 
and mouse cubes (Fidelity Feeds, Murrurnburrah, N.S.W.). 
2.2 TISSUE CULTURE MEDIA 
RPMl 1640 medium (M.A. Bioproducts, USA) was prepared by 
dissolving 10.4gm of medium powder in 1 litre of double 
distilled, de-ionised water supplemented with l.Ogm of 
sodium bicarbonate. 
Eagle's Minimal Essential Medium (EMEM) was prepared 
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by dissolving 10.0gm of medium powder (GIBCO) in l litre 
of double distilled, de-ionised water supplemented with 
2.2gm sodium bicarbonate. 
RPMI 1640 and EMEM were supplemented with antibiotics 
(penicillin, 100 units/ml; streptomycin, lOOµg/ml; 
neomycin, lOOµg/ml) and sterilized by filtration through 
a 0.22µ filter (Multipore Corporation). Every two weeks 
after the initial preparation, RPMI 1640 medium was 
supplemented with L-glutamine (0.3gm/100ml). 
Heat inactivated foetal calf serum (HIFCS) was pre-
pared by incubating each serum batch (Flow Laboratories, 
Australia) at 56°C for 30 minutes. 
Hanks Balanced Salt Solution (HBSS) was prepared 
according to the procedure described by Hanks and Wallace 
(1949). HBSS was sterilized by autoclaving at 112°C for 
20 minutes. 
HEPES buffer (N-2-Hydroxyethylpiperazine-N'-2-
ethanesulfonic acid) (Sigma) was prepared by adding 
25gm HEPES powder in 100ml HBSS adjusted to pH 7.4 and 
sterilized by filtration. 
Phosphate Buffered Saline (PBS; calcium and 
magnesium free, pH 7.3) was prepared according to the 
following formula: sodium chloride, 80gm; disodium 
hydrogen phosphate, 12.Sgm; monosodium hydrogen phos-
phate, 4.0gm; distilled water, 1 litre. PBS was steri-
lized by autoclaving at 121°C for 20 minutes. 
Normal saline (0.9 % sodium chloride) was prepared 
by dissolving 9.0gm sodium chloride in 1 litre of distil-
led water and sterilized in the same way as PBS. 
Bovine serum albumin (BSA) was prepared by dissolving 
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7.Sgm of bovine albumin powder (Armour Pharmaceutical, 
England) in 50ml of HEPES-buffered HBSS supplemented with 
antibiotics. The solution was sterilized by filtration 
through a 0.22 µ filter before use. 
2.3 ISOLATION AND CULTURE OF TISSUE 
2.3.1. Pancreatic islets 
The isolation and culture of pancreatic islets has 
been summarized diagrammatically in Fig. 2.1. Pancreatic 
islets were prepared by a modification of the method pre-
viously used in our laboratory (Bowen et al. 1980). The 
pancreas from 4 BALB/c donors was removed and placed in 
a siliconized 20ml glass scintillation vial containing 
collagenase (Boehringer Mannheim) at a concentration of 
l.Smg/ml, in 5ml HEPES-buffered HBSS supplemented with 
antibiotics (penicillin, lOOunits/ml; streptomycin, 
lOOµg/ml; neomycin, lOOµg/ml), BSA (1.Smg/ml) and 
deoxyribonuclease (DNase I: Sigma) (O.Olmg/ml). The 
collagenase and DNase had been filtered through a 0.22 µ 
disposable filter. The tissue was then digested for 
20 minutes using a water bath set at 37°C, with a 
mechanical shaker. The enzymatic digestion was 
arrested by the addition of 10-lSml of chilled HEPES-
HBSS solution . The digest was allowed to settle on ice for 5 
minutes before removing the supernatant. Five ml of 
half strength collagenase (0.75mg/ml) was added and a 
second digestion (5 minutes) was carried out. This 
short digestion was repeated 3 times. After the final 
digestion, individual islets were identified by using 
a stereomicroscope (Olympus SZ-111, Japan) set at 
16x magnification. Islets were picked using a sili-
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conized narrow bore pipette attached to a rubber tube for 
mouth suction, and transferred to a petri dish containing 
isolation medium ~ Islets were repicked 3 to 4 times to 
eliminate exocrine tissue contamination. This method gave 
a relatively high yield of approximately 80-100 islets 
per mouse pancreas. 
During the final pick, groups of 50 islets were trans-
ferred to siliconized 10ml glass centrifuge tubes contain-
ing 2ml RPMI 1640 culture medium supplemented with 10% 
HIFCS and allowed to settle on ice for 10 minutes. Most 
of the supernatant was then removed leaving 0.3-0.4ml. 
Using a siliconized Pasteur pipette this fluid was gently 
churned to resuspend the islets and then taken up and 
transferred to hydrophobic U-shaped wells in a 96 well 
microtitration plate (Linbro/Titertek, Cat. No. 76-212-05, 
Flow Laboratories, USA). After allowing the islets to 
settle for 5 minutes on ice, as much as possible of the 
medium was removed from each well, while taking care not 
to pick up islets and replaced with 100µ1 of fresh 
culture medium. Islets were then aggregated by centri-
fugation (200g) for 4 minutes using a TJ6 (Beckman) 
centrifuge. A later improvement involved the use of 
glass, bottomless tubes which were specifically made to 
fit firmly over the wells of the microtitration plate. 
In this way, groups of about 50 islets were transferred 
directly to the plate and allowed to settle. The super-
natant was then removed, the glass tubes tak~n off and 
the plate centrifuged as before. After centrifugation, 
the isolation medium was removed and replaced 
with culture medium (100µ1 per well) as before and re-
centrifuged. The microtitration plate was then placed 
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in a humidified portable incubator and charged for 10 
minutes with a 95 % o2 and 5% co2 gas mixture. The islets 
remained in this atmosphere for 3 days· during which time 
they formed into intact clusters. After 3 days, islet 
clusters were removed from the wells and each placed 
a separate 35mm hydrophobic petri dish (Falcon 1008) 
. in 
containing 0.75ml of fresh culture medium. The culture 
medium was subsequently changed every 2 days until day 7 
when the islets were ready for transplantation. Depend-
ing on the availability of sufficient tissue for one 
transplant (350 islets), tissue could be left in culture 
for as long as 9 days. The incubator was regased after 
each medium change and the ambient temperature was main-
tained at 37°C throughout the organ culture period. 
- 2.3.2. Foetal pancreas 
This procedure has been described by Simeonovic and 
Lafferty (1981). Briefly, BALB/c foetuses at 17 days 
gestation were killed by decapitation and the pancreas 
removed intact from each foetus and transferred to RPMI 
1640 culture medium supplemented with 10 % HIFCS. To 
facilitate gas diffusion, each pancreas was subsequently 
' cut into 3 segments, transferred to a 35mm hydrophobic 
petri dish (Falcon 1008) containing 1ml of culture medium 
and cultured in 95 % o2 and 5 % co 2 at 37°C for 10 days. 
Culture medium was changed 3 times per week. 
2.3.3. Thyroid tissue 
Thyroid lobes for culture were removed under sterile 
conditions from BALB/c donor mice which had been pretreated 
with cyclophosphamide (Endoxan-Asta, Bristol Laboratories, 
Australia). Cyclophosphamide powder was first prepared 
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for injection by diluting it with distilled water to a final 
concentration of 20mg/ml. Two intraperitoneal injections 
were given at a dose rate of 300mg/kg body weight on days 
-4 and -2. Mice were killed on day Oby chloroform 
inhalation. 
For removal of the thyroid, the neck region was 
swabbed with 70% ethanol and a 2cm midline incission was made 
using a large scalpel blade (number 22, Swann-Morton, 
England). Using blunt dissection, the underlying salivary 
glands were parted and the muscle sheath around the 
trachea was split longitudinally and separated. This 
allowed identification of the two thyroid lobes, one 
on either side of the trachea. The lobes were removed 
as intact as possible a,nd placed initially in HBSS 
supplemented with 0.013% w/v sodium bicarbonate and 
antibiotics. When all thyroids had been removed, two 
lobes were placed in each hydrophobic 35mm petri dish 
(Falcon 1008) containing 1ml of EMEM supplemented with 
10% HIFCS. Thyroid tissue was cultured in 95% o
2 
and 
5% co2 at 37°C for 21 days, during which time the 
culture medium was changed 3 times per week. 
2.4 ANAESTHESIA 
General anaesthesia was induced by peritoneal 
injection of avertin anaesthetic solution. Avertin was 
prepared by dissolving l.Ogm of 2,2,2-tribrom-aethanol 
(Fluka AG, Switzerland) in 1.0ml of 2-methyl~2-butanol 
(Fluka AG, Switzerland). The solution was diluted to 
a final volume of 50ml with hot tap water (50°C) and 
shaken vigorously to mix. The solution was then decanted 
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at a separate site but close together, under the kidney 
capsule. When the capsule was released the graft was held 
securely against the kidney. During the transplant pro-
cedure the kidney was swabbed regularly with HBSS to 
prevent dehydration. At the conclusion of the transplant- _ 
ation procedure, the kidney was replaced into the 
abdominal cavity and the wound closed with 3 to 4 autoclips 
(9mm; Clay Adams, USA). The transplanted animal was then 
placed under an incandescent lamp until fully revived. 
Recipients of islet tissue, in most cases received 7 
clusters or approximately 350 islets. 
2.6 INDUCTION OF DIABETES AND MANAGEMENT OF DIABETIC MICE 
2.6.1. Preparation of acetate buffer 
A stock solution of acetate buffer (pH 4.4) was pre-
pared according to the following formula: 30.5ml 0.2M 
acetic acid, 19.5ml 0.2M sodium acetate, 0.9gm sodium 
chloride. The solution was made up to a final volume of 
100 ml with distilled water. 
2.6.2. Induction of diabetes 
Diabetes was induced in CBA recipients of islet allo-
grafts by using a single tail vein injection of strepto-
zotocin (Calbiochem-Behring, La Jolla, California). 
Immediately before injection, 30mg of streptozotocin was 
dissolved in 1.0ml acetate buffer (Section 2.6.1). This 
solution was drawn up in a 1.0ml syringe and injected 
using a 26 guage needle, at a dose of 300mg/kg body 
weight. 
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2.6.3. Management of diabetic mice 
To control dehydration, mice were given intraperiton-
eally 1.0ml of warmed (37°C) normal saline per gram of lost 
body weight from days 3 to 6 (inclusive) post-streptozotocin 
injection. In addition, mice were maintained with a single, 
daily subcutaneous injection of 0.8 units of Ultralente 
insulin (CSL) from day 3 to 14 post-streptozotocin. At day 
17 and again just before transplantation, blood and urine 
glucose levels were determined (Section 2.8, 2.9). Animals 
which showed a consistent non-fasting blood glucose reading 
of 20 ~rnrnoles/litre were used as recipients of islet allo-
grafts. Diabetic mice were transplanted 17 to 35 days 
after streptozotocin treatment. 
2.7 THYROIDECTOMY OF THYROID ALLOGRAFT RECIPIENTS 
Recipients of cultured thyroid allografts were par-
tially thyroidectomized 3 days before thyroid trans-
plantation. This procedure facilitates the assay of graft 
function (Section 2.11) and stimulates the production of 
thyroid-stimulating hormone thereby promoting the growth 
of grafted thyroid tissue (Lafferty and Cunningham, 1975). 
The procedure used for removal of recipient thyroid tissue 
was the same as for the removal of donor thyroid tissue, 
except that animals for thyroidectomy were placed under 
anaesthesia (Section 2.4) and care had to be taken to 
avoid damage to local blood vessels and particularly to 
the recurrent laryngeal nerve which runs close to the left 
thyroid lobe. As much as possible of each thyroid lobe 
was excised by blunt dissection. The muscle sheath and 
salivary glands were then put in place and the incision 
closed with 2 or 3 autoclips. The mice were then placed 
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under an incandescent lamp until the y recovered from the 
anaesthesia. 
2.8 BLOOD GLUCOSE MEASUREMENTS 
Non-fasting blood glucose levels were determined in 
diabetic mice and recipients of islet allografts, using 
a Glucose Analyzer 2 (Beckman, USA). Whole blood (10µ1) 
was collected from the tip of the tail using a 10µ1 
microcap (Drummond, USA) and transferred immediately to 
a microcentrifuge tube (Vetri, 1.5ml with attached cap; 
Max Richter, West Germany) containing 40µ1 of 0.66M 
perchloric acid for blood deproteinization. The micro-
centrifuge tube was first vortexed to mix and then centri-
fuged for 90 seconds in a microcentrifuge (Beckman Micro-
fuge). Two 10µ1 aliquots were then taken from each super-
natant and the glucose content determined against a 
glucose standard. Duplicate assays were averaged and 
measurements corrected for sample dilution and expressed 
in mmoles of glucose/litre. The lower limit of sensitivity 
for the analyzer was 0.56 mmoles glucose/litre. The normal 
range for male CBA mice is given as the mean+ 1.96 
standard deviations. It was determined from several 
groups of normal, non-fasting male CBA mice (170 animals) 
which had been bled from the tail vein during early to mid 
afternoon. Data were pooled and the 95 % confidence 
interval for blood glucose levels was calculated. The 
normal range for non-fasting animals was determined as 
8.5 + 2.32 mmoles glucose/litre. 
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2. 9 URINE GLUCOSE MEASUREMENTS 
As with blood glucose measurements, urine glucose 
measurements were determined in animals which were diabetic 
or carried an islet allograft. Individual mice were placed 
in a round cage constructed with a wire mesh bottom. Urine ·-
was collected over a 24 hour period by means of a funnel 
which spanned the cage floor and drained into a 50ml 
cylinder. During this time, food and water were provided 
ad libitum. At 24 hours the volume or urine was noted and 
and an aliquot (100µ1) of urine was diluted in 10ml 
distilled water. If no urine was visible due to evapor-
ation, the collection cylinder was rinsed with 2ml of 
distilled water (reconstituted volume) and a sample was 
removed for glucose determination. A 400µ1 sample of the 
dilution was transferred to a microcentrifuge tube and 
centrifuged for 90 seconds to remove any debris. Two 
10µ1 aliquots were then taken from each supernatant and 
the glucose content assayed using the method described 
in Section 2.8. Measurements were corrected for sample 
dilution, and the amount of glucose excreted in 24 hours 
was calculated according to the following formula: 
Urine glucose 
output 
(mmoles/24hrs) 
24hr urine volume 
or 
reconstituted volume 
(ml) 
mmoles glucose/ 
litre x----------
1000 
Normal or diabetes-reversed CBA mice failed to excrete 
detectable amounts of glucose. 
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2.10 NEPHRECTOMY 
Animals carrying functional islet allografts had their 
graft removed by nephrectomy at the conclusion of the 
experiment. The kidney was exposed as described in Section 2.5 
above so that the main renal artery and vein were visible. 
These blood vessels were then ligated with sterile surgical 
silk (size 000, Ethicon, USA). The kidney was cut free 
and the excision site swaboed with HBSS. The incised skin was 
sutured with autoclips. After examination, the removed kidney 
was fixed in 10% formal saline for histology (Section 2.12). 
Non-fasting blood glucose levels were thereafter measured 
daily for one week. A return to the diabetic condition was 
an indication that the allograft had been functional and 
responsible for the maintenance of normoglycaemia. 
Nephrectomized animals usually returned to the diabetic condition 
within 1 - 3 days following the removal of the islet allograft . 
2.11 MEASUREMENT OF THYROID FUNCTION 
Thyroid function was followed by measuring the level 
of 
125
Iodine (125 I) uptake by transplanted thyroid tissue. 
Details of this assay have been descibred by Lafferty 
et al. (1976a). Briefly, transplant recipients received 
. t . t 1 . . t . of 15 1 1C i· of 12 5 I an in raperi onea inJec ion ~ (code IMS 
30, Amersham, England) at 21 days post transplantation 
and at 2 to 3 week intervals thereafter. Three days 
f th 125 . . . . 1 h . d d a ter e I inJection, anima s were anaest etize an 
the level of radiation emitted from the thyroid trans-
plant was measured by positioning a scintillation probe 
above the site of the grafted kidney. Grafts emitting 
- 108 -
more than 171 counts per minute (c.p.m.) were scored as 
functional. This figure is 2 standard deviations above the 
mean value obtained for known rejected allografts (Table 
2. 1) . 
2.12 HISTOLOGY 
2.12.1. Preparation of formal saline 
Formal saline was prepared according to the following 
formula: 100ml formaldehyde; 8.Sgrn sodium chloride; 4.0gm 
monosodium hydrogen phosphate; 6.Sgm disodium hydrogen 
phosphate. The solution was made up to 1 litre with 
distilled water. 
2.12.2. Preparation of tissue for histological examination 
All alloarafted tissue was evaluated at the conclusion .., 
of the experiment by histological examination. The kidney 
carrying the graft was fixed in 10% formal saline for at 
least 3 days before trimming the tissue for histology. 
Paraffin sections were cut and stained with haematoxylin 
and eosin or with aldehyde fuchsin. The latter selectively 
stains the insulin containing granules of the beta cells of 
pancreatic islets (Bussolati and Bassa, 1974). Thyroid 
tissue sections were stained only with haematoxylin and 
eosin. Tissue sections were examined to determine the 
extent of damage to the graft and mononuclear cell infil-
tration in and around the transplanted tissue. 
2.13 PREPARATION OF SPLEEN CELLS 
BALB/c spleens were removed aseptically and placed in 
HBSS buffered with 0.013 % w/v sodium bicarbonate. Spleens 
were then pressed through a fine stainless steel sieve 
into fresh HBSS. The resultant suspension was trans-
Table 2.1 
125 
I uptake by uncultured BALB/c thyroid allografts 
* two weeks after transplantation under the renal 
capsule of thyroidectomized CBA recipient mice 
CBA 
1251 uptake (mean cpm+SD) 
Recipient Background Graft 
* 
Net Graft 
1 127+11 225+10 98+10 
2 130+6 183+10 53+10 
3 136+15 284+15 148+15 
4 126+12 241+24 115+24 
5 127+16 252+15 126+15 
6 132+11 171+13 39+13 
7 124+9 257+15 133+15 
8 142+8 233+11 91+11 
9 146+17 229+14 83+14 
Mean value+ SD . 98+36 . 
The day following the 1251 assay all grafts were 
removed. All showed only scar tissue remaining. 
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£erred to a centrifuge tube and allowed to settle on ice 
for 5 minutes to remove cell clumps. The supernatant was 
transferred to a sterile centrifuge tube and centrifuged 
at 500g for 5 minutes. The cell pellet was resuspended in 
HBSS and spleen cells (SC) counted in a haemocytometer 
using white blood cell counting fluid or, where viable 
SC were required, viability was determined by trypan blue 
exclusion. The cell density was then adjusted to the 
required level. 
2.14 ULTRAVIOLET IRRADIATION OF SPLEEN CELLS 
An ultraviolet (UV) meter (Black-Ray) was set up on 
an adjustable stand beneath the UV source (Philips 
Oliphant germicidal G 3DT8 lamp) in a laminar flow hood, 
at intensity 960µW/cm 2 in the 230 to 270nm range (Talmage 
et al. 1977). The spleen cell suspension (up to 2ml) was 
then placed in a coverless 35mm glass petri dish on the 
stand beneath the UV source and irradiated for 4 minutes. 
The suspension was swirled several times during irradiation 
to ensure complete irradiation of cells. 
2.15 PREPARATION OF PERITONEAL CELLS 
Donor mice were killed by cervical dislocation and 
their abdomens swabbed with 70% ethanol. An incision was 
made in the skin of the abdominal wall and the skin gently 
stripped back to expose the peritoneum. The peritoneal 
cavity was then irrigated with 5ml HEPES-buffered HBSS. 
The resulting cell suspension was withdrawn by syringe 
and centrifuged at 800g for 5 minutes. The cell pellet 
was resuspended in 1ml HEPES-buffered HBSS and cell 
viability determined using the trypan blue exclusion test. 
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The density of viable cells was assessed using a haemocyto-
meter. 
2.16 PREPARATION AND INJECTION OF CYCLOSPORINE (CyA) 
CyA (a gift from Sandoz, Switzerland) was dissolved at 
25mg/ml in olive oil using a stirrer within a hot water 
bath (60°C) for 20 mins. Recipients of CyA treatment were 
injected subcutaneously at a dose rate of 75mg/kg body 
weight beginning at day -1 from the injection of sensiti-
sed cells, to day 7 post-injection of cells. 
2.17 ANTISERA 
2.17.1. CBA anti-BALB/c antiserum 
This antiserum was produced by immunizing 8 to 10 
week old male CBA mice with multiple intraperitoneal 
injections of BALB/c spleen cells or spleen and thymus 
cells. A total of four weekly immunizations were given at 
a dose of 0.25 donor spleen cells and approximately 6 . 0 x 107 
thymocytes per recipient . Animals were bled up to one week 
following the final injection . Antiserum titres of about 
1/4000 were demonstrated by haemolysis assay (Parr and Oei , 
1973) with rabbit complement (Section 2.18). 
2.17.2. Monoclonal antisera and treatment of sensitised 
spleen cells 
A monoclonal anti-Lyt 2.1 ascitic fluid was obtained 
from Australian Monoclonal Development (Sydney); mono-
clonal anti-Thy 1.2 was obtained from Dr I. Weissman. 
Normal rabbit serum which had been absorbed on outbred 
mouse spleen and tested to ensure low toxicity (Section 
2.18) was used as a source of complement. 
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Sensitised spleen cells (Section 2.20) at a concen-
tration of 2xl0 7/ml were incubated with a final antibody 
concentration of 1/10 (anti-Thy 1.2) or 1/100 (anti-Lyt 
2.1) in serum free HBSS for 30 minutes on ice. The cells 
were then washed and resuspended in a predetermined 
dilution of rabbit serum and incubated at 37°C for 30 
minutes. Cells were washed once more, suspended in HBSS 
and counted. In different experiments, 33 to 52% of 
spleen cells were killed by anti-Thy 1.2 treatment and 
23 to 34% by anti-Lyt 2.1 treatment. Less than 5% of 
spleen cells were killed by complement alone. Five 
7 x 10 untreated spleen cells or remaining cells after 
treatment with complement alone or antibody and comple-
ment, were injected intravenously into recipients. 
The specificity of the two antibodies was tested 
by measuring Concanavalin A (ConA)-induced Interleukin-
2 (IL-2) production from ConA spleen cell blasts 
(Andrus et al. 1981) treated as described above. Anti-
Thy 1.2 and complement treatment completely abolished 
the ability of the blasts to produce IL-2 whereas anti-Lyt 2.1 and 
complement treatment did not affect the ability of the 
blasts to produce IL-2. 
2.18 PREPARATION OF COMPLEMENT 
Normal rabbit serum was used as a source of complement. 
Young adult rabbits were anaesthetized with an intravenous 
injection of 1.5ml Nembutal (sodium pentobarbitone: Abbot 
Laboratories, Australia) and bled out via a cardiac 
puncture. The collected blood was placed in a 37°C room 
for 1 hour to promote clot formation, after which the 
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clotted blood was rimmed and placed on ice for 1 hour 
before collecting the serum in a precooled centrifuge 
(1380g for 10 minutes). Rabbit serum was absorbed for 
30 minutes on outbred mouse spleens and then removed 
and stored in 0.5 to 1.0ml aliquots at -80°C. Comple-
ment was tested using a standard chromium release assay 
(Section 2.23.3) 
2.19 CYTOTOXIC ANTIBODY ASSAY 
Cytotoxic antibody titrations were carried out using 
either trypan exclusion as an indicator of cell viability 
(Carlson and Terres, 1976) or a standard chromium release 
assay (Section 2.23.3) 
as targets. 
using 51 Cr labelled BALB/c cells 
2.20 PRODUCTION OF SENSITISED SPLEEN CELLS 
Male CBA mice were immunized in vivo by the intra-
7 peritoneal injection of 2.5 x 10 P815 or EL-4 cells grown 
from tissue culture (Section 2.22). Spleen cells were 
prepared from the mice 10 to 12 days later and tested 
for cytotoxic activity (Section 2.23.3) on P815 or EL-4 
before injection (intraven,ous) into recipients . While waiting for the 
determination of cytotoxic activity, spleen cells were maintained in isolation 
medium on ice for about 5 hours. · 
In vitro sensitisation was achieved by culturing 
CBA lymph node cells with BALB/c spleen cells in 1ml 
cultures in 24 well trays (Linbro 76-033-05) using EMEM. 
One million CEA lymph node cells were cultured with 
6 
2 x 10 BALB/c spleen cells. The spleen cells had 
previously been cultured with mitomycin C (Sigma) at a 
concentration of 35µg/ml in EMEM for 90min at 37°C in 
5% co2 in air. After 3 washes in EMEM they were plated 
with the responder lymph node cells. The cultures were 
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held at 37° in 5% co2 in air for 4 days. Expanded popula-
tions of activated T cells were prepared essentially as 
described by Woolnough and Lafferty (1979). The cells 
were subcultured on day 4 at 10 5/ml in EMEM containing 
spleen cell derived Interleukin 2 (IL-2) at a concentra-
tion predetermined to give optimal~ cell growth 
(Lafferty et al. 1980). Cells were cultivated in flasks 
at 37° in 5% co2 in air for a further 3 days. At this 
time the expanded populations were 99% viable and had 
high cytotoxic potential. 
2.21 PRODUCTION OF CONCANAVALIN A- ACTIVATED SPLEEN 
CELL SUPERNATANTS (CS) 
The method for CS production has been described by 
Andrus and Lafferty (1980). Spleen cells were suspended 
in serum-free EMEM supplemented with O.lmM 2-mercapto-
' ethanol (2ME, Sigma) and antibidtics. Five ml aliquots 
were plated into Falcon 3013 culture dishes and pulsed 
with Sµg/ml ConA (Sigma) for 2 hrs at 37°C. The cell 
monolayers were then washed with HBSS to remove unbound 
ConA, and incubated in 10ml fresh serum-free culture 
medium for a further 16-20 hours at 37°. The super-
natant was harvested, concentrated 10-fold through a 
Minicon macrosolute concentrator (B-15, Amicon, Lexing-
ton, Mass.), sterile filtered through a 0.22µm filter 
and stored at -20°C. 
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2.22 TUMOUR CELL LINES 
The tumour cell lines, P815, a mastocytoma from the 
DBA2 (H-2d) mouse strain, and EL-4, a T cell lymphoma from 
the C57BL/6J strain (H-2b), were maintained by passage in 
tissue culture every 3 or 4 days. Cells were maintained 
in 25 cm2 tissue culture flasks (Lux Scientific Corp., 
California) containing 5ml EMEM supplemented with 10% v/v 
HIFCS. The cells were incubated at 37°C in a humidified 
atmosphere of 10% co2 in air. 
2.23 IN VITRO TEST OF IMMUNE REACTIVITY 
.Pooled axillary and mesenteric lymph node cells (LNC) 
from normal control or allografted CBA mice were tested 
for their capacity to respond to donor type alloantigen 
stimulation in vitro. 
2.23.1. Mixed lymphocyte cultures (MLC) 
Stimulator BALB/c SC at 3 x 10 6 cells/ml were pre-
pared (Section 2.13) and incubated with mitomycin Cat 
30µg/ml of cell suspension at 37°C for 90 minutes in 
10% co2 in air. mitomycin C was prepared by dissolving 
2mg mitomycin C in 2ml normal saline and filtered through 
6 a 0.22µ disposable filter. Two x 10 LNC responders were 
mixed with 3 x 10 6 SC stimulators in a total volume of 2ml 
EMEM containing 10% v/v HIFCS and O.lmM 2 ME. Cultures 
were set up in 24 well trays (Linbro) and incubated at 
37°C in a humidified atmosphere of 10% co2 in air for 5 
days. 
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2.23.2 Preparation of tumour cell targets 
Lymphocyte preparations were tested for their cytotoxic 
activity against 51cr-labelled target cells. P815 or EL-4 
suspensions were centrifuged (500g) for 5 minutes and 
resuspended at a concentration of 5 x 10 6 viable cells/ml 
in RPMI 1640 supplemented with 5% v/v HIFCS. The cells 
were labelled by the addition of Na 2 
5lcr 04 (Amer sham) 
to give a final concentration of 250 µCi/ml. Following 
incubation for 1 hour at 37°C in 5% co2 and air, unbound 51
cr was removed by washing the cells 3 times in RPMI 
1640 and then resuspended at a concentration of 10 5 
viable cells/ml in EMEM supplemented with 10% v/v HIFCS. 
2.23.3. Cytotoxicity assay 
Using 96 U shaped well microtitration plates (Linbro/ 
Titertek), 100µ1 of labelled targets were mixed with 100µ1 
effector cells either in duplicate or quadruplicate and 
incubated for 4 hours at 37°C in a humidified atmosphere 
of 5% co 2 and air. Spontaneous lysis of the targets was 
determined by mixing 100µ1 of targets with 100µ1 of EMEM 
plus 10% v/v HIFCS in quadruplicate microtitre wells. 
Total releasable label was determined by mixing 100µ1 of 
targets with 900µ1 distilled water in quadruplicate 
plastic centrifuge tubes (water lysis). Following incu-
bation, the microtitre plate was centrifuged (500g for 1 
minute) and 100µ1 supernatant was removed from each well 
without disturbing the cells. The water lysis tubes were 
vortexed, centrifuged (500g for 5 minutes) and 500 µ1 
supernatant was removed. Supernatants were counted for 
10 minutes in a Packard Auto-Gamma 500 counter. Spontan-
eous release was generally 10 to 15% of the maximum release. 
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Cytotoxic activity is expressed in terms of log10 
cytotoxic units (C.U.) per culture well, where one C.U. 
is defined as the activity required to lyse one target 
cell. The derivation of the cytotoxic unit has been 
described in detail elsewhere (Lafferty et al. 1976a; 
Woolnough and Lafferty, 1979). 
CHAPTER 3 
RESISTANCE OF ESTABLISHED ISLET AND THYROID 
ALLOGRAFTS TO ANTIBODY AND COMPLEMENT 
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3.1 INTRODUCTION 
As discussed 1n Section 1.5, there has been consider-
able interest shown in the past over the respective roles 
of cell mediated and antibody mediated immunity in allograft 
rejection. Although graft rejection was considered in the 
1950's to be primarily a cell mediated process (Mitchison, 
1954; Snell, 1957; Brent, 1958), it is now evident that, 
depending on a number of factors, both humoral and cellular 
mechanisms may be involved. 
With the demonstration of hyperacute rejection of 
kidney allografts in man (Kissmeyer-Nielsen et al. 1966; 
Williams et al. 1968), and various other tissues and organs 
in animal models by using the passive transfer of anti-
donor antibody and complement (French, 1972; Koene et al. 
1973; McDowall et al. 1973 (, McKenzie and Henning, 1978; ) 
Section 1.5.1.2), it is clear t hat antibody can contribute 
significantly to the rejection process. In particular, the 
evidence indicates that the antibody mediated attack 1s 
targeted on the vascular endothelium of the graft 
(Williams et al. 1968; Winn et al. 1973; Hume, 1974; 
Bogman et al. 1980). 
That vascular endothelium and its possible replace-
ment may be an important factor regulating whether or not 
a graft is rejected, has long been suggested. For example, 
the replacement of graft endothelium with host cells has 
been proposed as a possible mechanism for graft adapta-
tion (Woodruff, 1959; Billingham, 1971; Williams et al. 
1971; Section 1.13.6.2). Graft adaptation is a phenome-
non based on a number of observations which have as their 
basis the fact that where an allograft is initially pro-
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tected in some way and for a certain time from the host's 
immune reaction, the graft then appears to have "adapted" 
or overcome the "critical period" and, as a consequence, 
becomes less vulnerable to attack by the host (Woodruff 
and Woodruff, 1950; Maumenee, 1951; Woodruff, 1952, 1954; 
Weber et al. 1954; Cannon, 1957; Hart et al. 1980). 
Billingham et al. (1956a) and Medawar (1965) also suggested 
that the vascular endothelium of long tolerated grafts may 
have been partly replaced by cells of host origin. However, 
it was with the studies of the pathology of hyperacute 
rejection that the endothelium was implicated as the target 
of attack. Any repopulation of the graft vasculature by 
the host, therefore, could have important implications. 
Organ culture in an oxygen-rich atmosphere not only 
reduces the immunogenicity of a tissue allograft (Lafferty 
et al. 1975; Sollinger and Bach, 1976; Talmage et al. 
19 7 6 ; Ke din ge r et a 1 . 1 9 7 7 ; Lafferty and Wool no ugh , 19 7 7 ) 
but also destroys vascular endothelium in pancreatic islet 
and thyroid tissue (Moskalewski, 1965; Andersson and 
Hellerstrom, 1972; Lafferty and Woolnough, 1977; Parr 
et al. 1980a). When the cultured tissue is transplanted, 
revascularization with host vascular endothelium occurs. 
The cultured tissues, however, retain recognizable antigen 
and can be rejected when the recipient is challenged with 
donor strain leucocytes, either at the time of transplanta-
tion (Lafferty et al. 1976a; Simeonovic et al. 1980) or 
after the graft has become well established in the recip-
ient (Lacy et al. 1979c; Bowen et al. 1981). 
In this chapter we examined the effect of passively 
transferred alloantibody and antibody plus complement on 
the function of pancreatic islet and thyroid allografts. 
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Figure 3.1 
Blood glucose levels (0) and body weight (e ) of 
four CBA mice transplanted with 350 BALB/c 
pancreatic islets. All animals were injected 
with donor alloantibody (Ab) and antibody plus 
complement (Ab+C). Neither treatment had any 
effect on graft function. The normal range for 
blood glucose for CBA male mice (mean+ 2 S.D.) 
is indicated by the hatched area. 
-"'-
-E 0 
C) E 
- E 
-
w .,_ 
V) I 0 c., u 
-w ::::> 
3"; __, c., 
>- 0 0 
0 0 
ca 0 
__, 
ca 
30~ ~ u ·-- ~ .. , Al 30~ 
!AfJ 
B .& .& 
Ab Ab+ C I I I ~ Graft removed -
20f!"" Graft removed 
10 ~ I 10 
ol I I I I I I I I I 0 
0 25 50 75 100 125 150 175 200 0 25 50 75 100 125 150 175 200 
cl 30f ••th •• =-30 
-~ 
~ D t f 1 Ab Ab+C Ab Ab+C I IJ Graft removed Graft removed 
I 20 
10~ ~ 10 
o...____.. _________________ __, 0 L----L _ __._ ____ .&.-_____ __.__ _ _._____. 
0 25 50 75 100 125 150 175 200 0 75 100 125 150 175 200 
TIME AFTER TRANSPLANTATION 
25 50 
(DAYS) 
Table 3.1 
Urine glucose outputa (mmoles/24hr) 
Animal Time after transplantation (days) 
0 7 21 50 85 
A 8.875 0.060 0. 0 02 0.003 0.001 
B 3.600 0.514 0.080 0.640 0.021 
C 10.520 0.300 0.003 0.003 0.001 
D 4.480 0.063 0.002 0.001 0.003 
a Normal animals excrete <0.2 mmoles glucose/ 
day (Bowen and Lafferty, 1980). 
Table 3.2 
Animal 
A 
B 
C 
D 
Cytotoxic antibody titres in islet 
allograft recipients 
Time 
(hr, 
after antibody 
injection 
hours; 
4 hr 
4 d 
7 d 
4 hr 
4 d 
7 d 
4 hr 
4 d 
4 hr 
4 d 
d, days) 
Antibody 
1:5120 
1:1352 
1:5120 
1:2048 
1:640 
1:640 
1:2048 
1:2560 
1:3379 
1:5120 
titre 
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as a source of complement. The source and amount of com-
plement was similar to that used by McKenzie and Henning 
(1978) to reject skin allografts . . in mice. Again, none of 
the four animals showed any functional evidence of rejection 
Fig. 3.1). When allografts were removed by nephrectomy 
about one month after the last injection, 2 animals returned 
rapidly to the diabetic condition (Fig. 3.1 A,B). One 
animal (Fig. 3.lC) died due to technical reasons associated 
with the nephrectomy, but histology of its pancreas did 
not reveal the presence of beta cells. It was assumed, 
therefore, that the graft in this animal, as with the 
other two, had been functional and responsible for the 
maintenance of normoglycaemia. The fourth animal 
(Fig. 3.lD) did not return to the diabetic state, suggest-
ing that this animal's pancreas had recovered from the 
streptozotocin induced damage. The histology of its 
pancreas, which showed a number of light to medium stained 
granulated beta cells when compared to normal pancreas, 
confirmed this diabetes reversal. It should be noted 
that this is only the second out of many hundreds of such 
experimental animals investigated in our laboratory which 
failed to revert to the diabetic condition following the 
removal of the islet graft. 
Histological examination of all the islet allografts 
showed that the tissue was normal and using aldehyde 
fuchsin staining, contained granulated beta cells 
(Fig. 3.2). 
Figure 3.2 
Histological appearance of islet allografts removed 
35 days after injection of anti-donor alloantibody 
and complement. A. Note the absence of mononuclear 
cell infiltration and lack of any damage to islets 
(i, islets; k, kidney parenchyma) (haematoxylin 
and eosin; x 164). B. Note the dark staining 
granulated beta cells present in the transplanted 
tissue (aldehyde fuchsin; x 164). 
(Note that these sections are representative of 
those taken from all experimental animals) 
• 
• 
3 . 2 . 2 . 
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Resistance of thyroid allografts to rejection by 
antibody and complement 
Eight male, thyroidectomized CBA mice were transplanted 
with BALB/c cultured thyroid. Four weeks after transplanta-
tion the iodine uptake was assayed and all grafts were shown 
to be functional (Fig. 3.3). One week following the assay, 
4 animals from this group were injected intraperitoneally 
with 0.5ml of donor specific alloantibody and 0.5ml of 
complement. The remaining 4 control animals were injected 
with a mixture of normal mouse serum and complement. One 
week after the passive antibody treatment, the iodine 
uptake was measured again and all 8 animals were found to 
carry functional grafts (Fig. 3.3). Cytotoxic antib9dy 
was also demonstrated in those animals which had been 
injected with donor specific alloantibody and complement 
(Table 3.3). Histological examination of the allografts 
removed the day following the last iodine uptake assay, 
similarly showed them to be normal (Fig. 3.4). 
3.3 DISCUSSION 
The results of this study show that neither graft 
specific antibody alone, nor antibody and complement, have 
any adverse effect on the function of cultured pancreatic 
islet and thyroid allografts that are established and re-
vascularized by their host. This finding is in marked 
contrast to the effect seen when immune serum was adminis-
tered to animals carrying tolerated but uncultured islets. 
Frangipane et al. (1977) demonstrated the vulnerability 
to donor specific antiserum of both ACl rat islets on WF 
rats and WF rat islets on irnmunosuppressed mice. Rats 
became normoglycaemic within 1 to 6 days and mice within 
Figure 3.3 
125 1 uptake by cultured BALB/c thyroid grafted 
under the renal capsule of allogeneic CBA recip-
ients; before treatment (e), and after treatment 
with donor specific alloantibody and complement (0), 
or normal mouse serum and complement (D). The 
shaded area represents iodine uptake levels up to 
2 S.D. 's above the mean uptake by rejected 
uncultured allografts (BALB/c~CBA) tested 23 days 
after transplantation. Points outside the shaded 
area indicate functional transplants. 
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Table 3.3 
Cytotoxic antibody titres in thyroid allograft recipients 
Animal Treatment 
1 Antibody and 
complement 
II 
2 II 
II 
3 II 
II 
4 II 
II 
5 Normal serum 
and complement 
II 
6 II 
II 
7 II 
II 
8 II 
II 
Time 
after injection 
(days) 
3 
7 
3 
7 
4 
7 
4 
7 
3 
7 
3 
7 
4 
7 
4 
7 
Antibody titre 
1:340 
1:220 
1:180 
1:220 
1:260 
1:200 
Not tested 
II 
<l: 20 
II 
II 
II 
II 
II 
II 
II 
Figure 3.4 
Histological appearance of thyroid allografts~ 
A. Thyroid graft from 
antibody and complement treated animal. 
B. Thyroid graft from control animal. 
Note in both the presence of intact thyroid 
follicles and lack of rejection response 
(haematoxylin and eosin; x 164). 
(Note that these sect ions are r e presentative of 
those taken from a ll e xperimen t a l a n imals) 
A 
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24 hours after the administration of donor specific anti-
serum. Similarly, Naji et al. (1975, 1979a) showed that ACl 
rat islets and skin transplanted to WF diabetic rats made 
tolerant to ACl antigens at birth by the intravenous 
injection of (WFxACl) F1 bone marrow cells, were vulnerable 
to WF anti-ACl serum given 21 to 65 days after restoration 
of normoglycaemia. Hyperglycaemia resulted in 1 to 6 days, 
although skin grafts were rejected much more slowly. Our 
finding is also in marked contrast to the effect seen when 
antibody and complement were administered to animals 
carrying tolerated kidney or skin allografts (French, 
1972; McKenzie and Henning, 1978; Hart et al. 1980; 
Section 1.5.1.2), that possess vascular endothelium of 
donor origin. 
rejected. 
In these studies, grafts were hyperacutely 
Endothelium replacement has been suggested as an 
explanation for the changes in sensitivity to antibody 
and complement seen in skin grafts over a period of weeks 
following transplantation. An initial delay in sensiti-
vity lasting about one week, is rapidly followed by 
increasing sensitivity, peaking at about 2 weeks and 
finally moving into a period of resistance by about 
5 to 6 weeks (Jooste et al. 1973; Gerlag et al. 1975; 
Jooste and Winn, 1975; Gerlag et al. 1980; Jooste et al. 
1981a). The explanation has been that once the initial 
vascular network has been established between the graft 
and the host, graft vascular endothelium is rapidly 
replaced by host cells, thereby rendering the established 
skin grafts resistant. In contrast, primary vascularized 
grafts, where extensive endothelial replacement would not 
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readily occur, retain their sensitivity for longer periods. 
Burdick et al. (1979) showed that 56 day ea:ablished rat to 
mouse heart xenografts could be rejected by the passive 
administration of antibody and complement but not similar-
ly established skin of the same donor type and on the same 
host. Convincing evidence for this proposal of endo-
thelium replacement has come from recent studies of 
Jooste and her colleagues (Jooste et a1. 1981a, b). Rat 
skin grafts transplanted to mice were removed at various 
times after transplantation and tested in vitro for 
reactivity with mouse anti-rat and rat anti-mouse serum. 
Using immunofluorescence techniques they showed that up 
to 14 days after grafting, rat or donor cell surface 
antigens were present but as the loss of sensitivity 
developed beyond this period, mouse or host cell surface 
antigens were detected. By day 109, all the graft 
vascular endothelium was of host origin. Thus, resist-
ance of long-term skin grafts was attributed to the 
replacement of donor vascular endothelium by host cells. 
With primary vascularized grafts, on the other hand, it 
would be expected that donor-type endothelium would 
persist for more prolonged periods. Hart et al. (1980) 
have in fact shown that, in contrast to skin, long term 
(>100 days) surviving DA kidneys on LEW rats are rejected 
in hyperacute fashion when given donor specific anti-
serum plus guinea pig complement. In a follow up study 
(Hart and Fabre, 1981a) using mouse monoclonal anti-
bodies to rat Ia and SD type antigens, they found that at 
SO days post transplantation such allografts still posses-
sed donor type endothelium. 
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In allografts which have been cultured in vitro, a 
different situation exists. Here, the vascular endothelium 
is already depleted by the time the cultured tissue is ready 
for transplantation (Parr et al. 1980a). In our study, 
therefore, it would appear that revascularization of the 
cultured tissue by host endothelium protects the islet 
and thyroid transplants from an antibody mediated attack. 
Using immunoferritin labelling, Parr (1979) reported 
that in contrast to mouse pancreatic duct, acinar and 
endothelial cells, beta cells lacked demonstrable H-2 
antigen. If this were the case, the revascularized graft 
would be protected from antibody-mediated attack simply 
because it lacked recognizable antigen. However, this 
does not appear to be so and other workers have since 
shown that pancreatic islet cells do express detectable 
levels of H-2 antigens. Faustman et al. (1980), using 
direct microcytotoxicity testing, demonstrated the 
presence of H-2K and H-2D but not Ia antigens from islets 
in 3 different mouse strains and Parr et al. (1980b) 
confirmed the lack of Ia antigen expression on the endo-
crine beta cells. Moreover, studies in our own laboratory 
and elsewhere indicate that both the established islet 
and thyroid allografts express recognizable antigen because 
such grafts can be rejected when the recipient is challenged 
with donor strain leucocytes (Lafferty and Woolnough, 
1977; Lacy et al. 1979c; Bowen et al. 1981). This 
rejection process is accompanied by a heavy mononuclear 
infiltrate into the allografts (Lafferty and Woolnough, 
1977). 
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The above discussion suggests that the cellular target 
of antibody mediated rejection is the vascular endothelium. 
The target antigens, therefore, are likely to be any 
expressed on its surface. HLA-A, B, C (class I) antigens 
which are present on most nucleated cells and HLA-DR 
(class II) antigens, as well as blood group antigens are 
likely targets and are expressed on endothelial cells in 
man (Hirshberg et al. 1979; Hayry et al. 1980; Natali 
et al. 1981; Scott et al. 1981). Both RTl.A (class I) 
and RTl.B (class II) antigens have been demonstrated on 
renal endothelium of ACl rats, although the class II 
antigens have a more restricted distribution (Paul et al. 
1981). Mouse skin can be rejected in hyperacute fashion 
by antibody directed against class I antigens (McKenzie 
and Henning, 1978; de Waal et al. 1980) but not by anti-
sera directed against class II alloantigens, even when 
very high doses of sera absorbed with donor strain red 
blood cells were used (Jansen et al. 1975a). This was 
confirmed by McKenzie and Henning (1978) using recombi-
nant mouse strain combinations. It was thought that this 
probably reflects the lack of, or low level expression of 
class II alloantigens on mouse endothelial cells. 
As to the mechanism of hyperacute rejection, several 
workers have described the likely sequence of events ( 
(Williams et al. 1968; Winn et al. 1973; Hurne, 1974; Bogrm.n et al. 
1980). Initially, the antibody becomes attached to the 
endothelium of the graft vasculature where complement is 
fixed and chernotactic factors are released. This results 
in the attraction of PMN leucocytes which, in turn, adhere 
to this complex on the endothelium causing further damage. 
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Using electron microscopy, bridges can be seen between PMN 
leucocytes and endothelial cells (Williams et al. 1968). 
The damaged cells in turn attract more polymorphs thereby 
exacerbating endothelial damage (Bogman et al. 1980). 
Destruction of the endothelial cells is followed by plate-
let adherence and production of thrombi, ultimately 
resulting in the occlusion of vessels and necrosis of 
tissue. 
It would appear, therefore, that revascularization of 
a graft with host endothelium does not protect the trans-
plant from cell-mediated damage. However, revascularized 
islet and thyroid allografts are both resis, nt to the 
action of antibody and complement. 
3.4 SUMMARY 
In this chapter we presented evidence indicating 
that cultured allografts of both islet and thyroid tissue 
are not susceptible to donor specific antibody and comple-
ment. This resistance is thought to be due to a revascular-
ization of the graft tissue by host endothelial cells. 
In the following Chapter we will assess the cellular 
requirements for rejection of cultured islet allografts. 
CHAPTER 4 
SENSITISED LYT 1+2+ CELLS TRIGGER ACUTE 
REJECTION OF PANCREATIC ISLET ALLOGRAFTS 
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4.1 INTRODUCTION 
For many years graft rejection has been considered a 
cell mediated function (Snell, 1957 ; Section 1.5.2), but 
only recently has direct evidence been obtained that T cells 
trigger the process of allograft rejection. For example, 
Hall et al. (1978a) demonstrated that lg-negative, long-
lived, T lymphocytes were responsible for initiating heart 
allograft rejection in rats; the transfer of cells from 
sensitised animals showed that memory was carried by long-
lived, non-recirculating lg-negative small lymphocytes 
(Hall et al. 1978b). More recently, Loveland and co-
workers (Loveland et al. 1981; Loveland and McKenzie, 
1982a,b; McKenzie, 1983) demonstrated that rejection of 
skin grafts in adult thymectomized, irradiated, bone 
marrow reconstituted (ATXBM) mice was triggered by 
Lyt 1+2- T cells from sensitised animals and drew 
analogies between graft rejection and delayed type hyper-
sensitivity (DTH) reactions. Although direct evidence 
+ + was lacking, they concluded that Lyt 1 2 cells were not 
involved in skin graft rejection. This conclusion was 
also based on the assumption that the Lyt 1+2-and Lyt 1+2+ 
T cell subsets have quite distinct functions. In a 
similar study, Dallman and Mason (1982) also found that 
skin allograft rejection in ATXBM rats could be restored 
by the injection of T helper (O X8 ) cells. 
The functions of lymphocyte subpopulations have been 
the subject of controversy for some time, with claims that 
+ -Lyt 1 2 or "helper" T cells have properties quite distinct 
+ + from the Lyt 1 2 subclass (Bach et al. 1976; Larsson 
et al. 1980; Wagner et al. 1980, reviewed by Swain and 
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Dutton, 1980). Lymphokine production, help for B cell 
responses and DTH reactions were considered to be the role 
+ -of the Lyt 1 2 subset. However, considerable evidence has 
accurnrnulated which suggests that it is incorrect to make a 
rigid distinction between the properties of the Lyt 1+2-
+ + + -and Lyt 1 2 subsets. Cells of the Lyt 1 2 subset can 
also mediate a cytotoxic effector function (Dennert and 
Yamagata, 1980). + + Similarly, the Lyt 1 2 subset, the 
traditional cytotoxic effector subset, . can also be cyto-
toxic and release lymphokine (Andrus et al. 1981), provide 
help for B cells (Swain and Panfili, 1979) and mediate DTH 
(Leung and Ada, 1980). 
In view of these findings, we examined the cellular 
requirements for rejection of cultured pancreatic islet 
allografts which, unlike the skin grafts, can survive 
indefinitely in fully irnrnunocompetent recipients (Bowen 
et al. 1980). The results demonstrate that the transfer 
of specifically sensitised cells, but not of normal or 
cells sensitis~d to unrelated antigens) to anima ls carryin g 
cultured islet allografts, triggers the acute rejection 
process. In vitro sensitised ·cells were also ineffective 
in triggering rejection. Treatment of the sensitised 
cells with either anti-Thy 1.2 antibody and complement or 
anti-Lyt 2.1 antibody and complemen~ abolished the ability 
of the cells to trigger rejection. 
4.2 RESULTS 
4.2.1. Transfer of in vivo sensitised cells triggers 
rejection of islet allografts 
Four CBA mice which had been carrying functional islet 
allografts ranging from 42-383 days, were injected intra-
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venously with 5 x 10 7 spleen cells from CBA mice previously 
immunized with P815. The total cytotoxic activity injected 
was 5.8 to 6.0 log10 cytotoxic units (Table 4.1). The 
blood glucose concentrations and the body weight of these 
animals were closely monitored. The islet allografts were _ 
acutely rejected following the cell transfer, with blood 
glucose concentrations rising out of the normal range in 
all animals within 6 days of cell transfer. A concomitant 
drop in body weight was observed (Fig. 4.1). In experi-
ments where blood glucose readings were taken daily, animals 
challenged in this way showed consistent rejection at 3 
days after cell transfer (Fig. 4.2; Chapter 5). It is also 
evident from these data (Fig. 4.1) that grafts are suscept-
ible to attack irrespective of the .length of time they have 
been in the recipient . . Grafts which had been in the recip-
ient for almost 400 days were just as susceptible to 
rejection as those which had been in the animal for 40-50 
days. 
Grafts were removed from the mice 1-2 weeks after 
challenge with sensitised cells and evaluated histologically. 
Tissue sections were examined to determine the degree, if 
any, of islet damage and mononuclear cell infiltration in 
and around the transplant tissue. The grafts from these 
animals contained very little or no islet tissue, with 
patches of scar tissue and a light to heavy mononuclear 
cell infiltration evident (Fig. 4.3). 
Table 4.1. 
Cytotoxic activity (log10 cytotoxic units) 
of spleen cells transferred 
Spleen cells transferred 
Normal CBA 
CBA anti-P815 
CBA anti-EL4 
CBA anti-P815 treated with 
complement 
anti-Thy 1.2 + complement 
anti-Lyt 2.1 + complement 
Mouse No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
Total cytotoxic 
activity 
N.T. 
N.T. 
5.8 
6.0 
5.8 
5.8 
-
5~6 
5.6 
5.8 
5.5 
5.0 
5.0 
5.4 
<4.2 
<4.0 
<3.8 
< 3. 8 
<3.8 
<3.8 
<4.0 
<4.0 
All mice received 5 x 10 7 spleen cells or remaining cells 
after treatment with antibody and complement. The cyto-
toxic activity is that measured on the immunising cell. 
N.T. not tested. 
Figure 4.1 
Non-fasting blood glucose levels (C) and body 
weight (•) of four CBA mice carrying functional 
islet allografts and injected intravenously with 
5 x 10 7 CBA anti-P815 spleen cells, between 42 
and 383 days post transplantation (shown by 
arrows). The shaded region indicates the range 
of normal blood glucose concentrations. All 
allografts were acutely rejected irrespective of 
the time of cell transfer after transplantation. 
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Figure 4.2 
Non-fasting glucose levels of 7 Cyclosporine treated 
animals (O,O) and 6 control animals (6), and their 
body weight respectively (e, ) , (i). All mice 
were injected with 5 x 10 7 CBA anti-P815 spleen 
cells at day 0. Transplantation of animals occurred 
between 30-70 days before injection of sensitised 
cells, with a reversal of diabetes occurring within 
1-2 weeks of transplantation. Note the rapid 
rejection (by 3 days following injection of sensiti-
sed cells) in control animals. 
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Figure 4.3 
Histological appearance of a representative section 
of those taken from all animals carrying an islet 
allograft and injected with 5 x 10 7 CBA anti-P815 
spleen cells . Grafts contained mainly scar tissue 
with a light to heavy mononuclear cell infiltrate 
(Haematoxylin and eosin, x 164) . 
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4.2.2. Failure of passively transferred, in vitro 
sensitised CBA anti-H-2d cells to reject islet 
allografts 
Since spleen cells from immunized mice could trigger the 
rejection of established allografts, it was of great inter-
est to determine if cells sensitised in vitro could perform 
the same function. Five CBA mice carrying BALB/c islet 
allografts were injected intravenously with 1 to 4.5 x 10 7 
CBA lymph node cells which had been sensitised against 
BALB/c spleen cells in vitro. These transferred cells 
failed to trigger graft rejection irrespective of the time 
of transfer (Table 4.2) and despite their high cytotoxic 
potential when compared with in vivo activated cells 
(Table 4.1). 
4.2.3. Failure of normal ~ells or anti-H-2b cells to 
trigger rejection of established islet allografts 
Since sensitised cells could trigger the rejection of 
established allografts, it was important to determine if 
normal cells or cells sensitised against a third party 
H-2 haplotype, H-2b, could trigger rejection. 
Two CBA mice carrying functional BALB/c islet allo-
grafts were injected intravenously with 5 x 10 7 normal 
CBA spleen cells. These animals remained normoglycaemic 
(Fig. 4.4) indicating that increased numbers of normal 
cells do not lead to allograft rejection. About 3 weeks 
later these animals were injected with 5 x 10 7 spleen 
cells from CBA mice which had been immunized with the 
b H-2 tumour, EL-4. The total cytotoxic activity of the 
injected cells measured on H-2b targets was 5.6 log10 
cytotoxic units (Table 4.1) and there was no detectable 
cytotoxic activity on H-2d targets. The mice still 
Table 4.2. 
Effect on BALE/ c islet allografts of passive transfer of 
CBA anti-H-2d cells sensitised in vitro 
Animal 
No. 
* 
1 
2 
3 
4 
5 
No. days 
post 
transplant 
256 
246 
48 
50 
47 
No. cells Cytotoxic activity cytotoxic 
injected log c.U/106 cells activity (x107) 10 
Total 
1.0 
1.0 
2.0 
1.5 
4.5 
5.5 
5.5 
5.5 
5.8 
5.2 
6.5 
6.5 
6.8 
7.0 
6.9 
Effect on blood glucose 
* Effect 
None 
None 
None 
None 
None 
Figure 4.4 
Non-fasting blood glucose levels (~, 0) and 
body weight (!,e) of 2 CBA mice carrying 
functional islet allografts and injected intra-
venously with normal CBA spleen cells and 
5 x 10 7 CBA anti-H-2b spleen cells at 32 and 50 
days post-transplantation respectively (shown by 
arrows). Both animals remained normoglycaemic . 
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remained normoglycaemic (Fig. 4.4), indicating that cells 
with cytotoxic activity against H-2b alloantigens are unable 
to trigger rejection of BALB/c allografts. 
4.2.4. The phenotype of cells responsible for triggering 
rejection of cultured allografts 
In order to determine the phenotype of the cells 
involved in triggering graft rejection, sensitised CBA anti-
P815 spleen cells were treated either with complement, anti-
Thy 1.2 and complement or anti-Lyt 2.1 and complement prior 
to intravenous injection into CBA mice carrying established 
BALB/c islet allografts. The total cytotoxic activity of 
the complement-treated cells was 5.0 to 5.8 log10 cytotoxic 
units (Table 4.1). Less than 4% of the cytotoxic activity 
remained following treatment with anti-Thy 1.2 and comple-
ment or anti-Lyt 2.1 and complement. 
In total, 4 animals were injected with complement 
treated cells and 3 out of 4 islet allografts were rapidly 
rejected as with untreated cells (Fig. 4.5). The fourth 
animal (Fig. 4.5C) went through a rejection crisis but 
recovered. When the graft was removed by nephrectomy 
(shown by the second arrow) the animal became diabetic. 
This rejection of the allografts in animals injected with 
complement treated cells, was reflected in the histology 
(Fig. 4.6). Scar tissue with various degrees of cellular 
infiltration was evident, although the graft in the 
animal which had undergone a rejection crisis still 
contained remnants of islet tissue surrounded by pockets 
of heavy cellular infiltration (Fig. 4.6B,C). 
Four animals were injected with anti-Thy 1.2 and 
complement treated cells. This abolished the ability of 
.· . ·.· .. _._.· .. ·.· .·.-.·.·. 
Figure 4.5 
Non-fasting blood glucose levels (D) and body weight 
(e) of 4 CBA mice transplanted with BALB/c islets 
and injected with 5 x 10 7 complement treated CBA 
anti-P815 spleen cells at the times indicated by 
the arrows. Three out of 4 animals rapidly 
rejected their graft; the fourth (panel C) went 
through a rejection crisis but recovered. 
Removal of its graft by nephrectomy (indicated by 
the second arrow) led to its hyperglycaemia. 
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Figure 4.6 
Histological appearance of islet allografts from 
2 representative animals which had been injected 
with 5 x 10 7 CBA anti-P815 spleen cells treated 
with complement. 
A. Section stained with haematoxylin and eosin 
showing scar tissue (xl09). 
B. Section of graft from animal which had under-
gone a rejection crisis (haematoxylin and eosin; 
xl09). Note the remnants of islet tissue (i) 
surrounded by pockets of heavy cellular infil-
tration. 
C. Section from the same animal as B, stained 
with aldehyde fuchsin (x109) showing the dark 
staining granulated beta cells (i) present in 
the remnant islet tissue. 
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sensitised cells to trigger the rejection process (Fig. 
4.7). Histologically the grafts showed intact islet tissue 
with the presence of a few pockets of cellular infiltration 
in some animals (Fig. 4.8). A further 4 animals were 
injected with anti-Lyt 2.1 and complement treated cells and 
this treatment similarly abolished the ability to reject 
the islet allografts (Fig. 4.9). This was confirmed histo-
logically by the presence of intact islet tissue (Fig. 
4.10). 
Thus, sensitised Lyt 1+2+ cells are responsible for 
triggering an acute rejection of cultured pancreatic islet 
allografts. 
4.3 DISCUSSION 
The results with cultured islet allografts show that 
in vivo sensitised Lyt 1+2+cells trigger an acute rejection 
of the allograft. In the experimental model used in this 
study, culture of islet tissue in 95% oxygen allows allo-
grafts to survive indefinitely in immunocompetent allo-
geneic recipients (Bowen et al. 1980; reviewed by Prowse 
et al. 1982a). This provides a model which can be used to 
unequivocally analyse the cells involved in triggering 
rejection because, unlike most other cell transfer systems, 
grafts are not rejected in untreated animals, nor in 
animals which receive normal cells. The complication of 
grafts rejecting spontaneously in . immunoincompetent or 
immuno-impaired animals, or following the transfer of 
normal or nonspecifically activated cells (Rouse and 
Wagner, 1972; Corley and Kindred, 1977; Rosenstein et al. 
1981; Loveland and McKenzie, 1982b) makes the interpre-
tation of results difficult. Similar rejection times seen 
Figure 4.7 
Non-fasting glucose levels (0) and body weight 
(8) of 4 CBA mice transplanted with BALB/c 
islets and injected with 5 x 10 7 anti-thy 1.2 
and complement treated CBA anti-P815 spleen 
cells at the times indicated by the arrows. 
All animals remained normoglycaemic. 
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Figure 4.8 
Histological appearance of islet allograft from an animal 
which had been injected with 5 x 10 7 CBA anti-P815 spleen 
cells treated with anti-Thy 1.2 and complement, showing 
some cellular infiltration (C) around but not within the 
islet tissue (i) (aldehyde fuchsin x 164). 
Figure 4.9 
Non-fasting blood glucose levels (0) and body 
weight (e) of 4 CBA mice transplanted with 
BALB/c islets and injected with 5 x 10 7 
anti-Lyt 2.1 and complement treated CBA anti-
P815 spleen cells at the times indicated by 
the arrows. All animals remained normoglycaemic. 
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Figure 4.10 
Histological appearance of islet allografts from 2 
representative animals which had been injected with 
5 x 10
7 
CBA anti- P815 spleen cells treated with anti-
Lyt 2.1 and complement. 
A. Section stained with haematoxylin and eosin 
(xl64) showing intact islet tissue and some infiltra-
tion. 
B. Section stained with aldehyde fuchsin (xl09) 
showing the dark staining beta cells of the islet tissue. 
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following transfer of normal cells or cells activated 
against a third party H-2 haplotype and specifically 
sensitised cells (Corley and Kindred, 1977; Loveland 
I et al. 1981; Loveland and McKenzie, 1982b) suggests that / 
differentiation and/or sensitisation could be occurring 
before rejection takes place. 
Our results with spleen cells from animals sensitised 
against a third party H-2 haplotype (H-2b), show that these 
cells were unable to trigger rejection, showing that the 
rejection process is a specific phenomenon. It is worth 
noting that in agreement with Rouse and Wagner (1972), 
cytotoxic cells activated against H-2b alloantigens showed 
negligible crossreactive cytotoxic activity bn H-2d 
targets. 
Another approach to the analysis of cellular rejection 
has been to study the effect of in vitro activated cyto~ 
toxic cells on graft survival - a method which has long 
been promoted as a good correlate of allograft rejection 
(Wagner et al. 1973). In our study, donor lymph node 
cells which were sensitised in vitro had no effect on 
allograft survival. This was somewhat surprising in view 
of the findings of other workers who demonstrated in vivo 
function of in vitro sensitised cells (Rouse and Wagner, 
1972; Corley and Kindred, 1977; Rosenstein et al. 1981). 
However, although these workers reported that in vitro 
sensitised cells were capable of accelerating allogeneic 
skin graft rejection, the effect did not correlate with 
the cytotoxic activity of the cell preparations (Rosen-
stein et .al. 1981) and in one model, cells failed to 
reject grafts in lethally irradiated mice (Rouse and 
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Wagner, 1972). It is possible that the in vivo effective-
ness of in vitro activated cells i s compromised by the poor 
recirculating ability of these cells. Lotze et al. (1980) 
found that in vitro activated and labelled cells injected 
into mice and humans, were largely removed from the 
circulation by early trapping in the lungs and subsequently 
in the liver and spleen. In an allograft situation, such 
removal would obviously limit their contact .with graft 
tissue. In tumour allograft models, attempts to show 
in vivo function of in vitro generated effector cells have 
generally met with limited success and Engers et al. (1982) 
have shown that in their model system the route ef injection 
also plays a role. 
+ -As already indicated, the role of Lyt 1 2 lymphocytes 
in graft rejection has received prominence through studies 
with ATXBM mice by Loveland and coworkers (Loveland et al. 
1981; Loveland and McKenzie, 1982a,b), who challenged the 
concept that cytotoxic T cells (Lyt 1+2+) mediate rejection. 
They proposed that it is the Lyt 1+2- T cell which is 
responsible for rejection and,in contras4 the Lyt 1+2+ cell 
plays no role, although a positive selection of these 
cells to test their ability to trigger rejection was not 
attempted. More recently they further characterised the 
Thy l+, Lyt 1+2- cell causing skin graft rejection in the 
+ - + - + mouse, as having the Lyt 1 2 5 6 7 phenotype; cytotoxic 
+ + -T cells carry the Lyt 5 6 7 phenotype (Loveland and 
McKenzie, 1982c). 
Studies by Vesole et al. (1982) on the cellular 
requirements of cultured thyroid allografts, also seemed 
+ -to indicate a role for ·Lyt 1 2 cells, although the cell 
type mediating rejection was not determined. They showed 
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Eha~, not only was there frequently a long delay in rejection 
following adoptive immunization, but also a lack of correla-
tion between the presence of cytotoxic cells in the innoculum 
and the capacity to trigger graft rejection. In a more 
recent study, however, Warren et al. (unpublished data), 
have shown that cultured thyroid allografts do require 
+ + sensitised Lytl 2 cells to trigger rejection. Thus, while 
Lyt 1+2- T cells may mediate skin rejection, the available 
data suggest it would be incorrect to conclude that cyto-
toxic or Lyt 1+2+ T cells play no role in graft rejection. 
Our data conclusively show that Thy l+, Lyt 1+2+ 
lymphocytes can trigger islet allograft rejection and 
while this conflicts with the findings of Loveland et al. 
(1981), the two findings can be reconciled. In considering 
interactions between sensitised cells and grafts, it is 
important to recognise that differences exist in cellular 
content and antigen expression between skin, organ grafts 
and cultured tissue. The above studies suggest that the 
subclass of T lymphocytes primarily responsible for 
triggering allograft rejection, probably depends on the 
type of tissue grafted, which in turn reflects the 
particular class of alloantigen expressed. Cultured 
islet and thyroid allografts express only class I antigens 
(Parr et al. 1980b) whereas cells present in the skin 
grafts express both class I and class II antigens 
(HaITllTlerling, 1976). Since the traditional view of T 
lymphocyte activation is that class I and class II antigen 
cause the activation of Lyt 1+2+ and Lyt 1+2- T cells 
respectively (Cantor and Boyse, 1976; Swain and Panfili, 
1979; Ledbetter et al. 1980), then it would be expected 
that there could be differences in cellular requirements 
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for rejection of skin and islet grafts. The cell donors 
used by Loveland et al. (1981) were immunized by skin 
grafts and cells from these animals would include Lyt 1+2-
cells activated against class II alloantigens and Lyt 1+2+ 
cells activated against class I alloantigens. The elimina-
+ + 
+ -tion of Lyt 1 2 cells could leave sensitised Lyt 1 2 cells 
capable of recognising and responding to class II antigens 
on responsive blood cells in skin grafts. Such an inter-
action would result in an inflammatory reaction and des-
truction of graft tissue (Lafferty and Talmage, 1976). In 
contrast, the sensitised cells used in our study were from 
animals immunized with P815 which expresses class I but 
not class II alloantigens. This would lead to the activa-
+ + tion of Lyt 1 2 cells and, as already indicated, the 
only target antigens on the parenchymal cells of cultured 
islet and thyroid allografts are of class I (Parr et al. 
1980b). Therefore, elimination of Lyt 1+2+ cells would 
eliminate cells capable of recognizing alloantigens on 
the graft. It should, however, be noted that there are 
some anomalies to the above explanation. Lyt 1+2- cells 
from sensitised animals were found to be active in 
rejectin:;rskin grafts differing only at the H-2K (class I) 
locus (Loveland and McKenzie, 1982b) and sensitised 
+ -Lyt 1 2 T c~lls also induced the rejection of allogeneic 
EL-4 lymphoma which does not carry class II alloantigens 
(Loveland and McKenzie, 1982a). 
We have shown, therefore, that in the case of cultured 
+ + islet tissue, Lyt 1 2 cells are important in allograft 
rejection - a rejection which may be mediated through 
lymphokine release (Chapter 5). Taking our data together 
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+ -with the findings of Loveland and coworkers, both Ly t 1 2 
and Lyt 1+2+ cells can trigger graft rejection; the actual 
effector cell phenotype being determined by the antigens 
on the immunising tissue and the antigens expressed on the 
graft. 
4.4 SUMMARY 
In this Chapter we presented data to show that 
cultured islet allografts in immunocompetent animals are 
very rapidly rejected following the passive transfer of 
in vivo sensitised cells. Non-specific or normal cells 
did not trigger rejection. Similarly, it was shown that 
in vitro sensitised cells are not effective in triggering 
rejection. 
The cells triggering rejection were found to belong 
to the Thy l+, Lyt 1+2+ and not the Lyt 1+2- subpopulation 
of T lymphocytes. The apparent conflict between our 
findings and that of other workers was discussed. 
In the following chapter (Chapter 5) we extend our 
investigations into the mode of function of Lyt 1+2+ cells 
in rejecting islet allografts. 
CHAPTER 5 
CYCLOSPORINE: A TOOL FOR ANALYSING MODE OF 
FUNCTION OF LYT 1+2+ CELLS IN ISLET ALLOGRAFT REJECTION 
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5.1 INTRODUCTION 
Cyclosporine (CyA) has, since the demonstration of its 
immunosuppressive activity and purification in the mid 1970's 
(Borel, 1980), made an important impact as a drug in clin-
ical inununosuppression (for recent reviews see Green, 1982; 
White and Calne, 1982; Beveridge, 1983; Thomson, 1983). 
This has come about because of several important advan- · 
tages it has over other inununosuppressive drugs, including 
its very low myelotoxicity and lymphocyte specificity 
which leaves undamaged the animal's phagocytic cell 
function (Borel, 1981; Britton and Palacios, 1982). While 
it is not without its side effects, particularly that of 
nephrotoxicity, its superior features has enabled its use 
to generally give better clinical results, especially in 
bone marrow and renal transplantation, than those 
obtained with conventional inununosuppressive therapy 
(Beveridge, 1983). 
CyA has also made an impact as an important inununo-
logical tool. Yet, while there is agreement that CyA 
affects a variety of T cell functions (see Britton and 
Palacios, 1982; Thomson, 1983), the precise mode of 
action of CyA is still under discussion. Two basic 
models (reviewed by Lafferty et al. 1983b) have been 
proposed to account for the activity of CyA. The subset 
model, which claims that the different T cell subsets 
are functionally different from one another and react 
differently to CyA, postulates that the drug exerts its 
effect by inhibition of the helper subset (Bunjes et al. 
(1981). The signalling model, which sees all T cells as 
having the same potential, proposes that CyA interferes 
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with the transmission of the antigen specific signal within 
the T cell following antigen binding (Andrus et al. 1981). 
Irrespective of the conflicting interpretation of CyA 
action, however, its differential effects on activated T 
cell function have been widely confirmed. + + Lyt 1 2 cells 
are both cytotoxic and can also release lymphokine (Andrus 
et· al. 1981). CyA has the differential effect on activated 
T cells of preventing lymphokine release without affecting 
the cell's cytotoxic function (Borel, 1981; Bunjes et al. 
1981; Andrus and Lafferty, 1982; Orosz et al. 1982). 
This drug can, therefore, be used as an analytical tool 
to discriminate between these two functions. 
The acute nature of the rejection of cultured islet 
allografts by Lyt 1+2+ cells demonstrated in Chapter 4, 
suggested that this rejection was due to cells of the 
cytotoxic subset. In this Chapter we have used CyA to 
investigate which function of activated Lyt 1+2+ cells 
is responsible for rejection of islet allografts. The 
results indicate that lymphokine release plays an 
important role. 
5.2 RESULTS 
Data presented in Chapter 4 has shown that cultured 
islet allografts are rejected by Thy l+, Lyt 1+2+ T cells. 
In this chapter we tested for the mode of action of Lyt 1+2+ 
cells by treating recipients of pancreatic islet allo-
grafts with subcutaneous injections of 75 mg /kg of CyA 
daily, beginning at day 1 to day 7 following the intra-
venous injection of 5 x 10 7 CBA anti-P815 spleen cells. 
The total cytotoxic activity measured in vitro of the 
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injected cells, was 5.4 to 6.1 log10 cytotoxic units. 
A total of 7 CBA mice carry ing established islet allo-
grafts were treated with CyA and injected with sensitised 
CBA spleen cells, generally between day 30 to 50 post 
transplantation. Another group of 6 animals, also carrying 
islet allografts but not treated with CyA, were used as 
controls. These were similarly injected with 5 x 10 7 
sensitised spleen cells. Blood glucose concentrations and 
body weight were determined daily for the first week and 
thereafter as required. Six of the CyA treated animals 
failed to reject their graft following the transfer of 
sensitised cells (Fig. 5.1). The seventh animal (Fig. 
5.1 Panel C) appeared to have undergone a rejection 
crisis and was on its way to recovery. At this point it 
was killed to examine its graft histologically. 
Unfortunately, the presence of numerous adhesions 
resulted in the loss of the graft tissue. In contrast, 
the untreated control animals consistently rejected their 
graft within 3 days of the cell transfer (Fig. 5.1). 
Histologically, the grafts from animals treated with CyA 
showed intact islet tissue with some pockets of cellular 
infiltration around the graft (Fig. 5.2 A, B). Grafts 
from untreated control animals showed massive cellular 
infiltration with essentially no islet tissue remaining 
intact (Fig. 5.2C). These results indicate that lyrnpho-
kine release by Lyt 1+2+ cells is of major importance 
the rejection of cultured islet allografts. 
. in 
It was also of interest to determine whether animals 
which had been treated with CyA, developed tolerance once 
the drug treatment ceased. In 4 CyA treated animals, the 
blood glucose levels and body weight were monitored for 
Figure 5.1 
Non-fasting blood glucose levels of 7 CyA treated 
animals (0,0) and 6 control animals (~), and their 
body weight respectively (e,•), (i). All mice 
were injected with 5 x 10 7 CBA anti-P815 spleen 
cells at day 0. CyA injections were given from 
day 1 to day 7 following injection of sensitised 
cells. Transplantation of animals occurred 
between 30-70 days before injection of sensitised 
cells, with a reversal of diabetes occurring 
within 1-2 weeks. 
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Figure 5.2 
Histological appearance of representative islet 
allografts following challenge with sensitised 
spleen cells. A, graft from CyA treated animal 
(haematoxylin and eosin, x 109); B, graft from 
a similarly treated animal showing the dark 
staining insulin producing beta cells (aldehyde 
fuchsin, x 109); C, graft from an untreated 
control showing complete infiltration (haema-
toxylin and eosin, x 109). 

• 
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several weeks following the withdrawal of the drug treatment. 
Two animals immediately rejected their graft (Fig. 5.1, 
Panel F). One animal appeared to go through a minor rejec-
tion crisis but then returned to within the normal blood 
glucose range (Fig. 5.1, Panel E). This and another CyA 
• treated animal (Fig. 5.1 Panel D) were injected intraperi-
toneally 3 weeks later with 10 6 normal spleen cells of 
donor origin. In both animals, this challenge with donor 
type cells led to the rapid rejection of the graft. The 
treatment with CyA, therefore, had not induced tolerance 
to donor antigens. 
5.3 DISCUSSION 
+ + As demonstrated in Chapter 4, Lyt 1 2 cells are 
required to trigger the rejection of cultured pancreatic 
islet allografts. Although rejection may occur through a 
direct cytotoxic attack on islet cells, or through lymphokine 
+ + release from Lyt 1 2 cells (Andrus et al. 1981) and an 
associated inflammatory response, our data showing the 
acute rejection of islet allografts was thought to be more 
consistent with a direct cytotoxic effect of the immune 
cells on transplanted islet cells. The results presented 
in this Chapter, using CyA as a tool to discriminate 
between the two functions, shows that the drug prevents 
rejection by sensitised Lyt 1+2+ T cells. This suggests 
the cytotoxic activity alone is not a sufficient require-
ment for graft rejection by this cell population. Animals 
treated with CyA still showed pockets of cellular infiltra-
tion around the grafts, although histologically the islet 
tissue itself appeared intact. These inflammatory foci 
may be associated with damage to the kidney capsule and 
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underlying parenchyma tissue produced at the time of trans-
plantation. It is also possible that these pockets of cells 
represent that proportion of transferred cells which 
managed to circulate and attach themselves to the graft 
tissue. Once attached, however, inhibition to release 
lymphokine abolished their ability to recruit more 
effector cells to the graft site and hence abolished their 
ability to reject the islet allograft. 
The data presented in this study indicates, therefore, 
that lymphokine release is important, although the precise 
role that lymphokine plays remains uncertain. This inter-
pretation does not exclude a role for the cytotoxic 
function of these cells, as lymphokine may be required to 
maintain the growth and viability of the activated T cells, 
or to attract other sensitised cytotoxic cells to the site, 
thereby magnifying the reaction. Against the first 
possibility is the fact that two animals rejected their 
graft when CyA was withdrawn (Fig. 5.1, Panel F), indica-
ting that the T cells were still viable up to that point 
in time. Some evidence that cytotoxicity by itself can 
play a role in rejection, is seen in the animals which 
went through a rejection crisis (Fig. 5.1, Panels C and E). 
However, this evidence is not sufficient to totally exclude 
the possibility that cytotoxicity plays no role and that 
lymphokine release by itself leads to allograft rejection. 
It would be of interest to deliver the sensitised cells 
directly into the graft site under the kidney capsule and 
determine whether the onslaught of such a large number of 
cytotoxic cells would still prevent the graft from being 
rejected in a CyA treated animal. An interesting feature 
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is that recovery can occur when the drug is withdrawn. 
The findings from this study are consistent with other 
work from our laboratory where CyA was used to determine 
which function is responsible for the local GVH reaction 
produced when T cells sensitised to class I MHC antigens 
are injected into the footpad of mice bearing the priming 
antigen (Hodgkin et al. 1983). Such sensitised cells 
induce footpad swelling within 24 hours of injection. 
CyA does not affect the cytotoxic activity of these cells, 
but does inhibit lymphokine release. Treatment of 
recipient animals with CyA, using 75mg/kg on day 1, 
0 and 1, inhibited the expression of the local GVH reaction. 
In vitro treatment of cells with lµg/ml of CyA for 1 hour 
before injection into the footpad, resulted in a delayed 
response and a reduced peak in footpad swelling compared 
to controls (Hodgkin - personal communication). That 
is, the effect of CyA on cells treated in vitro wears 
off and these cells recover some lymphokine releasing 
function. However, by treating the cells as well as 
the recipient, this recovery is prevented and the 
swelling reaction is completely inhibited. 
The question of whether CyA can induce tolerance 
has been investigated by a number of workers, with some 
conflicting results, although the majority have reported 
varying degrees of tolerance following CyA treatment 
(White et al. 1980; Reece-Smith et al. 1981; Deeg 
et al. 1982; Du Toit et al. 1982; Nagao et al. 1982; 
Bordes-Aznar et al. 1983; Hess et al. 1983). With 
our system, which is quite different to those used by 
these workers, we were not able to induce tolerance. 
- 144 -
However, one interesting finding from these reports has 
been that following withdrawal of CyA and then challenge 
with a second donor specific graft, the degree of responsive-
ness varies with time; that is, graft acceptance passes 
through different phases so that, with the passage of time, 
the degree of specificity and stability of tolerance 
increases (White et al. 1980; Nagao et al. 1982; Bordes-
Aznar et al. 1983). Thus, a short course of CyA treat-
ment can lead to indefinite survival even after treatment 
with the drug has ceased. Until this tolerant state is 
reached, however, rejection occurs; that is, the graft 
is in a metastable state. This aspect is explored in 
the following Chapter. It seems that the drug permits the 
initial success in grafting and the continued provision of 
graft antigen is then required for the development of 
tolerance without the need for the continuous presence 
of the drug (Kasahara et al. 1982; White, 1983). 
5.4. SUMMARY 
CyA was used as an analytical tool to determine the 
+ + mode of function of Lyt 1 2 cells in their rejection of 
cultured islet allografts. The data show that lymphokine 
production is required for adequate function of the Lyt 1+2+ 
subset which is responsible for rejection. In this system, 
treatment with CyA does not lead to the induction of 
transplantation tolerance. In the following Chapter, we 
will assess the stabilization of islet allografts and 
induction of tolerance. 
CHAPTER 6 
STABILIZATION OF ISLET ALLOGRAFTS BY TREATMENT OF 
RECIPIENTS WITH ULTRAVIOLET IRRADIATED DONOR 
SPLEEN CELLS - INDUCTION OF ADULT TOLERANCE 
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6.1 INTRODUCTION 
Removal or inactivation by organ culture, of leucocytes 
associated with mouse pancreatic islets and thyroid tissue 
prior to transplantation, allows the successful grafting of 
these tissues to normal MHC incompatible recipient animals, 
where the allografts remain functional indefinitely 
(Lafferty and Woolnough, 1977; Bowen et al. 1980; Donohoe 
et al. 1983). However, although the immunogenicity of these 
tissues can be reduced by organ culture, such treatment 
does not prevent their rejection when the recipient is 
challenged with lymphoreticular cells of donor origin at, 
or for some time after transplantation (Lafferty et al. 
1976b; Talmage et al. 1976; Lafferty and Woolnough, 
1977; Simeonovic et al. 1980; Bowen et al. 1981; Vesole 
et al. 1982). Rat islet allografts have similarly been 
rejected following challenge with peritoneal cells 
syngeneic to the islet donor (Lacy et al. 1979c). There-
fore, the immediate post-transplantation period is one of 
graft vulnerability. 
The length of this vulnerable period is limited. An 
earlier study from our laboratory, aimed at defining the 
vulnerability of an established pancreatic islet allograft 
in mice, showed that functional tolerance develops in a 
proportion of recipients of long-standing allografts 
(~100 days) (Bowen et al. 1981). Zitron et al. (1981b) 
reported a similar finding in the rat. The same phenomenon 
was also seen in mice grafted with thyroid tissues where, 
after prolonged residence in the recipient ( >100 ~350 days), 
only a proportion of allografts were rejected when the 
recipient was challenged with 10 5 followed by 10 6 perito-
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neal cells of donor origin (Donohoe et al. 1983). Vesole 
et al. (1982) earlier reported a similar finding in mice 1 
carrying cultured thyroid allografts. Only 50% of such 
animals rejected their graft when challenged with 5 x 10 6 
spleen cells of donor origin; 73% of those rejected had 
been established in the recipient for less than 6 months. 
Thus, although there is some variation between different 
tissues, it does seem that, as the post-transplantation 
period increases, the allograft becomes progressively 
less susceptible to rejection. Grafts which cannot be 
rejected following challenge of the recipient with donor 
spleen cells, are considered to have moved from the 
metastable post-transplantation phase into a phase 
characterized by a stable interaction with the host. 
The major question under study here concerns 
whether the metastable phase can be shortened by 
appropriate treatment of the recipient. The hypothesis 
tested is that stabilization can be achieved by the 
administration to recipients of donor antigen alone; 
such antigen is provided by ultraviolet (UV) killed 
spleen cells (Lafferty et al. 1974). 
In this study, spleen cells of donor origin were 
killed with UV light before injection into recipients 
carrying metastable islet allografts. Following this 
treatment, recipients were tolerant to a challenge of 
live spleen cells. Graft stability was therefore 
hastened by treatment with UV irradiated cells. More-
over, this graft stabilization is shown to result from 
the induction of specific tolerance to tissues of donor 
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6.2 RESULTS 
6.2.1. Imrnunogenicity of UV irradiated spleen cells 
The capacity of killed (UV irradiated) and live spleen 
cells to induce allograft rejection was compared. Fourteen 
diabetic CBA mice were each transplanted with 7 cultured 
BALB/c islet clusters (350 islets). Following the return 
of the blood glucose level to normal, nine of these 
diabetes-reversed animals were injected (intraperitoneally) 
with 10 6 UV irradiated spleen cells of donor origin at 
about 30 days post-transplantation. The remaining five 
animals were challenged with an intraperitoneal injection 
of 10 6 live spleen cells of donor origin at day 30. 
The results of this study show that, in general, UV 
irradiated cells do not induce allograft rejection (Fig. 
6.1). Of the nine animals injected with UV irradiated 
cells, only one rejected its graft (Fig 6.lH). Even 
after a further two doses of UV irradiated cells, the 
blood glucose level in the remaining eight animals 
(Fig. 6.1 A-G, I), remained within the normal range and 
body weight continued to increase. In contrast, of the 
five animals challenged with 10 6 live spleen cells at 
day 30, all rejected their graft (Fig. 6.2). All five 
animals returned to the diabetic condition by 6-15 days 
after challenge. UV irradiated spleen cells, therefore, 
are very much less immunogenic than living spleen cells. 
6.2.2. UV irradiated cells stabilize the islet allograft 
A total of 9 animals received 3 doses at weekly intervals, of 106 
UV irradiated cells. Eight failed to reject their graft 
following this treatment and were then challenged (intra-
peritoneally) two weeks after the final dose of UV irradia-
Figure 6.1 
Non-fasting blood glucose levels (D) and body 
weight (•) of 9 CBA mice transplanted with 
350 cultured allogeneic (BALB/c) islets and 
treated with UV-irradiated spleen cells of donor 
origin from about 30 days after transplantation . 
Only 1 animal (H) rejected its graft after this 
treatment. Each of the other 8 animals was then 
challenged with 10 6 followed by 10 7 live cells 
of donor origin. Only one animal (I) rejected 
its graft after injection with 10 6 live cells. 
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Figure 6.2 
Non-fasting blood glucose levels (0) and body 
weight (e) of 5 CBA mice transplanted with 
350 cultured allogeneic (BALB/c) islets and 
challenged with 10 6 live cells of donor origin 
at 30-34 days post transplantation. 
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ted cells (about 60 days post-transplantation), with 10 6 
live spleen cells of donor origin (Fig. 6.1). Seven out of 
8 animals maintained normal blood glucose levels and a 
corresponding increase in body weight following the chall-
enge with living spleen cells (Fig. 6.1). Only one animal 
(Fig. 6.1I) became diabetic after this challenge. As a 
control, another group of 5 animals which carried an 
established islet allograft but not treated with UV 
irradiated spleen cells, were injected with 10 6 live 
spleen cells at about day 60. Four of these animals 
rejected their graft within two weeks of challenge 
(Fig. 6.3). The fifth animal was rechallenged two weeks 
later with 10 7 live cells but again it failed to reject 
its graft (Fig. 6.3E). This animal had spontaneously 
developed a stable interaction with the cultured allo~ 
graft, which was shown to be histologically normal at 
termination of the study. The 7 UV cell treated animals 
which maintained normal blood sugar following the first 
challenge with live spleen cells, were again challenged 
two to four weeks later (75-90 days post-transplantation) 
with 10 7 live spleen cells, and they continued to maintain 
a functional graft. 
Clearly, treatment of recipients with UV irradiated 
cells had the effect of stabilizing the established allo-
graft, whereas untreated animals rejected their graft 
following challenge. 
6.2.3. Stabilization results from the induction of 
specific tolerance 
Following the stabilization of the islet allografts 
with UV irradiated cell treatment, we asked whether this 
1111 
Figure 6.3 
Non-fasting blood glucose levels (6) and body 
weight (!) of 5 CBA mice transplanted with 350 
cultured allogeneic (BALB/c) islets and 
challenged with 10 6 live cells of donor origin 
at 56-61 days post transplantation. Only 1 
animal (E) did not reject its graft after 
challenge. 
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stability might be due to the induction of specific tolerance. 
To test this proposition, 5 animals carrying stabilized allo-
grafts were transplanted in their opposite kidney with un-
cultured thyroids of both donor origin (BALB/c) and from a 
third party strain (C57BL10J). This protocol is shown 
diagrammatically in Fig 6.4. This procedure did not cause 
a return to the diabetic condition. One month later the 
animals were killed and all grafts examined. Macroscopic-
ally, the BALB/c uncultured thyroid appeared intact with no 
macroscopically obvious infiltration into the follicles. 
The C57BL10J uncultured thyroids appeared milky white, 
suggesting heavy infiltration. The primary islet allograft 
appeared intact and well vascularized. These observations 
were confirmed histologically (Fig. 6.5); 3 of the 5 
BALB/c thyroids showed some minor inflammation around the 
follicles (Fig. 6.SA). In contrast the C57BL thyroids 
were heavily infiltrated with mononuclear cells and 
essentially destroyed (Fig. 6.SB). The acceptance of 
only the BALB/c secondary graft indicates that allograft 
tolerance was induced and that the tolerance induced was 
strain specific. 
Because previous studies in our laboratory of the 
10 day cultured foetal pancreas had shown uniform rejection 
of this tissue within 2 weeks of transplantation, we were 
interested to see if the tolerance induced by treatment 
with UV irradiated cells, extended to this highly irnrnuno-
genic tissue. Two stabilized animals were transplanted 
in their second kidney with tissue from 2 foetal pancreases 
of donor origin which had been cultured in 95 % o2 and 5% co2 forl0 
days. This procedure did not cause a return to the 
diabetic state (Fig. 6.6). At 2 and 4 weeks after trans-
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Figure 6.4 
Diagrammatic representation of the protocol 
used to stabilize mouse islet allografts and 
to test the specificity of tolerance using 
uncultured thyroid of donor (BALB/c; H-2d) 
and third party (C57BL10J; H-2b) origin. 
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Figure 6.5 
Histological appearance of primary and secondary 
allografts in a stabilized CBA recipient. 
A. BALB/ c uncultured thyroid. Note the presence 
of intact thyroid follicles. 
B. C57 BL10J uncultured thyroid showing a vigorous 
allograft response with thyroid tissue essentially 
destroyed. 
C. BALB/c cultured islet tissue - the primary 
allograft. (haematoxylin and eosin, x 109). 
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Figure 6.6 
Non-fasting blood glucose levels (O,D) and body 
weight (e,a) of 2 stabilized CBA mice challenged 
with 10 6 and 10 7 live spleen cells of donor 
origin, and then given a second allograft of 
10 day cultured foetal pancreas syngeneic 
with the primary islet allograft. 
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plantation of the foetal pancreas, animals were sacrificed 
and both the primary and secondary grafts were examined. 
While the original graft of adult islets remained intact, 
only scar tissue remained of the foetal pancreas allo-
grafts at 4 weeks post-transplantation (Fig. 6.7). This 
tolerance, therefore, does not extend to 10 day cultured 
foetal pancreas• 
6.2.4. Tolerance is not due to clonal deletion 
At the time of sacrifice, mesenteric and axillary 
lymph nodes were removed from those animals which had 
received secondary uncultured thyroid allografts. The 
lymph node cells were then tested for their capacity to 
respond to alloantigenic stimulation in vitro. All 
d animals showed a cytotoxic T cell response to H-2 
antigens comparable in magnitude to the response of normal 
10-12 week old mice (Table 6.1). Clearly the tolerance 
induced was not due to the deletion of antigen reactive 
cells. 
6.2.5. Role of antibody 
Five animals which became tolerant following treat-
ment with UV irradiated cells and which went on to receive 
secondary uncultured thyroid allografts, were bled just 
before sacrifice. Cytotoxic antibody titrations were 
51 carried out using Cr-labelled BALB/c spleen cells as 
targets, but no cytotoxic antibody was detected. 
Figure 6.7 
Histological appearance of 10 day cultured 
foetal BALB/c pancreas 2 weeks after trans-
plantation beneath the kidney capsule of a 
CBA recipient carrying an established BALB/c 
islet allograft. Note the presence of 
rejection response (haematoxylin and eosin, 
X 164). 
Table 6.1 
Log10cytotoxic units (CU) per culture 
Grafted Animal Control 
5.6 5.6 
5.3 5.3 
5.1 4.7 
4.8 4.7 
5.0 5.3 
Mean + S.D. 5.2 + 0.3 5.1 + 0.4 
-
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6.3 DISCUSSION 
The results of this study demonstrate that there is a 
marked difference in irnrnunogenicity between UV irradiated 
and live spleen ceLls. Treatment with UV irradiated cells, 
with one exception, did not induce the rejection of the 
islet allograft, whereas live cells injected at the same 
time following transplantation, rapidly destroyed the graft. 
This is consistent with the finding that UV irradiated 
cells are unable to stimulate allogeneic T cells in vitro 
(Lafferty et al. 1974). We are not sure why one animal 
out of nine rejected its graft after treatment with UV 
irradiated cells although it could have been the result 
of a technical error. A different UV irradiation source 
was used for treating cells for that particular animal, 
and as a result, some cells may have escaped killing. 
It is known that as few as 10 3 viable lymphocytes 
are capable of leading to allograft rejection (Lafferty 
et al. 1976b; Talmage et al. 1976). 
The treatment of islet recipients with UV irradiated 
spleen cells of donor origin led to the stabilization of 
the islet allograft by inducing a state of tolerance. 
Animals treated in this way were, in all but one case, 
able to withstand subsequent challenge with 10 6 and 10 7 
live spleen cells. Moreover, the acceptance of uncult-
ured thyroids of donor origin by stabilized recipients, 
but not thyroids from a third party strain, illustrates 
the specificity of the tolerance induced. It should be 
noted, however, that H-2d uncultured thyroids that were 
transplanted to animals whose islet graft had been 
stabilized,showed minor inflammation around the follicles. 
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While we cannot be certain of the mechanism underlying this 
reactivity, this response may be due to antigenic differ-
ences between cultured and uncultured tissue. Animals 
tolerant of the cultured islet allograft, from which Ia 
(class II) antigens have been eliminated during organ 
culture prior to grafting (Parr et al. 1980), might not 
be expected to be tolerant of class II antigens carried 
on the surface of leucocytes in the uncultured thyroid. 
While the tolerance induced enabled recipients to 
maintain an 'Uncultured thyroid allograft of donor origin, 
it was not sufficient to allow the survival of 10 day 
cultured foetal pancreas of similar origin. At 2 weeks 
this tissue was totally destroyed. We suggest that the 
rejection of the cultured foetal pancreas may be due to 
the existence in that tissue, despite its culture, of 
sufficient residual class II positive lymphoid cells 
which can lead to non-specific graft destruction via 
an inflammatory reaction. When explanted, foetal tissue 
is known to carry a lymphoid component which acts to 
supplement the population of blood cells carried as 
passengers within the tissue vasculature (Simeonovic 
et al. 1980). Human foetal pancreas has also been 
shown to carry numerous DR-positive (class II) 
lymphoid cells and dendritic cells (Danilovs et al. 
1982). This large component makes the mouse foetal 
pancreas difficult for preparation for transplantation 
using organ culture (Simeonovic et al. 1980,. 1983). 
In contrast, this is not a problem for thyroid or 
islet tissue; the latter being relatively purified 
from the lymphoid component by the hand-picking pro-
cedure (Section 2.3.1). Regarding the inflammatory 
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response to class II MHC anti gens in the foetal pancreas, 
there are two ways this might occur. In addition to lympho-
kine secretion (following antigen recognition by activated 
host T cells) which then activates a host inflammatory 
response by the migration, activation and proliferation of 
host cells, the lymphokines can also act on donor (that 
is, of foetal pancreas origin) responsive blood cells 
causing them to proliferate and lead to non-specific 
damage. Both potential mechanisms could contribute to 
graft destruction. Thus, while the degree of class II 
contamination is only sufficient to cause a light infil-
tration into the uncultured thyroid tissue, in the 
foetal pancreas the class II component is sufficient to 
lead to destruction via an inflammatory response. This 
difference in size of class II antigen component may 
also account for the findings of White et al. (1980). 
They investigated the stability of established grafts, 
and found that where a heart was the primary established 
allograft, a secondary skin allograft given a long time 
after the withdrawal of CyA irnmunosuppression, was 
rejected. In contrast, the primary heart allograft 
was retained. Again, class II region mediated 
reactivity could account for this effect if class II 
bearing cells are eliminated from the heart allografts 
during the period of irnmunosuppression. Yet, where skin 
was the primary established graft, withdrawal of CyA 
resulted in its rejection; a secondary donor specific 
graft led to the rejection of both skin and the secondary 
graft. This may indicate that CyA was not able to 
eliminate all class II bearing cells in skin - a tissue 
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highly positive for class II antigen (Hamrnerling, 1976). 
As already alluded above, this class II region 
difference may be reflected in differences in culture 
period requirements for graft survival. In our laboratory, 
mouse pancreatic islets can be successfully allografted 
after only 7 days in culture (Bowen et al. 1980), where-
as foetal pancreas is consistently rejected after 7 and 
10 days culture, and requires 17-20 days for significant 
survival (Simeonovic et al. 1980, 1983) and is functional 
at 20 days culture (Simeonovic and Lafferty, 1981). 
Thyroid allografts ~an survive with 12 days culture 
(Lafferty et al. 1975) although we routinely culture 
for 21 days. 
The treatment of recipients with UV irradiated 
cells of donor origin is, therefore, able to markedly 
reduce the period of graft vulnerability by the induction 
of specific tolerance. Functional tolerance will 
ultimately develop in a proportion of animals carrying 
a cultured allograft (Bowen et al. 1981; Donohoe et al. 
1983) although the period required to induce this 
tolerance can be as long as 350 days. Nagao et al. 
(1982) have also shown this development of tolerance 
with the passage of time in rats carrying heart allo-
grafts and immune suppresssed with CyA. Following the 
withdrawal of CyA two weeks after the heart allograft, 
they found that the heart continues to function but 
can be rejected if the recipient is challenged with 
donor skin; at this stage the heart allograft is in 
a metastable condition. With the further passage of 
time, at over 100 day s, the heart graft was not affected 
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and skin survival was prolonged; the latter graft now 
undergoing a chronic rather than an acute rejection. 
The mechanism of tolerance induction in these allo-
grafted animals is not known. The classical view of 
tra.nsplantation tolerance is one based on the clonal 
elimination of reacting cells (Burnet, 1959; Section 
1.14). However, both in the case of thyroid (Donohoe 
et al. 1983) and in the present study with islets, we 
have shown that this phenomenon is not a deletion form 
of t olerance. In both models ,lymphocyt es from tolerant animals respond 
normally to donor alloantigen in vitro. In the case of 
thyroids, tolerant animals are hyporesponsive to 
in vivo challenge with donor cells (Donohoe et al. 
1983). We have suggested that the slow, continued 
administration of alloantigen, by way of UV irradiated 
cells, might induce a state of tolerance in a manner 
somewhat similar to active enhancement (Donohoe et al. 
1983). According to the original two signal model for 
lymphocyte activation, provision of antigen (signal 1) 
alone is tolerogenic (Bretscher and Cohn, 1970). UV 
treated cells are an effective source of signal l; 
antigen is left intact on the cell surface of the 
irradiated cell (Lafferty et al. 1974; Talmage et al. 
19 7 7) . 
The mechanism by which enhancing antibodies prolong 
allograft survival is unresolved (Section 1.13.6). 
However, the idea that antigen-antibody complexes might 
be important in preventing rejection of allografts, 
gained some support with the work of the Hellstroms 
(reviewed by Hellstrom & Hellstrom, 1974; Section 1.14.2). 
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Hutchinson (1980) proposed that antigen reactive cells are 
opsonized by graft antigen-antibody complexes and are 
subsequently destroyed by Fe-receptor bearing host cells 
s uc h as macrophages (Section 1.13.6.1). We have not been 
able to detect cytotox · c an tibody, although this does not 
necessarily preclude i ts existence. 
Lacy's group have suggested such tolerance might be 
due to the action of suppressor cells (Faustman et al. 
1981, 1982ap;Zitron et al. 1981b). T suppressor cells 
as an active mechanism in the maintenance of transplan-
tation tolerance has been increasingly demonstrated and 
is discussed in Chapter 1 ( Section 1.14.4). UV 
irradiation is known to impair immune responses 
(reviewed by Fox et al. 1980) and Greene et al. (1979) 
using UV irradiated mice, were able to demonstrate 
defective antigen-presenting cells in their spleens for 
both DTH and antibody responses. But whether the 
induction of suppressor cells can be accounted for by 
abnormalities in antigen presenting cells is not quite 
clear, although the evidence from Greene's group suggests 
that inappropriate presentation of antigen may lead to 
suppression and that the suppression can be transferred 
with T cells. Priming for DTH responses with antigen 
presenting cells from UV treated mice gave rise to 
suppressor T cells (Greene et al. 1979) and more recently, 
in a study using in vivo irradiated spleen cells, they 
again suggested that antigen presented on such cells 
could generate suppressors by the demonstration that 
such cells could suppress DTH responses (Fox et al. 1981). 
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We have shown, therefore, that in the mouse pancreatic 
islet model, the metastable condition of the graft following 
transplantation can be eliminated by treatment of the 
recipient with UV irradiated spleen cells of donor origin. 
It would be of interest to determine whether UV irradiated 
cells on their own are tolerogenic. That is, can pre-
treatment of the recipient with UV irradiated cells followed 
by an uncultured allograft, lead to the acceptance of that 
graft? Attempts to transplant uncultured isolated 
pancreatic islets under the kidney capsule proved technic-
ally difficult because of the unclustered nature of the 
islets. However, some preliminary work in our laboratory 
using uncultured thyroids (unpublished data) is encouraging. 
Histological data show that pretreatment of the recipient 
with UV irradiated cells is definitely beneficial to the 
graft when compared to untreated controls. The UV cell 
dosage, however, seems to be of critical importance and 
further work is required to establish the optimum antigen 
dose and time course of treatment. Lau et al. (1983) very 
recently demonstrated that prolonged islet allograft 
survival in rats could be achieved by treating recipients 
with whole donor blood which had first been UV irradiated. 
Our demonstration in the mouse pancreatic islet 
model that a state of specific tolerance can be induced 
in adult animals without a requirement for recipient 
irnrnunosuppression, has potential for clinical trans-
plantation where grafts are constantly under the threat 
of rejection. 
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6.4 SUMMARY 
A comparison of the capacity of UV irradiated and live 
spleen cells of donor origin to induce islet allograft 
rejection showed that UV irradiated spleen cells were not 
. . immunogenic; live spleen cells were immunogenic and their 
• 
injection triggered allograft rejection. Following treat-
ment with irradiated spleen cells from about day 30 post-
transplantation, recipient animals were able to withstand 
subsequent challenges with 10 6 and 10 7 viable donor spleen 
cells. Untreated animals rejected their graft when 
challenged with 10 6 donor spleen cells. That is, treat-
ment with UV irradiated cells stabilized the islet allo-
graft by inducing a state of tolerance. Subsequent 
transplantation of stabilized animals with uncultured 
thyroids of both donor and third party origin, demon-
strated that the tolerance was specific. In vitro 
test of immune reactivity showed this tolerance was not 
due to the deletion of antigen reactive cells. 
CHAPTER 7 
GENERAL DISCUSSION 
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This thesis was primarily concerned with determining 
the vulnerability of established islet and thyroid allo-
grafts to rejection. While cultured allografts can be 
transplanted without a requirement for suppressing the 
recipient's immune system, such allografts are constantly 
under the threat of rejection. Clinically, this could 
have great importance. For example, a blood transfusion 
given for some therapeutic reason unconnected with the 
transplant could trigger rejection of the allograft if 
the blood cells carried MHC antigens common to those 
in the graft. The experimental work described in this 
report was, therefore, basically an investigation of 
potential threats to the established allograft, and the 
cellular requirements for its rejection. Furthermore, 
the possibility of rendering such grafts stable, was 
also investigated. This stabilization was achieved in 
recipients of islet allografts and was found to be due 
to the induction of specific tolerance - a finding which 
is most encouraging both from the basic immunobiological 
and clinical viewpoints. 
Using in vitro culture to modulate tissue immuno-
genicity, islet and thyroid allografts were successfully 
transplanted across an MHC barrier without the use of 
. . immunosuppression. Such grafts are functional and are able 
to reverse diabetes or take up labelled iodine. This 
procedure of organ culture is one which is based on the 
theory that donor leucocytes carried within the graft 
initiate the rejection process (Section 1.7). The 
success achieved by using this technique, has 
potential clinical relevance in the treatment of insulin 
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dependent diabetes and its many de generative comp l ications. 
Challenge of animals carrying islet and thyroid allo-
grafts with donor specific antibody and complement, was 
not able to lead to a rejection of the graft. This resis-
tance is thought to be due to a revascularization of the 
graft tissue with host vascular endothelium. Revasculari-
zation occurs because culture of tissue results in the 
degeneration and loss of its own vascular endothelium 
(Parr et al. 1980b) - a loss which was thought by 
Hirschberg and coworkers (Section 1.7.2) to account for 
the reduction in immunogenicity. That is, they proposed 
that vascular endothelial cells have a stimulatory 
capacity in allograft rejection. However, there is now 
cons idera ble e v idence which suggests that reduction in 
i mmunoge n icity followi n g organ culture, is not due to the 
loss of vascular endothelium but, rather, to the 
inactivation or elimination of passenger leucocytes 
(Section 1.7.2). Such revascularization, however, is 
not able to protect bhe transplant from cell mediated 
damage. Challenge with cells of donor origin will lead 
to the prompt rejection of the allograft (Lafferty et al. 
1976b; Talmage et al. 1976; Lafferty and Woolnough, 1977; 
Simeonovic et al. 1980; Vesole et al. 1982; Lacy et al. 
1979c). That is, the cultured tissue remains antigenic 
and can be rejected once the recipient is activated with 
leucocytes of donor origin. 
Other work from our laboratory has shown that 
cultured islet allografts are also resistant to non-
specific stimulation of the host's immune response 
mechanisms (Bowen et al. 1981). Mice carrying established 
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allografts were able to resist challenge with Freund's 
complete adjuvant. This is also an important finding 
because the mycobacterial component of the adjuvant can 
stimulate the release of interleukin I from macrophages 
(Togawa et al. 1978). That is, non-specific stimulation 
could raise Cos activity levels and consequently lead to 
rejection of the graft. This finding suggests that 
cultured allografts would probably be resistant to other 
non-specific stimulation, such as infections. 
In Chapters 4 and 5 we examined the cellular require-
ments and mode of action of these cells in the rejection 
of islet allografts. Such grafts are acutely rejected by 
sensitised cells of the Lyt 1+ 2+ subclass. Loveland 
et al. ( 19 81) concluded that Lyt 1 + 2- T cells from sensi-
tised mice could trigger skin graft rejection in ATXBM 
mice and concluded that cytotoxic cells (Lyt 1+2+) were 
not involved in allograft rejection. Our findings, 
however, would indicate that their conclusion cannot 
generally hold. We attempted to reconcile this conflict 
by suggesting that the subclass of T cell responsible for 
triggering graft rejection, probably depends on the type 
of tissue grafted which, in turn, is a reflection of the 
class of alloantigen expressed on that tissue. 
The acute rejection of islet allografts following 
the transfer of sensitised cells, was initially thought 
to be consistent with a direct cytotoxic effect by the 
immune cells, although rejection via lymphokine release 
was not excluded. To answer this question, we used the 
irnrnunosuppressive drug, CyA, in this case, as an analytical 
tool. CyA is known to inhibit the release of lymphqkine 
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without affecting the cell's cytotoxic capacity. Our 
results indicate that lymphokine release plays an important 
role in the triggering of islet allograft rejection by 
+ + Lyt 1 2 cells. These findings are also consistent with 
other work, both in vivb and in vitro, from our laborator.y, 
and with virus elimination (Schiltknecht and Ada 
personal communication). An interesting aspect of CyA 
treatment is that recovery can occur once the drug is withdrawn. 
Earlier work from our laboratory had produced the 
unexpected finding that functional tolerance can develop 
in recipients of long-standing islet and thyroid allo-
grafts (Bowen et al. 1981; Donohoe et al. 1983). Such 
recipients are resistant to challenge with peritoneal 
or spleen cells of donor origin. However, until such 
tolerance develops, which can take from 3 to 12 months 
depending on the type of tissue, the graft remains in a 
metastable phase. We extended these studies, with our 
initial aim being to try and reduce the metastable 
period. We attempted to do this by treatment of the 
host with antigen alone given in the form of donor 
spleen cells which had been killed by UV irradiation. 
It has already been demonstrated that transplantation 
antigen is highly immunogenic when presented to T cells 
on the surface of metabolically active cells which 
also provide a source or Cos activity; these are the 
S + cells (Section 1.6.2). The metabolic inactivation 
of these cells with UV irradiation destroys their capacity 
to activate a cytotoxic T cell response (Lafferty et al. 
1983a). We now demonstrated that treatment of islet 
allograft recipients with UV irradiated donor spleen cells 
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does indeed bring on a s i t u ation o f g raft stability - suc h 
recipients can now withstand challenge with 10 6 and 10 7 
live spleen cells of donor type. The treatment with UV 
irradiated cells induced a state of specific tolerance · -
such recipients were now able to accept uncultured 
thyroid grafts of donor origin. This evidence is con-
firmatory of the 2 signal model for lymphocyte activation 
proposed by Bretscher and Cohn (1970) and Lafferty and 
coworkers (Section 1.6.2), which predicts that presenta-
tion of antigen in a non-immunogenic form is tolerogenic. 
Support for this view has also come from Faustman et al. 
(1982a,b) who were able to obtain prolonged islet allo-
graft survival following preimmunization of mice with 
donor specific blood depleted of class II antigen bearing 
cells. More recently, Lau et al. (1983) achieved the same 
effect by treating recipients with whole donor blood which 
had first been UV irradiated. Clinically, our findings are 
also importa nt because they demonstrate t h e possibility 
of inducing allograft tolerance. Such treatment could 
potentially not only offer protection against the initia-
tion of graft rejection following transplantation, but also 
give protection later in a situation where the patient 
might be exposed to cross reacting antigens such as 
might occur during a blood transfusion. Such immuno-
logical manipulation of the recipient is further encourag-
ing clinically, because it can produce a protective effect 
without harming the recipi e nt by reducing his immunity to 
infection - a problem long recognized with drug immuno-
suppression (Section 1.12.1). 
One question which remains to be answered is the 
mechanism of this tolerance. Although this phenomenon is 
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not due to a deletion for m o f tolerance, since we showed 
that lymphocytes from such tolerized animals respond 1. 
normally to donor alloantigens in vitro, further work is 
required to elucidate the possible mechanism(s). Although 
we have no firm evidence concerning the nature of this 
tolerance or how it is induced, it would seem that the 
way the antigen is delivered to the immune system a ffects 
its response. We have proposed, therefore, that this form 
of tolerance might develop as a result of the slow liber-
ation of antigen into the host's immune system which 
could then lead to tolerance induction in a way somewhat 
similar to active enhancement (Lafferty et al. 1983a). 
The mechanisms responsible for the induction and 
maintenance of immunological enhancement are still 
subject to speculation and controversy (Section 1.13.6). 
However, of the several mechanisms proposed, there is 
little support for clonal deletion, with the more 
favoured explanations being the induction of antiidio-
typic antibodies and suppresssor cells. Mechanisms for 
transplantation tolerance are discussed in Sectionl.14. 
In view of the increasing evidence for the role o f T 
suppressor cells (Dorsch and Roser, 1977; Hilgert, 
1979; Tutschka et al. 198la,b; Roser et al. 1983; 
Section 1.14.4), further work would be required in the 
cultured islet allograft model to investigate their 
possible role in this system. Work along these lines by 
Lacy and his coworkers (Zitron et al. 1981b) have 
already implicated suppressor cell activity in rats 
carrying long-term islet allografts. Further work is 
also required to determine if the tolerance state can be 
transferred to a naive animal of recipient genotype and 
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the effect UV irradiation has on antigen presenting cells. 
Such studies by Benacerraf's group (Greene et al. 1979; 
Fox et al. 1980, 1981) suggest that antigen presentation 
by such cells is affected and this may lead to the 
induction of suppressor cells. Because of the potential 
these findings hold for clinical transplantation in 
general, more information concerning the nature of the 
antigens that induce this tolerance is also required. 
Finally, the results presented in this report have 
demonstrated that cultured allografts, although they 
can be successfully transplanted across MHC barriers 
without the use of immunosuppression, still retain their 
antigenicity. That is, they remain susceptible to 
rejection for some time after transplantation. The cellu-
lar requirements for their demise are T cells of the 
Lyt 1+2+ or cytotoxic subclass and these can trigger 
rejection by lymphokine release. Of some interest has 
been the finding that such metastable grafts can in fact 
be stabilized by the induction of specific tolerance. 
The mechanism of this tolerance seems to be due to 
suppression, by an unknown mechanism, of the process of 
recipient sensitisation. Many other questions, unfortu-
nately, remain unanswered and await further investigation. 
From these findings, and the review of the literature in 
Chapter 1, it is clear that the field of organ transplan-
tation is one which, despite great progress, many prob-
lems still require resolution. Nonetheless, one of the 
most encouraging aspects of transplantation biology today, 
is the fact that there have probably never been so many 
tools with which to seek answers to the problems. 
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